,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,1,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line,Confirmatory,,
1,3,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H226 Non-Small Cell Lung cell line,Confirmatory,,
2,5,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H322M Non-Small Cell Lung cell line,Confirmatory,,
3,9,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-62 Non-Small Cell Lung cell line,Confirmatory,,
4,13,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line,Confirmatory,,
5,15,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the NCI-H522 Non-Small Cell Lung cell line,Confirmatory,,
6,17,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LXFL 529 Non-Small Cell Lung cell line,Confirmatory,,
7,19,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the A549/ATCC Non-Small Cell Lung cell line,Confirmatory,,
8,21,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the EKVX Non-Small Cell Lung cell line,Confirmatory,,
9,23,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the LOX IMVI Melanoma cell line,Confirmatory,,
10,25,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M14 Melanoma cell line,Confirmatory,,
11,27,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the M19-MEL Melanoma cell line,Confirmatory,,
12,29,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MALME-3M Melanoma cell line,Confirmatory,,
13,31,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-62 Melanoma cell line,Confirmatory,,
14,33,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UACC-257 Melanoma cell line,Confirmatory,,
15,35,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-2 Melanoma cell line,Confirmatory,,
16,37,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line,Confirmatory,,
17,39,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-28 Melanoma cell line,Confirmatory,,
18,45,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-268 Central Nervous System cell line,Confirmatory,,
19,47,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-295 Central Nervous System cell line,Confirmatory,,
20,49,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line,Confirmatory,,
21,51,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the XF 498 Central Nervous System cell line,Confirmatory,,
22,53,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-19 Central Nervous System cell line,Confirmatory,,
23,55,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-75 Central Nervous System cell line,Confirmatory,,
24,57,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SNB-78 Central Nervous System cell line,Confirmatory,,
25,59,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the U251 Central Nervous System cell line,Confirmatory,,
26,63,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DMS 114 Small Cell Lung cell line,Confirmatory,,
27,65,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HT29 Colon cell line,Confirmatory,,
28,67,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the COLO 205 Colon cell line,Confirmatory,,
29,69,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the DLD-1 Colon cell line,Confirmatory,,
30,71,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-15 Colon cell line,Confirmatory,,
31,73,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM12 Colon cell line,Confirmatory,,
32,75,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the KM20L2 Colon cell line,Confirmatory,,
33,79,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HCT-116 Colon cell line,Confirmatory,,
34,81,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SW-620 Colon cell line,Confirmatory,,
35,99,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-3 Ovarian cell line,Confirmatory,,
36,101,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the IGROV1 Ovarian cell line,Confirmatory,,
37,103,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SK-OV-3 Ovarian cell line,Confirmatory,,
38,105,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-4 Ovarian cell line,Confirmatory,,
39,107,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-5 Ovarian cell line,Confirmatory,,
40,109,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the OVCAR-8 Ovarian cell line,Confirmatory,,
41,113,1,1,,92119,5743,Unspecified,,,,,NCI human tumor cell line growth inhibition assay. Data for the RPMI-8226 Leukemia cell line,Confirmatory,,
42,115,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the SR Leukemia cell line,Confirmatory,,
43,119,1,1,,92119,5743,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the CCRF-CEM Leukemia cell line,Confirmatory,,
44,121,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the K-562 Leukemia cell line,Confirmatory,,
45,123,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the MOLT-4 Leukemia cell line,Confirmatory,,
46,125,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the HL-60(TB) Leukemia cell line,Confirmatory,,
47,131,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the CAKI-1 Renal cell line,Confirmatory,,
48,137,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the 786-0 Renal cell line,Confirmatory,,
49,139,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line,Confirmatory,,
50,141,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the TK-10 Renal cell line,Confirmatory,,
51,143,1,1,,92119,5743,Inactive,,,,,NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line,Confirmatory,,
52,145,1,1,,92119,5743,Active,,,,,NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line,Confirmatory,,
53,155,1,1,,92119,5743,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
54,157,1,1,,92119,5743,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
55,161,1,1,,92119,5743,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
56,165,1,1,,92119,5743,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
57,167,1,1,,92119,5743,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
58,175,1,1,,92119,5743,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
59,179,1,1,,92119,5743,Inactive,,,,,NCI AIDS Antiviral Assay,Confirmatory,,
60,180,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Adenocarcinoma 755 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
61,190,1,1,,92119,5743,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Lymphoma AKR (Transplanted) (intraperitoneal) in AKR/Lw mice,Other,,
62,192,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
63,196,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intracerebral) in B6D2F1 (BDF1) mice,Other,,
64,200,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
65,206,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
66,208,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
67,212,1,1,,92119,5743,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
68,220,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
69,248,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
70,256,1,1,,92119,5743,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
71,264,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
72,268,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P1798 Lymphosarcoma (subcutaneous) in CD2F1 (CDF1) mice,Other,,
73,296,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
74,328,1,1,,92119,5743,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
75,330,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
76,342,1,1,,92119,5743,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Sarcoma 180 (subcutaneous) in Swiss mice,Other,,
77,421,1,3,,17389945,5743,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
78,426,1,2,,17389945,5743,Inactive,,,,,Cell Viability - Jurkat,Confirmatory,,
79,427,1,1,,17389945,5743,Inactive,,,,,Cell Viability - Hek293,Confirmatory,,
80,433,1,1,,17389945,5743,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
81,434,1,2,,17389945,5743,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
82,435,1,2,,17389945,5743,Inactive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
83,445,3,1,,17389945,5743,Inconclusive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
84,530,1,1,,17389945,5743,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
85,540,1,1,,17389945,5743,Inactive,,,,,Cell Viability - N2a,Confirmatory,,
86,541,1,1,,17389945,5743,Inconclusive,,,,,Cell Viability - NIH 3T3,Confirmatory,,
87,542,1,1,,17389945,5743,Inactive,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
88,543,1,1,,17389945,5743,Inactive,,,,,Cell Viability - H-4-II-E,Confirmatory,,
89,544,2,1,,17389945,5743,Inactive,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
90,545,1,1,,17389945,5743,Inactive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
91,546,1,1,,17389945,5743,Inactive,,,,,Cell Viability - Mesenchymal,Confirmatory,,
92,584,1,3,,17389945,5743,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
93,585,1,4,,17389945,5743,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
94,595,1,3,,17389945,5743,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
95,596,1,2,,17389945,5743,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
96,603,1,2,,17389945,5743,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
97,605,1,2,,17389945,5743,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
98,654,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
99,655,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
100,656,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
101,657,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
102,658,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
103,659,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
104,660,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
105,661,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
106,662,1,1,,17389945,5743,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
107,663,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
108,664,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
109,665,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
110,666,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
111,667,1,1,,17389945,5743,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
112,875,1,2,,17389945,5743,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
113,880,2,1,,17389945,5743,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
114,880,2,1,,17389945,5743,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
115,880,2,1,,26752876,5743,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
116,880,2,1,,26752876,5743,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
117,881,2,2,,17389945,5743,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
118,884,1,2,,17389945,5743,Inconclusive,13435386.0,1576.0,31.6228,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
119,885,1,2,,17389945,5743,Inactive,13435386.0,1576.0,31.6228,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
120,886,1,2,,17389945,5743,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
121,886,1,2,,17389945,5743,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
122,887,1,2,,17389945,5743,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
123,889,1,3,,17389945,5743,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
124,892,1,2,,17389945,5743,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
125,893,1,2,,17389945,5743,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
126,893,1,2,,17389945,5743,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
127,894,2,1,,17389945,5743,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
128,900,1,3,,17389945,5743,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
129,902,1,2,,17389945,5743,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
130,912,1,2,,17389945,5743,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
131,921,1,2,,17389945,5743,Inconclusive,,,0.0251,Potency,Cell Viability - LYMP2-001,Confirmatory,,
132,923,1,2,,17389945,5743,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
133,924,1,2,,17389945,5743,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
134,925,1,2,,17389945,5743,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
135,926,1,2,,17389945,5743,Inconclusive,38016895.0,7253.0,0.0126,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
136,938,1,2,,17389945,5743,Inactive,38016895.0,7253.0,0.0126,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
137,946,1,2,,17389945,5743,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
138,947,1,2,,17389945,5743,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
139,948,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
140,955,1,2,,17389945,5743,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
141,960,1,2,,17389945,5743,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
142,961,1,2,,17389945,5743,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
143,962,1,2,,17389945,5743,Inactive,,,,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
144,963,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
145,964,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
146,965,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-003,Confirmatory,,
147,966,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-004,Confirmatory,,
148,967,1,2,,17389945,5743,Inconclusive,,,31.6228,Potency,Cell Viability - LYMP2-005,Confirmatory,,
149,968,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-009,Confirmatory,,
150,969,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-011,Confirmatory,,
151,970,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-013,Confirmatory,,
152,971,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-015,Confirmatory,,
153,972,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-017,Confirmatory,,
154,973,1,2,,17389945,5743,Inconclusive,,,0.0126,Potency,Cell Viability - LYMP2-019,Confirmatory,,
155,974,1,2,,17389945,5743,Inconclusive,,,0.005,Potency,Cell Viability - LYMP2-021,Confirmatory,,
156,975,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
157,976,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
158,977,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-002,Confirmatory,,
159,978,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-006,Confirmatory,,
160,979,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-007,Confirmatory,,
161,980,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-008,Confirmatory,,
162,981,1,2,,17389945,5743,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-010,Confirmatory,,
163,982,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-012,Confirmatory,,
164,983,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
165,984,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
166,985,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-018,Confirmatory,,
167,986,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-020,Confirmatory,,
168,987,1,2,,17389945,5743,Inconclusive,,,0.01,Potency,Cell Viability - LYMP2-022,Confirmatory,,
169,988,1,2,,17389945,5743,Inconclusive,,,0.02,Potency,Cell Viability - LYMP2-024,Confirmatory,,
170,989,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
171,993,1,2,,17389945,5743,Inactive,,,,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
172,994,1,2,,17389945,5743,Inconclusive,,,0.0251,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
173,995,1,2,,17389945,5743,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
174,1030,2,1,,17389945,5743,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
175,1030,2,1,,26752876,5743,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
176,1189,1,5,,48413526,5743,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
177,1195,1,2,,48415859,5743,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
178,1204,1,2,,48421979,5743,Inactive,,,,,DSSTox (NCTRER) National Center for Toxicological Research Estrogen Receptor Binding Database,Screening,,
179,1208,1,3,,48413526,5743,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
180,1452,1,1,,17389945,5743,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
181,1457,1,1,,17389945,5743,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
182,1457,1,1,,26752876,5743,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
183,1458,1,1,,17389945,5743,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
184,1458,1,1,,26752876,5743,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
185,1460,1,3,,26752876,5743,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
186,1463,1,1,,26752876,5743,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
187,1468,1,1,,26752876,5743,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
188,1469,1,1,,17389945,5743,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
189,1469,1,1,,26752876,5743,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
190,1469,1,1,,26752877,5743,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
191,1469,1,1,,26752878,5743,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
192,1471,2,1,,17389945,5743,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
193,1471,2,1,,26752876,5743,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
194,1476,2,1,,17389945,5743,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
195,1477,1,1,,17389945,5743,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
196,1477,1,1,,26752876,5743,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
197,1477,1,1,,26752877,5743,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
198,1478,2,1,,17389945,5743,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
199,1479,1,2,,17389945,5743,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
200,1479,1,2,,26752876,5743,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
201,1479,1,2,,26752877,5743,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
202,1479,1,2,,26752878,5743,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
203,1490,2,1,,26752876,5743,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
204,1490,2,1,,26752877,5743,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
205,1511,1,3,,56320685,5743,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
206,1554,1,1,,56320685,5743,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
207,1662,1,2,,56320685,5743,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
208,1663,1,2,,56320685,5743,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
209,1672,1,3,,56320685,5743,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
210,1766,1,1,,26752877,5743,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
211,1766,1,1,,26752877,5743,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
212,1768,1,1,,26752877,5743,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
213,1768,1,1,,26752877,5743,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
214,1813,1,2,,56320685,5743,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
215,1814,1,2,,56320685,5743,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
216,1832,2,1,,56320685,5743,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
217,1850,2,1,,56320685,5743,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
218,1863,2,1,,56320685,5743,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
219,1865,1,1,,26752876,5743,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
220,1875,2,1,,56320685,5743,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
221,1885,2,1,,56320685,5743,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
222,1899,1,3,,56320685,5743,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
223,1903,2,3,,56320685,5743,Inactive,297591903.0,29031019.0,,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
224,1906,1,3,,56320685,5743,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
225,1910,1,2,,56320685,5743,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
226,1947,1,2,,56320685,5743,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
227,1948,1,1,,17389945,5743,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
228,1950,1,3,,56320685,5743,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
229,1962,1,2,,56320685,5743,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
230,1974,1,2,,56320685,5743,Inactive,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
231,1979,1,1,,56320685,5743,Inactive,994798.0,,,,Fluorescence Cell-Based Primary HTS of C.albicans growth in the presence of Fluconazole and compound,Screening,,
232,1987,1,2,,56314873,5743,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
233,1987,1,2,,56320685,5743,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
234,2016,1,3,,56314873,5743,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
235,2016,1,3,,56320685,5743,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
236,2023,1,3,,56314873,5743,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
237,2023,1,3,,56320685,5743,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
238,2025,1,3,,56314873,5743,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
239,2025,1,3,,56320685,5743,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
240,2029,1,3,,56314873,5743,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
241,2029,1,3,,56320685,5743,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
242,2052,2,1,,56314873,5743,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
243,2052,2,1,,56320685,5743,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
244,2057,1,2,,56314873,5743,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
245,2057,1,2,,56320685,5743,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
246,2066,1,4,,56314873,5743,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
247,2066,1,4,,56320685,5743,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
248,2094,1,2,,56320685,5743,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
249,2094,1,2,,56320685,5743,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
250,2094,1,2,,56320685,5743,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
251,2097,1,2,,56320685,5743,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
252,2098,1,1,,56320685,5743,Active,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
253,2099,1,1,,56314873,5743,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
254,2099,1,1,,56320685,5743,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
255,2101,1,1,,17389945,5743,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
256,2101,1,1,,26752876,5743,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
257,2101,1,1,,26752877,5743,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
258,2101,1,1,,56320685,5743,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
259,2107,1,1,,17389945,5743,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
260,2107,1,1,,26752876,5743,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
261,2107,1,1,,26752877,5743,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
262,2112,1,1,,17389945,5743,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
263,2112,1,1,,26752876,5743,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
264,2112,1,1,,26752877,5743,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
265,2120,1,1,,17389945,5743,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
266,2129,1,2,,56314873,5743,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
267,2129,1,2,,56320685,5743,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
268,2130,1,3,,56314873,5743,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
269,2130,1,3,,56320685,5743,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
270,2156,2,2,,56320685,5743,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
271,2174,1,3,,56314873,5743,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
272,2174,1,3,,56320685,5743,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
273,2177,1,3,,56314873,5743,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
274,2177,1,3,,56320685,5743,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
275,2216,1,3,,56320685,5743,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
276,2221,1,2,,56320685,5743,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
277,2227,1,2,,56320685,5743,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
278,2234,1,2,,56314873,5743,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
279,2234,1,2,,56320685,5743,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
280,2235,1,2,,56314873,5743,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
281,2235,1,2,,56320685,5743,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
282,2237,1,2,,56320685,5743,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
283,2239,1,2,,56320685,5743,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
284,2240,1,1,,85787759,5743,Inactive,38156699.0,4286.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of MITF,Screening,,
285,2241,1,1,,85787759,5743,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1,Screening,,
286,2247,1,2,,56320685,5743,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
287,2275,1,1,,85787759,5743,Inactive,,,,,Luminescence Cell-Based Primary HTS to Measure Viability of BJeLR cells,Screening,,
288,2280,2,3,,56314873,5743,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
289,2280,2,3,,56320685,5743,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
290,2300,1,3,,56314873,5743,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
291,2300,1,3,,56320685,5743,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
292,2313,1,1,,85787759,5743,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of the Sonic Hedgehog Signaling Pathway,Screening,,
293,2314,1,2,,26752877,5743,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
294,2314,1,2,,26752877,5743,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
295,2315,1,2,,26752877,5743,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
296,2315,1,2,,26752877,5743,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
297,2316,1,1,,85787759,5743,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Activators of the Reversal of PD-1 Mediated Inhibitors of T-Cell Inhibition,Screening,,
298,2322,1,1,,85787759,5743,Inactive,,,,,Luminescence Homogenous Primary HTS to Identify Inhibitors of STK33 Activity,Screening,,
299,2330,1,1,,85787759,5743,Inactive,12830367.0,65975.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33,Screening,,
300,2380,1,2,,56314873,5743,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
301,2380,1,2,,56320685,5743,Inactive,,,,,uHTS identification of small molecules that induce b-cell replication in the MIN-6 cell line,Screening,,
302,2382,1,1,,56320685,5743,Inconclusive,62740231.0,15499.0,,EC50,Luminescence Cell-Based  Dose Confimation HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1),Confirmatory,,
303,2391,1,1,,56314873,5743,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
304,2391,1,1,,56320685,5743,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
305,2435,1,2,,56314873,5743,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
306,2435,1,2,,56320685,5743,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
307,2445,1,2,,56314873,5743,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
308,2445,1,2,,56320685,5743,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
309,2451,1,2,,26752877,5743,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
310,2462,1,1,,56314873,5743,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
311,2462,1,1,,56314873,5743,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
312,2462,1,1,,56320685,5743,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
313,2462,1,1,,56320685,5743,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
314,2472,1,2,,26752877,5743,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
315,2517,2,1,,17389945,5743,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
316,2517,2,1,,26752876,5743,Inactive,6980812.0,,5.6234,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
317,2517,2,1,,26752877,5743,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
318,2517,2,1,,56314873,5743,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
319,2517,2,1,,56320685,5743,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
320,2520,1,4,,56314873,5743,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
321,2520,1,4,,56320685,5743,Inactive,4885057.0,187.0,,,uHTS identification of small molecule agonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
322,2521,1,3,,56314873,5743,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
323,2521,1,3,,56320685,5743,Inactive,4885057.0,187.0,,,uHTS identification of small molecule antagonists of the APJ  receptor  via a luminescent beta-arrestin assay,Screening,,
324,2524,1,2,,56314873,5743,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
325,2524,1,2,,56320685,5743,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase,Screening,,
326,2528,1,2,,26752877,5743,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
327,2540,1,2,,56314873,5743,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
328,2540,1,2,,56320685,5743,Inactive,262118306.0,123228.0,,,HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8),Screening,,
329,2544,1,2,,56314873,5743,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
330,2544,1,2,,56320685,5743,Inactive,124376142.0,248.0,,,uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase,Screening,,
331,2546,1,1,,17389945,5743,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
332,2546,1,1,,26752877,5743,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
333,2549,1,1,,17389945,5743,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
334,2549,1,1,,26752876,5743,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
335,2549,1,1,,26752877,5743,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
336,2550,1,3,,56320685,5743,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
337,2551,1,1,,17389945,5743,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
338,2551,1,1,,26752877,5743,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
339,2553,1,2,,56320685,5743,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
340,2557,1,3,,56314873,5743,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
341,2557,1,3,,56320685,5743,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
342,2563,1,1,,56320685,5743,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
343,2599,1,2,,56314873,5743,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
344,2599,1,2,,56320685,5743,Inactive,6166485.0,26054.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6),Screening,,
345,2606,1,2,,56314873,5743,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
346,2606,1,2,,56320685,5743,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
347,2629,1,1,,56314873,5743,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
348,2629,1,1,,56320685,5743,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
349,2642,1,2,,56320685,5743,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
350,2648,1,2,,56320685,5743,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
351,2650,2,1,,56314873,5743,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
352,2650,2,1,,56320685,5743,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
353,2661,1,1,,56314873,5743,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
354,2661,1,1,,56320685,5743,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
355,2676,1,2,,56314873,5743,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
356,2676,1,2,,56320685,5743,Inactive,85986601.0,59350.0,,Potency,qHTS Assay for Agonists of the Relaxin Receptor RXFP1,Confirmatory,,
357,2685,1,1,,56314873,5743,Inconclusive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
358,2685,1,1,,56320685,5743,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators in Drosophila S3 Cells,Confirmatory,,
359,2690,1,2,,56314873,5743,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
360,2690,1,2,,56320685,5743,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
361,2716,1,1,,56314873,5743,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
362,2716,1,1,,56320685,5743,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
363,2717,1,2,,56314873,5743,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
364,2717,1,2,,56320685,5743,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
365,2718,1,1,,56314873,5743,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
366,2718,1,1,,56320685,5743,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
367,2751,2,2,,56314873,5743,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
368,2751,2,2,,56320685,5743,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
369,2796,1,4,,56314873,5743,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
370,2796,1,4,,56320685,5743,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
371,2797,1,2,,56314873,5743,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
372,2797,1,2,,56320685,5743,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
373,2805,2,2,,56314873,5743,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
374,2805,2,2,,56320685,5743,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase,Screening,,
375,2806,2,2,,56314873,5743,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
376,2806,2,2,,56320685,5743,Inactive,124487323.0,76768.0,,,uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase,Screening,,
377,2825,1,2,,56314873,5743,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
378,2825,1,2,,56320685,5743,Inactive,219518789.0,114548.0,,,uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast,Screening,,
379,6808,9,5,,104234229,5743,Unspecified,729945.0,25290.0,25.0,IC50,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,Confirmatory,,
380,7077,9,3,,104234229,5743,Unspecified,,,120.0,IC50,Tested for its inhibitory activity against 5-lipoxygenase,Confirmatory,,
381,7783,3,4,,104234229,5743,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
382,8002,5,2,,104234229,5743,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
383,19262,5,1,,104234229,5743,Unspecified,,,,,Aqueous solubility,Other,10866370.0,
384,19419,3,4,,104234229,5743,Unspecified,,,,,Partition coefficient (logD7.4),Other,9544199.0,
385,19424,3,4,,104234229,5743,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
386,19427,3,3,,104234229,5743,Unspecified,,,,,HPLC capacity factor (k),Other,10956200.0,
387,19468,3,3,,104234229,5743,Unspecified,,,,,Partition coefficient (logP),Other,12699389.0,
388,20050,3,3,,104234229,5743,Unspecified,,,,,Human absorption A (%),Other,9544199.0,
389,22293,4,4,,104234229,5743,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
390,23672,3,3,,104234229,5743,Unspecified,,,,,Partition coefficient (logP),Other,7381857.0,
391,24428,3,3,,104234229,5743,Unspecified,,,,,Partition coefficient (logP),Other,3965714.0,
392,24434,3,5,,104234229,5743,Inconclusive,,,,,Partition coefficient is determined in octanol/buffer solution at pH; NT=Not tested,Other,12039573.0,
393,26304,4,4,,104234229,5743,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
394,26380,3,3,,104234229,5743,Inconclusive,,,,,Dissociation constant (pKa),Other,14971904.0,
395,27580,3,3,,104234229,5743,Unspecified,,,,,Partition coefficient (logP),Other,10956200.0,
396,28233,3,3,,104234229,5743,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
397,28235,3,3,,104234229,5743,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
398,28236,3,3,,104234229,5743,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
399,29360,4,3,,104234229,5743,Inconclusive,,,,,Ionization constant (pKa),Other,10891117.0,
400,29421,3,3,,104234229,5743,Unspecified,,,,,Partition coefficient (logP) (HPLC),Other,10956200.0,
401,29423,3,4,,104234229,5743,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
402,29811,4,3,,104234229,5743,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
403,29925,5,2,,104234229,5743,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
404,32842,3,7,,104234229,5743,Unspecified,,,,,Relative transcriptional activation in HeLa cells expressing glucocorticoid receptor,Other,12431067.0,
405,39012,8,8,,104234229,5743,Inconclusive,1018618719.0,367.0,,,Binding affinity for human Androgen receptor; ND = Not determined,Other,8627601.0,
406,39320,4,7,,104234229,5743,Unspecified,,,,,Relative binding affinity for androgen receptor of prostate of rat at 2 hr,Other,2897467.0,
407,50906,4,8,,104234229,5743,Unspecified,341941191.0,12355.0,,,Inhibition of mouse constitutive androstane receptor (mCAR) activity at 10 uM was determined as percent remaining activity,Other,14561088.0,
408,54923,6,5,,104234229,5743,Unspecified,,,50.0,IC50,Inhibition of human cytochrome P450 3A4,Confirmatory,12699389.0,
409,68901,8,4,,104234229,5743,Inconclusive,,,,,Binding affinity determined for human estrogen receptor; ND = Not determined,Other,8627601.0,
410,74220,7,2,,104234229,5743,Active,,,0.0055,Ki,Binding affinity was determined for human glucocorticoid receptor(hGR).,Confirmatory,8627601.0,
411,74244,3,7,,104234229,5743,Unspecified,,,,,Displacement of [3H]dexamethasone from Glucocorticoid receptor of rabbit kidney,Other,8360885.0,
412,74246,3,11,,104234229,5743,Unspecified,1169883.0,24413.0,,,Relative binding affinity against glucocorticoid receptor in rat liver cytosol extract,Other,8164266.0,
413,74373,4,6,,104234229,5743,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 24 hr,Other,2897467.0,
414,74374,4,6,,104234229,5743,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from hepatoma tissue cells at 4 hr,Other,2897467.0,
415,74375,4,6,,104234229,5743,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from liver at 24 hr,Other,2897467.0,
416,74376,4,6,,104234229,5743,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from liver at 4 hr,Other,2897467.0,
417,74377,4,7,,104234229,5743,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 24 hr,Other,2897467.0,
418,74378,4,7,,104234229,5743,Unspecified,,,,,Relative binding affinity to glucocorticoid receptor on cytosol from thymus at 4 hr,Other,2897467.0,
419,74386,4,7,,104234229,5743,Unspecified,,,,,Relative binding affinity against glucocorticoid receptor.,Other,8230118.0,
420,78478,3,4,,104234229,5743,Unspecified,,,,,Binding to guinea pig atrial homogenate,Other,7381857.0,
421,90104,5,1,,104234229,5743,Unspecified,,,,,"Potency relative to fluocinolone 16,17-acetonide in the human vasoconstictor test",Other,6827553.0,
422,91224,4,3,,104234229,5743,Inactive,,,,,Antiinflammatory activity measured by using McKenzie-Stoughton human vasoconstrictor assay,Other,3783574.0,
423,91480,3,8,,104234229,5743,Unspecified,,,,,Ability to bind to human serum albumin (HSA),Other,7381857.0,
424,91778,6,2,,104234229,5743,Unspecified,,,169.5,IC50,Inhibitory activity against nitric oxide production in lipopolysaccharide (LPS)-activated macrophage -like J774.1 cell,Confirmatory,12467611.0,
425,107280,3,4,,104234229,5743,Unspecified,,,,,Compound was administered orally to mice before increase in foot-pad thickness at a dose of 2.5 mg/kg,Other,3494125.0,
426,117871,3,3,,104234229,5743,Unspecified,,,,,Percent reduction in mice after oral administration 2.5 mg/kg,Other,3494125.0,
427,122891,6,2,,104234229,5743,Active,,,0.0047,IC50,Compound was evaluated for IL 4 production inhibition from mice splenocytes stimulated by anti-CD3 mAb,Confirmatory,10052971.0,
428,122892,6,2,,104234229,5743,Active,,,0.0035,IC50,Compound was evaluated for IL 5 production inhibitio from mice splenocytes stimulated by anti-CD3 mAb,Confirmatory,10052971.0,
429,126285,3,7,,104234229,5743,Unspecified,,,,,Displacement of [3H]aldosterone from mineralocorticoid receptor of rabbit kidney,Other,8360885.0,
430,126435,4,7,,104234229,5743,Unspecified,,,,,Relative binding affinity for mineralocorticoid receptor of rat kidney at 24 hr,Other,2897467.0,
431,131935,3,3,,104234229,5743,Unspecified,,,,,Tested for its antiinflammatory activity in the A-23187 (calcium ionophore) ear edema model.,Other,,
432,131937,3,3,,104234229,5743,Unspecified,,,,,Tested for its antiinflammatory activity in the arachidonic acid(AA) induced ear edema model,Other,,
433,131938,3,3,,104234229,5743,Unspecified,,,,,Tested for its antiinflammatory activity in the contact sensitive (CS) ear edema model,Other,,
434,131941,4,3,,104234229,5743,Inconclusive,,,,,Tested for its antiinflammatory activity in the tetradecanoyl phorbol acetate induced ear edema model (TPA Ear); ND: not determined,Other,,
435,132323,6,2,,104234229,5743,Active,,,1.0,IC50,Ability to inhibit the accumulation of PGE-2 in stimulated murine peritoneal macrophages,Confirmatory,10579834.0,
436,132324,6,2,,104234229,5743,Active,,,35.8,IC50,Ability to inhibit the generation of NO by stimulated murine peritoneal macrophages,Confirmatory,10579834.0,
437,132692,6,2,,104234229,5743,Active,,,0.0001,IC50,Inhibitory activity against production of nitric oxide induced by interferon-gamma in mouse macrophages,Confirmatory,10617085.0,
438,134687,3,3,,104234229,5743,Unspecified,,,,,In vivo antiinflammatory activity of 0.04 uM concentration of compound was determined by inhibition of oxazolone-induced allergic contact dermatitis (ACD) in mouse up on tropical application,Other,15125973.0,
439,134690,3,3,,104234229,5743,Unspecified,,,,,In vivo antiinflammatory activity of 0.4 uM concentration of compound was determined by inhibition of oxazolone-induced allergic contact dermatitis (ACD) in mouse up on tropical application,Other,15125973.0,
440,134693,3,3,,104234229,5743,Unspecified,,,,,In vivo antiinflammatory activity of 40 uM concentration of compound was determined by inhibition of oxazolone-induced allergic contact dermatitis (ACD) in mouse up on tropical application,Other,15125973.0,
441,134695,3,3,,104234229,5743,Unspecified,,,,,In vivo antiinflammatory activity of compound was determined by inhibition of oxazolone-induced allergic contact dermatitis (ACD) in mouse up on tropical application,Other,15125973.0,
442,140447,5,2,,104234229,5743,Active,,,0.0001,IC50,Inhibitory activity against production of nitric oxide induced by interferon gamma in mouse macrophages,Confirmatory,11909709.0,
443,144364,6,2,,104234229,5743,Active,,,0.07400000000000001,IC50,Inhibitory activity against TNF-alpha release in N9 cells in the supernatant,Confirmatory,12361395.0,
444,150751,7,1,,104234229,5743,Unspecified,,,,,Inhibition of P-glycoprotein using ATPase in MDR1 membranes,Other,12699389.0,
445,150752,6,3,,104234229,5743,Unspecified,,,50.0,IC50,"Inhibition of P-glycoprotein, human L-MDR1 expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
446,150753,6,3,,104234229,5743,Unspecified,,,50.0,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1a expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
447,150754,6,3,,104234229,5743,Unspecified,,,50.0,IC50,"Inhibition of P-glycoprotein, mouse L-mdr1b expressed in LLC-PK1 epithelial cells using calcein-AM polarisation assay",Confirmatory,12699389.0,
448,150755,6,3,,104234229,5743,Unspecified,,,50.0,IC50,Inhibition of P-glycoprotein using calcein-AM assay transfected in porcine PBCEC,Confirmatory,12699389.0,
449,150756,3,7,,104234229,5743,Unspecified,,,,,Inhibition of P-gp was determined using rhodamine-assay in human CaCo-2 cells,Other,12699389.0,
450,150757,3,7,,104234229,5743,Unspecified,,,,,"P-gp activity was measured by a direct transport assay, using polarized LLC-MDR1 epithelial cells",Other,12699389.0,
451,150758,3,7,,104234229,5743,Unspecified,,,,,"P-gp activity was measured by a direct transport assay, using polarized LLC-PK1 epithelial cells",Other,12699389.0,
452,150759,3,7,,104234229,5743,Unspecified,,,,,"P-gp activity was measured by a direct transport assay, using polarized LLC-mdr1a epithelial cells",Other,12699389.0,
453,152781,6,2,,104234229,5743,Active,,,0.01,IC50,Inhibitory concentration against TNF-alpha production from human peripheral blood mononuclear cells stimulated by LPS,Confirmatory,11229767.0,
454,152782,6,2,,104234229,5743,Active,,,0.04,IC50,Inhibitory concentration against growth of LPS stimulated human peripheral blood mononuclear cells,Confirmatory,11229767.0,
455,159080,9,3,,104234229,5743,Unspecified,,,750.0,IC50,Tested for its inhibitory activity against Phospholipase A2 (PLA2),Confirmatory,,
456,159248,10,5,,104234229,5743,Unspecified,129416.0,29526.0,750.0,IC50,Inhibitory activity against polymorphonuclear cell phospholipase-A2 in rat,Confirmatory,,
457,159548,3,3,,104234229,5743,Unspecified,,,,,In vivo antiinflammatory activity of 130 uM concentration of compound was determined by inhibition of oxazolone-induced allergic contact dermatitis (ACD) in pig up on tropical application,Other,15125973.0,
458,159550,3,3,,104234229,5743,Unspecified,,,,,In vivo antiinflammatory activity of 40 uM concentration of compound was determined by inhibition of oxazolone-induced allergic contact dermatitis (ACD) in pig up on tropical application,Other,15125973.0,
459,159551,3,3,,104234229,5743,Unspecified,,,,,In vivo antiinflammatory activity of 400 uM concentration of compound was determined by inhibition of oxazolone-induced allergic contact dermatitis (ACD) in pig up on tropical application,Other,15125973.0,
460,160896,8,8,,104234229,5743,Inconclusive,3914301.0,282023.0,,,Tested for its inhibitory activity against PGS (prostaglandin synthetase); Not determined,Other,,
461,160896,8,8,,104234229,5743,Inconclusive,166897622.0,282022.0,,,Tested for its inhibitory activity against PGS (prostaglandin synthetase); Not determined,Other,,
462,160908,9,5,,104234229,5743,Unspecified,3914304.0,443460.0,25.0,IC50,Inhibition of ovine seminal vesicle prostaglandin synthetase,Confirmatory,,
463,160908,9,5,,104234229,5743,Unspecified,754286265.0,443551.0,25.0,IC50,Inhibition of ovine seminal vesicle prostaglandin synthetase,Confirmatory,,
464,162590,8,8,,104234229,5743,Inconclusive,90110048.0,5241.0,,,Binding affinity for human Progesterone receptor A isoform; ND = Not determined,Other,8627601.0,
465,162613,4,8,,104234229,5743,Unspecified,,,,,Relative binding affinity for progestin receptor of uterus of rabbit at 24 hr,Other,2897467.0,
466,166393,6,2,,104234229,5743,Active,,,0.42,IC50,Inhibitory activity against TNF-alpha release in RAW 264.7 cells in the supernatant,Confirmatory,12361395.0,
467,177034,5,1,,104234229,5743,Unspecified,,,,,Compound was tested for its oral antiinflammatory activity in the rat carrageenan paw edema assay (CAR),Other,,
468,177814,6,2,,104234229,5743,Unspecified,,,,,Compound was evaluated in vivo for the inhibition of LPS-stimulated serum TNF-alpha production in rat after oral administration of the compound,Other,12039573.0,
469,179054,6,2,,104234229,5743,Active,,,0.02,IC50,In vitro inhibition of lipopolysaccharide stimulated tumor necrosis factor-alpha production in rat whole blood,Confirmatory,12039573.0,
470,181693,6,3,,104234229,5743,Active,,,0.02,IC50,Evaluated for its ability to inhibit LPS stimulated production of TNF-alpha in rat whole blood,Confirmatory,12113803.0,
471,185435,3,3,,104234229,5743,Unspecified,,,,,Percent inhibition value on the Sephadex-induced lung eosinophilia model at an intraperitoneal (ip) dose of 0.1 mg/kg,Other,9685237.0,
472,185788,3,3,,104234229,5743,Unspecified,,,,,Percentage inhibition of Carrageenan-induced rat paw edema at a concentration of 0.3 mg/kg,Other,6094808.0,
473,186124,4,3,,104234229,5743,Unspecified,,,,,"Radiographic change was judged in the area of the talus joint, using an arbitrary scoring system upon termination of the test (0.5 mg/kg 1-5 days dosing,0.25 mg/kg 6-15 days dosing)in a model of type II collagen arthritis in the rat.",Other,1995900.0,
474,186288,6,2,,104234229,5743,Inconclusive,,,,,"TNF-alpha inhibiting activity was assessed by In vivo inhibition of serum TNF production in rat at 50 mg/kg, peroral administration; Not tested ( ED50= 0.12 mg/kg, po)",Other,12113803.0,
475,187585,3,3,,104234229,5743,Unspecified,,,,,Recovery of steroid from cecum at 3h after administration of 7.5 mg of the compound,Other,6699871.0,
476,187586,3,3,,104234229,5743,Unspecified,,,,,Recovery of steroid from cecum at 4 hr after administration of 7.5 mg of the compound,Other,6699871.0,
477,187587,3,3,,104234229,5743,Unspecified,,,,,Recovery of steroid from cecum at 5 hr after administration of 7.5 mg of the compound,Other,6699871.0,
478,187588,3,3,,104234229,5743,Unspecified,,,,,Recovery of steroid from cecum at 6 hr after administration of 7.5 mg of the compound,Other,6699871.0,
479,187589,3,4,,104234229,5743,Unspecified,,,,,Recovery of steroid from small intestine at 3h after administration of 7.5 mg of the compound,Other,6699871.0,
480,187590,3,4,,104234229,5743,Unspecified,,,,,Recovery of steroid from small intestine at 4 hr after administration of 7.5 mg of the compound,Other,6699871.0,
481,187591,3,4,,104234229,5743,Unspecified,,,,,Recovery of steroid from small intestine at 5 hr after administration of 7.5 mg of the compound,Other,6699871.0,
482,187592,3,4,,104234229,5743,Unspecified,,,,,Recovery of steroid from small intestine at 6 hr after administration of 7.5 mg of the compound,Other,6699871.0,
483,188016,4,1,,104234229,5743,Unspecified,,,,,"Anti-inflammatory effect in rat granuloma assay, activity relative to hydrocortisone and hydrocortisone 21-acetate",Other,6827553.0,
484,194295,5,2,,104234229,5743,Unspecified,,,,,Tested for sephadex-induced lung Eosinophilia inhibition at 30 mg/kg in rat,Other,8709136.0,
485,205635,3,11,,104234229,5743,Unspecified,1169883.0,24413.0,,,Binding affinity to Steroid Hormone Receptor was determined using [2-3H]dexamethasone as radioligand,Other,7401101.0,
486,209811,6,4,,104234229,5743,Active,,,0.005,IC50,Inhibitory concentration against T cell proliferation using concanavalin A stimulated mice spleen cells,Confirmatory,11229767.0,
487,213396,4,8,,104234229,5743,Unspecified,,,,,Glucocorticoid induced Tyrosine Aminotransferase activity relative to Dexamethasone,Other,2897467.0,
488,215260,3,3,,104234229,5743,Unspecified,,,,,Tested in vivo for inhibition of serum tumor necrosis factor alpha production in rats at 100 ug/kg subcutaneous dose,Other,15109623.0,
489,221922,3,10,,104234229,5743,Unspecified,1169883.0,24413.0,,,Inhibition of [3H]dexamethasone binding to glucocorticoid receptor of rat liver cytosol,Other,12431067.0,
490,224258,6,2,,104234229,5743,Active,,,0.0003,IC50,Compound was evaluated for inhibitory activity against production of nitric oxide (NO) induced by interferon-gamma (IFN-gamma) in mouse macrophages,Confirmatory,9873608.0,
491,224269,6,2,,104234229,5743,Active,,,0.0001,IC50,Inhibition of nitric oxide (NO) production induced by interferon-gamma (IFN-gamma) in mouse macrophages,Confirmatory,11063620.0,
492,225651,3,4,,104234229,5743,Unspecified,,,,,Inhibition of monocyte accumulation (DNA content) in a rat pleural exudate model of inflammation at 45 ug administered perorally,Other,3681891.0,
493,225653,3,4,,104234229,5743,Unspecified,,,,,Inhibition of monocyte accumulation (exudate volume) in a rat pleural exudate model of inflammation at 45 ug administered perorally,Other,3681891.0,
494,227718,7,1,,104234229,5743,Unspecified,,,,,Binding energy by using the equation deltaG obsd = -RT ln KD,Other,6094812.0,
495,243152,7,1,,104234229,5743,Active,,,0.007940000000000001,IC50,Binding affinity for glucocorticoid receptor,Confirmatory,15999989.0,
496,243422,3,10,,104234229,5743,Unspecified,116241312.0,1576.0,,,log (1/Km) value for human liver microsome cytochrome P450 3A4,Other,15990295.0,
497,249546,8,4,,104234229,5743,Unspecified,121069.0,2908.0,,IC50,Glucocorticoid receptor mediated transrepression of NFkB reporter gene in human A549 lung epithelial cells,Confirmatory,15999989.0,
498,249547,8,4,,104234229,5743,Active,121069.0,2908.0,10.0,IC50,Antagonist activity for Glucocorticoid receptor in MMTV transactivation assay in human A549 lung epithelial cells at 10 uM,Confirmatory,15999989.0,
499,251749,3,3,,104234229,5743,Unspecified,,,,,inhibition of acute TPA-induced ear swelling in mice on oral administration of 0.1 nmol/kg,Other,15454241.0,
500,251803,3,3,,104234229,5743,Unspecified,,,,,Percent inhibition of acute TPA-induced ear swelling in mice upon topical application at 2x 100 ug,Other,15454241.0,
501,255211,8,1,,104234229,5743,Unspecified,113832.0,24208.0,81.2831,IC50,Inhibitory concentration against recombinant rat androgen receptor expressed in Escherichia coli using [3H]methyltrienolone (R 1881),Confirmatory,16134935.0,
502,255663,5,6,,104234229,5743,Active,121069.0,2908.0,0.001,EC50,Effective agonist concentration for transcriptional repression of IL-6 production in IL-1 stimulated human foreskin fibroblasts,Confirmatory,16112571.0,
503,256204,3,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Percent efficacy for transcriptional repression of IL-6 production in IL-1 stimulated human foreskin fibroblasts at 2 uM,Other,16112571.0,
504,266763,4,1,,104234229,5743,Unspecified,,,,,Membrane retention in 70% silicon-30% IPM membrane,Other,16789751.0,
505,266764,3,3,,104234229,5743,Unspecified,,,,,"Membrane permeability, CA(t)/CD(0) in 70% silicon-30% IPM membrane",Other,16789751.0,
506,266765,6,1,,104234229,5743,Unspecified,,,,,Effective permeability coefficient in 70% silicon-30% IPM membrane,Other,16789751.0,
507,266771,6,1,,104234229,5743,Unspecified,,,,,Permeability in human skin,Other,16789751.0,
508,267709,3,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Binding affinity to GR relative to Dexamethasone,Other,16644222.0,
509,267710,3,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Stimulatory activity at HeLa cells by alkaline phosphatase bioassay relative to Dexamethasone,Other,16644222.0,
510,267771,9,5,,104234229,5743,Active,121069.0,2908.0,0.007940000000000001,IC50,Inhibition of fluorescent-labeled Dexamethasone binding to GR,Confirmatory,16821781.0,
511,267772,7,6,,104234229,5743,Active,121069.0,2908.0,0.00117,IC50,Agonist activity at GR assessed as NF-kappaB-mediated transrepression of secreted placental alkaline phosphatase gene in human A549 cells,Confirmatory,16821781.0,
512,267773,4,12,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at GR assessed as NF-kappaB-mediated transrepression of secreted placental alkaline phosphatase gene in human A549 cells relative to Dexamethasone,Other,16821781.0,
513,267774,7,6,,104234229,5743,Unspecified,121069.0,2908.0,10.0,IC50,Activity at GR assessed as ability to antagonize dexamethasone-induced MMTV luciferase reporter gene transactivation in human A549 cells,Confirmatory,16821781.0,
514,267775,7,6,,104234229,5743,Unspecified,121069.0,2908.0,,EC50,Agonist activity at GR assessed as MMTV-mediated transactivation of renilla luciferase gene in human A549 cells relative to Dexamethasone,Confirmatory,16821781.0,
515,267776,4,2,,104234229,5743,Unspecified,,,,,Anti-inflammatory activity against oxazolone-induced ear skin delayed types hypersensitivity model in topically dosed BALB/c mouse,Other,16821781.0,
516,268293,3,3,,104234229,5743,Unspecified,,,,,"Reduction of edema in mouse ear inflammation model at 1 mg/kg, po",Other,16697190.0,
517,268301,3,3,,104234229,5743,Unspecified,,,,,Reduction of swelling in mouse ear at 30 ug,Other,16697190.0,
518,274990,7,2,,104234229,5743,Active,,,0.003,IC50,Inhibition of tetramethylrhodamine labeled dexamethasone binding to GR by FP assay,Confirmatory,17181172.0,
519,274991,7,2,,104234229,5743,Unspecified,,,2.0,IC50,Inhibition of tetramethylrhodamine labeled RU486 binding to PR by FP assay,Confirmatory,17181172.0,
520,274992,7,2,,104234229,5743,Active,,,0.033,IC50,Inhibition of tetramethylrhodamine labeled dexamethasone binding to MR by FP assay,Confirmatory,17181172.0,
521,274993,4,4,,104234229,5743,Active,,,0.0005099999999999999,IC50,Inhibition of IL1-stimulated IL6 production in HFF cells,Confirmatory,17181172.0,
522,274995,4,4,,104234229,5743,Active,,,0.0019,EC50,Induction of aromatase activity in HFF cells assessed as production of beta estradiol by aromatase assay,Confirmatory,17181172.0,
523,274997,4,4,,104234229,5743,Active,,,0.017,EC50,Activation of MMTV in HeLa cells measured by luciferase activity,Confirmatory,17181172.0,
524,281280,3,3,,104234229,5743,Active,,,,,"Antiinflammatory activity against carrageenan-induced paw inflammation in golden Syrian hamster at 10 mg/kg, im",Other,17361995.0,
525,281328,4,4,,104234229,5743,Active,,,0.02,IC50,Inhibition of interferon gamma-stimulated NO production in RAW 264.7 cells after 24 hrs,Confirmatory,17367124.0,
526,286319,8,1,,104234229,5743,Unspecified,,,,,Inhibition of PGE2 production in LPS-stimulated mouse RAW264.7 cells at 1 uM after 18 hrs,Other,17407277.0,
527,286321,8,1,,104234229,5743,Unspecified,,,,,Inhibition of PGE2 production in LPS-stimulated mouse RAW264.7 cells at 1 uM after 2 hrs,Other,17407277.0,
528,286323,3,4,,104234229,5743,Active,,,,,Inhibition of mPGES1 expression in LPS-stimulated mouse RAW264.7 cells after 2 hrs by Western blot analysis,Other,17407277.0,
529,286325,3,3,,104234229,5743,Active,,,,,Decrease of mPGES1 expression in zymosan-stimulated Swiss mouse air pouch model after 24 hrs,Other,17407277.0,
530,286326,3,3,,104234229,5743,Active,,,,,Inhibition of COX2 expression in zymosan-stimulated Swiss mouse air pouch model after 24 hrs,Other,17407277.0,
531,286329,3,4,,104234229,5743,Active,,,,,Inhibition of COX2 expression in LPS-stimulated mouse RAW264.7 cells after 2 hrs by Western blot analysis,Other,17407277.0,
532,288184,9,1,,104234229,5743,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
533,288185,7,1,,104234229,5743,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
534,288192,3,4,,104234229,5743,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
535,292548,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of peritoneal cell count in zymosan-induced Swiss mouse peritoneal fluid at 1 mg/kg, po",Other,17608466.0,
536,292549,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of peritoneal granulocyte count in zymosan-induced Swiss mouse peritoneal fluid at 1 mg/kg, po",Other,17608466.0,
537,292550,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of monocyte count in zymosan-induced Swiss mouse peritoneal fluid at 1 mg/kg, po",Other,17608466.0,
538,292551,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of lymphocyte count in zymosan-induced Swiss mouse peritoneal fluid at 1 mg/kg, po",Other,17608466.0,
539,292552,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of granulocyte count in zymosan-induced Swiss mouse peritoneal fluid at 1 mg/kg, po",Other,17608466.0,
540,292895,3,3,,104234229,5743,Unspecified,,,,,"Suppression of lipopolysaccharide-induced TNFalpha release in mouse at 3 mg/kg, po after 30 mins",Other,17095218.0,
541,292897,3,3,,104234229,5743,Inconclusive,,,,,"Suppression of lipopolysaccharide-induced TNFalpha release in mouse at 3 mg/kg, po after 120 mins",Other,17095218.0,
542,292936,3,8,,104234229,5743,Active,341940333.0,12773.0,,,"Inhibition of ovalbumin-induced eosinophil infiltration in BALB/c mouse allergic inflammation model at 5 mg/kg, po",Other,17098428.0,
543,293006,9,5,,104234229,5743,Active,121069.0,2908.0,0.0034,IC50,Inhibition of human GR,Confirmatory,17118655.0,
544,293009,9,5,,104234229,5743,Unspecified,90110048.0,5241.0,2.0,IC50,Inhibition of human PR,Confirmatory,17118655.0,
545,293010,9,5,,104234229,5743,Active,126885.0,4306.0,0.033,IC50,Inhibition of human MR,Confirmatory,17118655.0,
546,297837,5,6,,104234229,5743,Active,121069.0,2908.0,0.0002,EC50,Agonist activity at human GR expressed in CV1 cells by GRE activation assay,Confirmatory,17705362.0,
547,297838,3,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist efficacy at human GR expressed in CV1 cells by GRE activation assay relative to Dexamethasone,Other,17705362.0,
548,297839,8,5,,104234229,5743,Active,121069.0,2908.0,0.0014,IC50,Activity at human GR expressed in NHDFneo cells assessed as inhibition of IL-6 production,Confirmatory,17705362.0,
549,297840,3,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Absolute efficacy at human GR expressed in NHDFneo cells assessed as repression of IL-6 production relative to Dexamethasone,Other,17705362.0,
550,297841,4,4,,104234229,5743,Active,,,0.0065,IC50,Antiproliferative activity against human RPMI8226 cells after 4 days,Confirmatory,17705362.0,
551,297842,3,5,,104234229,5743,Unspecified,,,,,Antiproliferative activity against human RPMI8226 cells after 4 days relative to Dexamethasone,Other,17705362.0,
552,297845,7,2,,104234229,5743,Active,,,0.0021,Ki,Binding affinity to GR,Confirmatory,17705362.0,
553,297847,7,2,,104234229,5743,Active,,,0.0072,Ki,Binding affinity to MR,Confirmatory,17705362.0,
554,300612,7,1,,104234229,5743,Active,,,0.00759,IC50,Binding affinity to glucocorticoid receptor,Confirmatory,17616395.0,
555,300613,8,4,,104234229,5743,Active,121069.0,2908.0,0.001,IC50,Agonist activity at glucocorticoid receptor in human A549 cells by NF-kappaB transrepression assay,Confirmatory,17616395.0,
556,300614,6,1,,104234229,5743,Active,121069.0,2908.0,0.005370000000000001,EC50,Agonist activity at glucocorticoid receptor in human A549 cells by MMTV transactivation assay,Confirmatory,17616395.0,
557,300615,8,4,,104234229,5743,Active,121069.0,2908.0,1.0,IC50,Antagonist activity at glucocorticoid receptor in human A549 cells transfected with MMTV luciferase reporter gene assessed as inhibition of dexamethasone-induced activation,Confirmatory,17616395.0,
558,300618,4,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human A549 cells by NF-kappaB transrepression assay relative to dexamethasone,Other,17616395.0,
559,300619,4,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human A549 cells by MMTV transactivation assay relative to Dexamethasone,Other,17616395.0,
560,300916,8,5,,104234229,5743,Active,121069.0,2908.0,0.003,IC50,Displacement of TAMRA labeled Dexamethasone at human glucocorticoid receptor in insect cell,Confirmatory,17692519.0,
561,300917,8,5,,104234229,5743,Unspecified,90110048.0,5241.0,2.0,IC50,Displacement of TAMRA labeled Dexamethasone at human progesterone receptor in insect cell,Confirmatory,17692519.0,
562,300918,8,5,,104234229,5743,Active,126885.0,4306.0,0.033,IC50,Displacement of TAMRA labeled mifepristone at human mineralocorticoid receptor in insect cell,Confirmatory,17692519.0,
563,300919,4,5,,104234229,5743,Active,,,0.0005,EC50,Antiinflammatory activity assessed as inhibition of IL1 stimulated IL6 production in HFF cells by transrepression assay,Confirmatory,17692519.0,
564,300921,4,5,,104234229,5743,Active,,,0.002,EC50,Antiinflammatory activity assessed as upregulation of aromatase in HFF cells by transactivation assay,Confirmatory,17692519.0,
565,302098,4,4,,104234229,5743,Active,,,0.048,IC50,Inhibition of LPS-induced TNFalpha production in mouse J774A.1 cells,Confirmatory,17892941.0,
566,304379,8,2,,104234229,5743,Active,,,0.007940000000000001,IC50,Displacement of fluorescent labeled Dexamethasone from glucocorticoid receptor,Confirmatory,18038970.0,
567,304380,7,6,,104234229,5743,Active,121069.0,2908.0,0.00117,IC50,Agonist activity at glucocorticoid receptor in human A549 cells by NF-kappaB transrepression assay,Confirmatory,18038970.0,
568,304381,7,6,,104234229,5743,Active,121069.0,2908.0,0.0050100000000000006,EC50,Agonist activity at glucocorticoid receptor in human A549 cells by MMTV transactivation assay,Confirmatory,18038970.0,
569,304382,4,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human A549 cells at 10 mM by NF-kappaB transrepression assay relative to Dexamethasone,Other,18038970.0,
570,304383,4,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human A549 cells at 10 mM by MMTV transactivation assay relative to Dexamethasone,Other,18038970.0,
571,304384,7,6,,104234229,5743,Unspecified,121069.0,2908.0,10.0,IC50,Antagonist activity at glucocorticoid receptor in human A549 cells transfected with MMTV luciferase reporter gene assessed as inhibition of dexamethasone-induced activation,Confirmatory,18038970.0,
572,304385,3,4,,104234229,5743,Active,,,,,Agonist activity at glucocorticoid receptor Q570A mutant in COS7 cells at 1 uM by NF-kappaB-luciferase reporter gene assay,Other,18038970.0,
573,304386,3,4,,104234229,5743,Inactive,,,,,Agonist activity at glucocorticoid receptor R611A mutant in COS7 cells at 1 uM by NF-kappaB-luciferase reporter gene assay,Other,18038970.0,
574,310931,3,4,,104234229,5743,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17300161.0,
575,310932,3,6,,104234229,5743,Unspecified,,,,,Permeability across human Skin,Other,17300161.0,
576,310933,3,4,,104234229,5743,Unspecified,,,,,Permeability across PAMPA membrane after 7 hrs,Other,17300161.0,
577,311367,3,6,,104234229,5743,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
578,327509,3,6,,104234229,5743,Unspecified,,,,,Agonist activity at glucocorticoid receptor-mediated luciferase reporter gene assay assessed as ratio of firefly luciferase activity to renilla luciferase activity at 10 uM,Other,18177009.0,
579,330359,5,3,,104234229,5743,Active,121069.0,2908.0,0.0001,ED50,Activity at human glucocorticoid receptor expressed in CV1 cells assessed as repression of TNF and IL-1-beta-induced E-selectin gene expression by luciferase reporter gene assay,Confirmatory,18032610.0,
580,330373,3,10,,104234229,5743,Unspecified,121069.0,2908.0,,,Activity at human glucocorticoid receptor expressed in CV1 cells assessed as repression of TNF and IL-1-beta-induced E-selectin gene expression by luciferase reporter gene assay relative to control,Other,18032610.0,
581,332633,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in Swiss mouse assessed as inhibition of ethylphenylpropiolate-induced ear edema at 0.5 mg/ear administered tropically 16 hrs prior to ethylphenylpropiolate challenge,Other,7760072.0,
582,334022,3,3,,104234229,5743,Unspecified,,,,,Antiinflammatory activity against TPA-induced ear edema in Swiss mouse assessed as reduction in ear thickness at 0.05 mg/ear after 10 days,Other,9392883.0,
583,334024,3,3,,104234229,5743,Unspecified,,,,,Effect on oxazolone-induced delayed type hypersensitivity in Swiss mouse assessed as reduction in ear thickness at 0.05 mg/ear after 24 hrs,Other,9392883.0,
584,334025,3,3,,104234229,5743,Unspecified,,,,,Effect on oxazolone-induced delayed type hypersensitivity in Swiss mouse assessed as reduction in ear thickness at 0.05 mg/ear after 48 hrs,Other,9392883.0,
585,334026,3,3,,104234229,5743,Unspecified,,,,,Effect on oxazolone-induced delayed type hypersensitivity in Swiss mouse assessed as reduction in ear thickness at 0.05 mg/ear after 72 hrs,Other,9392883.0,
586,334027,3,3,,104234229,5743,Unspecified,,,,,Effect on oxazolone-induced delayed type hypersensitivity in Swiss mouse assessed as reduction in ear thickness at 0.05 mg/ear after 96 hrs,Other,9392883.0,
587,334028,3,3,,104234229,5743,Unspecified,,,,,Effect on oxazolone-induced delayed type hypersensitivity in Swiss mouse assessed as reduction in ear thickness at 0.05 mg/ear after 102 hrs,Other,9392883.0,
588,338894,6,2,,104234229,5743,Active,,,0.7,IC50,Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as effect on TNFalpha formation pretreated 1 hr before LPS challenge measured after 24 hrs,Confirmatory,11908984.0,
589,346025,3,3,,104234229,5743,Unspecified,,,,,Binding affinity to beta cyclodextrin,Other,19056282.0,
590,346462,8,7,,104234229,5743,Active,121069.0,2908.0,,IC50,Displacement of radiolabeled Dexamethasone from human glucocorticoid receptor,Confirmatory,18983139.0,
591,349564,3,3,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in mouse ear edema model assessed as inhibition of PMA-induced ear edema at 1 mg/ear administered 2 times 30 mins before and 15 mins after PMA challenge measured after 6 hrs of PMA application relative to control,Other,19303290.0,
592,350879,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity against zymosan-induced peritonitis in Swiss mouse assessed as peritoneal protein concentration at 3 mg/kg, po administered 1 hr before zymosan challenge by spectrophotometry",Other,19362486.0,
593,350880,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity against zymosan-induced peritonitis in Swiss mouse assessed as granulocyte content in peritoneal cavity lavage at 3 mg/kg, po administered 1 hr before zymosan challenge measured after 4 hrs",Other,19362486.0,
594,350881,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity against zymosan-induced peritonitis in Swiss mouse assessed as monocyte and lymphocyte content in peritoneal cavity lavage at 3 mg/kg, po administered 1 hr before zymosan challenge measured after 4 hrs",Other,19362486.0,
595,350887,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity against zymosan-induced peritonitis in Swiss mouse assessed as inhibition of granulocyte infiltration into peritoneal cavity at 3 mg/kg, po administered 1 hr before zymosan challenge measured after 4 hrs",Other,19362486.0,
596,351549,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of chemotaxis in zymosan-induced peritonitis Swiss mouse model assessed as peritoneal protein concentration at 3 mg/kg, po pretreated 1 hr before zymosan-challenge measured 4 hrs post inducer challenge (Rvb=1961+/-160 million)",Other,19394230.0,
597,351552,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of chemotaxis in zymosan-induced peritonitis Swiss mouse model assessed as number of peritoneal granulocytes per cavity at 3 mg/kg, po pretreated 1 hr before zymosan-challenge measured 4 hrs post inducer challenge (Rvb=27.1+/-3.5 million)",Other,19394230.0,
598,351553,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of chemotaxis in zymosan-induced peritonitis Swiss mouse model assessed as number of peritoneal cells per cavity at 3 mg/kg, po pretreated 1 hr before zymosan-challenge measured 4 hrs post inducer challenge (Rvb=31.5+/-1.2 million)",Other,19394230.0,
599,351941,8,5,,104234229,5743,Active,121069.0,2908.0,0.0011,Ki,Displacement of FITC-dexamethasone from human recombinant glucocorticoid receptor alpha by fluorescence polarization assay,Confirmatory,19321341.0,
600,351942,8,5,,104234229,5743,Active,121069.0,2908.0,0.0025,EC50,Transrepression activity at GR in PMA-stimulated human A549 cells assessed as inhibition of AP1 response element-induced luciferase reporter gene activity,Confirmatory,19321341.0,
601,351943,8,5,,104234229,5743,Active,121069.0,2908.0,0.0011,EC50,Transrepression activity at GR in IL-1-beta-stimulated human A549 cells assessed as inhibition of NF-kappaB-dependent E-selectin transcription by luciferase reporter gene assay,Confirmatory,19321341.0,
602,351946,7,1,,104234229,5743,Active,,,0.0042,EC50,Agonist activity at GR ligand binding domain expressed in human NP1 cells assessed as glucocorticoid response element transactivation by GAL4 luciferase reporter gene assay,Confirmatory,19321341.0,
603,360335,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of TNFalpha formation at 10 uM pretreated 1 hr before LPS challenge measured after 24 hrs by enzyme immunoassay,Other,11374953.0,
604,360337,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in LPS/IFN-gamma-stimulated mouse N9 cells assessed as inhibition of TNFalpha formation at 10 uM pretreated 1 hr before LPS/IFNgamma challenge measured after 24 hrs by enzyme immunoassay,Other,11374953.0,
605,360411,3,3,,104234229,5743,Active,,,,,Antiinflammatory activity against ip dosed zymosan-induced C57BL/6J mouse inflammed paw model assessed as effect on paw swelling administered 30 mins before zymosan challenge,Other,17150968.0,
606,360412,3,3,,104234229,5743,Active,,,,,Reduction of IL6 protein level in ip dosed zymosan-induced C57BL/6J mouse inflammed paw model measured 6 hrs after zymosan challenge,Other,17150968.0,
607,365558,6,2,,104234229,5743,Active,,,0.05,IC50,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha by ELISA,Confirmatory,18625560.0,
608,365559,6,2,,104234229,5743,Active,,,0.006999999999999999,IC50,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL6 by ELISA,Confirmatory,18625560.0,
609,365560,6,2,,104234229,5743,Unspecified,,,100.0,IC50,Cytotoxicity against human THP1 cells,Confirmatory,18625560.0,
610,365567,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha at 1 uM by ELISA,Other,18625560.0,
611,365568,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL6 at 1 uM by ELISA,Other,18625560.0,
612,365569,3,4,,104234229,5743,Unspecified,,,,,Cytotoxicity against human THP1 cells at 1 uM,Other,18625560.0,
613,374988,6,2,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in sc dosed mouse assessed as inhibition of LPS-induced TNFalpha upregulation measured 2 hrs after LPS challenge,Other,19425597.0,
614,374989,3,3,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in sc dosed mouse assessed as inhibition of LPS-induced TNFalpha upregulation measured 2 hrs after LPS challenge relative to control,Other,19425597.0,
615,375006,7,2,,104234229,5743,Inconclusive,,,,,Antiinflammatory activity in po dosed mouse assessed as inhibition of LPS-induced TNFalpha upregulation measured 2 hrs after LPS challenge,Other,19425597.0,
616,375007,5,3,,104234229,5743,Inconclusive,,,,,Antiinflammatory activity in po dosed mouse assessed as inhibition of LPS-induced TNFalpha upregulation measured 2 hrs after LPS challenge relative to control,Other,19425597.0,
617,375303,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha upregulation at 300 pg, sc measured 2 hrs after LPS challenge",Other,19425597.0,
618,375304,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha upregulation at 0.003 ug, sc measured 2 hrs after LPS challenge",Other,19425597.0,
619,375305,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha upregulation at 0.03 ug, sc measured 2 hrs after LPS challenge",Other,19425597.0,
620,375306,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha upregulation at 0.3 ug, sc measured 2 hrs after LPS challenge",Other,19425597.0,
621,375307,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha upregulation at 0.003 mg, sc measured 2 hrs after LPS challenge",Other,19425597.0,
622,375308,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha upregulation at 0.015 mg, sc measured 2 hrs after LPS challenge",Other,19425597.0,
623,375309,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha upregulation at 0.03 mg, sc measured 2 hrs after LPS challenge",Other,19425597.0,
624,375310,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha upregulation at 0.06 mg, sc measured 2 hrs after LPS challenge",Other,19425597.0,
625,375311,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in mouse assessed as inhibition of LPS-induced TNFalpha upregulation at 0.12 mg, sc measured 2 hrs after LPS challenge",Other,19425597.0,
626,376629,11,2,,104234229,5743,Active,121069.0,2908.0,0.001,EC50,Activity at glucocorticoid receptor in human A549 cells assessed as effect on GRE promoter response by luciferase reporter assay,Confirmatory,16643060.0,
627,379153,3,6,,104234229,5743,Unspecified,,,,,Agonist activity at glucocorticoid receptor transfected in mouse RAW264.7 cells assessed as firefly/renilla luciferase ratio at 10 uM by dual liciferase reporter assay,Other,17067160.0,
628,379448,3,3,,104234229,5743,Unspecified,,,,,Antiinflammatory activity against Swiss mouse chronic dermatitis model assessed as inhibition of TPA-induced edema at 0.5 mg/ear applied twice daily for 4 days measured after 6 hrs,Other,10217718.0,
629,379449,3,3,,104234229,5743,Unspecified,,,,,Antiinflammatory activity against Swiss mouse chronic dermatitis model assessed as inhibition of TPA-induced tissue myeloperoxidase activity at 0.5 mg/ear applied twice daily for 4 days measured after 6 hrs,Other,10217718.0,
630,382421,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity against formalin-induced chronic paw edema rat inflammatory model assessed as reduction of paw volume at 5 mg/kg, po after 1 day relative to control",Other,17467123.0,
631,382422,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity against formalin-induced chronic paw edema rat inflammatory model assessed as reduction of paw volume at 5 mg/kg, po after 2 days relative to control",Other,17467123.0,
632,382423,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity against formalin-induced chronic paw edema rat inflammatory model assessed as reduction of paw volume at 5 mg/kg, po after 3 days relative to control",Other,17467123.0,
633,382424,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity against formalin-induced chronic paw edema rat inflammatory model assessed as reduction of paw volume at 5 mg/kg, po after 4 days relative to control",Other,17467123.0,
634,382425,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity against formalin-induced chronic paw edema rat inflammatory model assessed as reduction of paw volume at 5 mg/kg, po after 5 days relative to control",Other,17467123.0,
635,382431,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity against carrageenan-induced acute paw edema Sprague-Dawley rat inflammatory model assessed as reduction of paw volume at 5 mg/kg, po after 3 hrs relative to control",Other,17467123.0,
636,384955,4,4,,104234229,5743,Unspecified,,,,,Intrinsic aqueous solubility at pH 10 by shake-flask method,Other,18396854.0,
637,387831,3,4,,104234229,5743,Active,,,,,Inhibition of LPS-stimulated COX2 expression in mouse RAW264.7 cells at 10 uM by Western blot,Other,18790649.0,
638,387832,3,4,,104234229,5743,Active,,,,,Inhibition of LPS-stimulated microsomal prostaglandin E synthase 1 expression at 10 uM in mouse RAW264.7 cells by Western blot,Other,18790649.0,
639,394153,3,3,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in DNBS-induced Sprague-Dawley rat colitis model assessed as effect on body weight loss at 0.25 umol/kg, ip for 7 days administered 1 day before colitis induction",Other,19226143.0,
640,394157,3,4,,104234229,5743,Active,,,,,"Antiinflammatory activity in DNBS-induced Sprague-Dawley rat colitis model assessed as reduction in DNBS-induced increase in spleen weight at 0.25 umol/kg, ip for 7 days administered 1 day before colitis induction",Other,19226143.0,
641,394162,3,3,,104234229,5743,Active,,,,,"Antiinflammatory activity in DNBS-induced Sprague-Dawley rat colitis model assessed as reduction in DNBS-induced macroscopic damage in colon at 0.25 umol/kg, ip for 7 days administered 1 day before colitis induction",Other,19226143.0,
642,394163,3,3,,104234229,5743,Active,,,,,"Antiinflammatory activity in DNBS-induced Sprague-Dawley rat colitis model assessed as reduction in DNBS-induced increase in colonic tissue malondialdehyde level at 0.25 umol/kg, ip for 7 days administered 1 day before colitis induction",Other,19226143.0,
643,394164,3,3,,104234229,5743,Active,,,,,"Antiinflammatory activity in DNBS-induced Sprague-Dawley rat colitis model assessed as reduction in DNBS-induced increase in colonic tissue malondialdehyde level at 5 to 45 umol/kg, ip for 7 days administered 1 day before colitis induction",Other,19226143.0,
644,394166,3,3,,104234229,5743,Active,,,,,"Antiinflammatory activity in DNBS-induced Sprague-Dawley rat colitis model assessed as reduction in DNBS-induced increase in colonic tissue TNFalpha level at 0.25 umol/kg, ip for 7 days administered 1 day before colitis induction",Other,19226143.0,
645,398496,6,2,,104234229,5743,Unspecified,,,170.0,IC50,Inhibition of LPS-induced NO production in mouse J774.1 cells after 24 hrs,Confirmatory,12608860.0,
646,401469,7,1,,104234229,5743,Unspecified,,,,,Effect on 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes assessed as glutamic-pyruvic transaminase activity at 1 uM,Other,6677713.0,
647,401470,3,7,,104234229,5743,Inactive,,,,,Effect on 1.5 hrs galactosamine pretreatment-induced cytotoxicity in Wistar rat hepatocytes at 1 uM,Other,6677713.0,
648,401563,6,2,,104234229,5743,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells after 2 days by MTT assay,Other,15165136.0,
649,401579,7,5,,104234229,5743,Inconclusive,,,,,Inhibition of LFA1/ICAM1-mediated HL60 cell aggregation,Other,15165136.0,
650,401580,7,2,,104234229,5743,Inconclusive,,,,,Cytotoxicity against human HL60 cells by XTT assay,Other,15165136.0,
651,401582,7,4,,104234229,5743,Inconclusive,,,,,Inhibition of LFA1/ICAM1-mediated adhesion of HL60 cells to CHO-ICAM1 cells,Other,15165136.0,
652,401583,7,2,,104234229,5743,Inconclusive,,,,,Cytotoxicity against CHO cells transfected with ICAM1 by MTT assay,Other,15165136.0,
653,401585,6,2,,104234229,5743,Unspecified,,,,,Inhibition of iNOS production in LPS-activated mouse RAW264.7 cells after 20 hrs,Other,15165136.0,
654,401586,3,3,,104234229,5743,Unspecified,,,,,"Specific index, ratio of IC50 for mouse RAW264.7 to IC50 for iNOS production in mouse RAW264.7",Other,15165136.0,
655,407366,9,5,,104234229,5743,Active,119810.0,24360.0,22.1,Ki,Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay,Confirmatory,18533710.0,
656,407369,9,5,,104234229,5743,Active,119810.0,24360.0,41.3,Ki,Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP low binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay,Confirmatory,18533710.0,
657,407492,7,1,,104234229,5743,Active,,,0.005,IC50,Inhibition of glucocorticoid receptor-glucocorticoid complex transfected in rat R1 cells assessed as down-regulation of TPA-responsive element proinflammatory gene expression at 10 uM after 24 hrs by beta-galactosidase assay,Confirmatory,18412397.0,
658,408833,7,2,,104234229,5743,Active,,,0.005,IC50,Inhibition of glucocorticoid receptor,Confirmatory,18490170.0,
659,409954,4,9,,104234229,5743,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
660,409956,4,9,,104234229,5743,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
661,415129,4,3,,104234229,5743,Active,,,0.005,IC50,Inhibition of pro-inflammatory cytokine IL5 production in ovalbumin-stimulated BALB/c mouse TH2 cells after 48 hrs by sandwich-ELISA,Confirmatory,19323483.0,
662,415130,4,3,,104234229,5743,Active,,,0.005,IC50,Inhibition of pro-inflammatory cytokine IL13 production in ovalbumin-stimulated BALB/c mouse TH2 cells after 48 hrs by sandwich-ELISA,Confirmatory,19323483.0,
663,415131,3,3,,104234229,5743,Unspecified,,,,,Inhibition of pro-inflammatory cytokine IL5 production in ovalbumin-stimulated BALB/c mouse TH2 cells at 5 nM after 48 hrs by sandwich-ELISA relative to control,Other,19323483.0,
664,415134,5,1,,104234229,5743,Unspecified,,,7.1,LD50,Cytotoxicity against BALB/c mouse TH2 cells after 48 hrs by Trypan blue assay,Confirmatory,19323483.0,
665,417707,3,10,,104234229,5743,Unspecified,119600.0,24890.0,,,Binding affinity to rat uterus estrogen receptor at 0.01 uM,Other,18472187.0,
666,417711,3,10,,104234229,5743,Unspecified,113832.0,24208.0,,,Binding affinity to rat ventral prostate androgen receptor at 0.01 uM,Other,18472187.0,
667,417715,3,10,,104234229,5743,Unspecified,18202596.0,25154.0,,,Binding affinity to rat uterus progesterone receptor at 0.01 uM,Other,18472187.0,
668,417719,3,10,,104234229,5743,Unspecified,1169883.0,24413.0,,,Binding affinity to rat liver glucocorticoid receptor at 0.01 uM,Other,18472187.0,
669,420358,8,5,,104234229,5743,Active,121069.0,2908.0,0.005,IC50,Displacement of fluormone from human recombinant glucocorticoid receptor ligand binding domain by fluorescence polarization assay,Confirmatory,19610652.0,
670,425652,7,2,,104234229,5743,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
671,425653,7,2,,104234229,5743,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
672,429115,9,1,,104234229,5743,Active,1018618719.0,367.0,,,Agonist activity at androgen receptor in human MDA-kb2 cells assessed as stimulation of luciferase activity by luciferase reporter gene assay,Other,19592245.0,
673,429117,9,1,,104234229,5743,Active,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human MDA-kb2 cells assessed as stimulation of luciferase activity by luciferase reporter gene assay,Other,19592245.0,
674,429130,8,6,,104234229,5743,Active,121069.0,2908.0,0.001,IC50,Agonist activity at GR in human A549 cells by NF-kappaB transrepression assay,Confirmatory,19592247.0,
675,429131,4,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at human GR in A549 cells by NFkappaB transrepression assay relative to Dexamethasone,Other,19592247.0,
676,434955,1,2,,56314873,5743,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
677,434955,1,2,,56320685,5743,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
678,434959,1,1,,85787759,5743,Inactive,,,,,Fluorescence Cell-Based Primary HTS to Measure Inhibition of Y box Binding Protein 1 Expression,Screening,,
679,434962,1,2,,56314873,5743,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
680,434962,1,2,,56320685,5743,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
681,434973,1,3,,56314873,5743,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
682,434973,1,3,,56320685,5743,Inactive,120538355.0,57337.0,,,uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7),Screening,,
683,434989,1,1,,56314873,5743,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
684,434989,1,1,,56320685,5743,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
685,435003,1,3,,56314873,5743,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
686,435003,1,3,,56320685,5743,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of T-cell specific antigen receptor-induced NF-kB activation,Screening,,
687,435005,1,1,,56314873,5743,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
688,435005,1,1,,56320685,5743,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
689,435022,2,2,,56314873,5743,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
690,435022,2,2,,56320685,5743,Inactive,,,,,uHTS luminescence assay for the identification of chemical inhibitors of B-cell specific antigen receptor-induced NF-kB activation,Screening,,
691,435030,1,2,,56314873,5743,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
692,435030,1,2,,56314873,5743,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
693,435030,1,2,,56320685,5743,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
694,435030,1,2,,56320685,5743,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
695,443585,7,5,,104234229,5743,Active,121069.0,2908.0,0.0012,Ki,Displacement of GS-red from human glucocorticoid receptor by fluorescent polarization assay,Confirmatory,20047280.0,
696,443586,6,1,,104234229,5743,Active,,,0.0025,EC50,Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of PMA-induced AP1 activity after 6 hrs by luciferase reporter gene assay,Confirmatory,20047280.0,
697,443588,6,1,,104234229,5743,Active,,,0.0011,EC50,Transrepression activity at glucocorticoid receptor expressed in human A549 cells assessed as inhibition of IL-1-beta-induced NF-kappaB dependent E-selection promoter activation after 6 hrs by luciferase reporter gene based ELAM assay,Confirmatory,20047280.0,
698,443590,6,1,,104234229,5743,Active,,,0.0045,EC50,Transactivation of GAL-4 tagged glucocorticoid receptor ligand binding domain expressed in human HeLa cells assessed as NP1 activation by luciferase reporter gene assay,Confirmatory,20047280.0,
699,443592,3,8,,104234229,5743,Unspecified,,,4.0,IC50,Binding affinity to androgen receptor,Confirmatory,20047280.0,
700,443593,3,6,,104234229,5743,Unspecified,,,,,Antagonist activity at mineralocorticoid receptor at 10 uM by antagonist mode functional assay,Other,20047280.0,
701,443594,3,6,,104234229,5743,Inactive,,,,,Agonist activity at mineralocorticoid receptor at 10 uM by agonist mode functional assay,Other,20047280.0,
702,444050,7,1,,104234229,5743,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
703,444051,6,2,,104234229,5743,Unspecified,,,,,Total clearance in human,Other,20070106.0,
704,444052,6,2,,104234229,5743,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
705,444053,6,2,,104234229,5743,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
706,444054,6,1,,104234229,5743,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
707,444055,3,3,,104234229,5743,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
708,444056,3,3,,104234229,5743,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
709,444057,3,3,,104234229,5743,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
710,444058,6,2,,104234229,5743,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
711,449728,1,2,,56314873,5743,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
712,449728,1,2,,56320685,5743,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
713,449762,1,2,,56314873,5743,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
714,449762,1,2,,56320685,5743,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
715,449763,1,3,,56314873,5743,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
716,449763,1,3,,56320685,5743,Inactive,,,,,uHTS identification of small molecule activators of the apoptotic arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
717,450810,3,5,,104234229,5743,Unspecified,,,,,Inhibition of LPS-induced NF-kappaB transcriptional activation expressed in mouse RAW264.7 cells assessed as NF-kappaB activity at 10 uM treated after LPS challenge measured after 24 hrs by luciferase reporter gene assay relative to control,Other,19648015.0,
718,450811,3,6,,104234229,5743,Unspecified,,,,,Inhibition of LPS-induced AP1 transcriptional activation expressed in mouse RAW264.7 cells assessed as AP1 activity at 10 uM treated after LPS challenge measured after 24 hrs by luciferase reporter gene assay relative to control,Other,19648015.0,
719,453203,3,4,,104234229,5743,Unspecified,,,,,"Lipophilicity, log D of the compound",Other,19963379.0,
720,453204,3,6,,104234229,5743,Unspecified,,,,,Permeability in human skin after 48 hrs by Franz cell permeability assay,Other,19963379.0,
721,454141,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha release at 1 uM/mL after 24 hrs by ELISA,Other,19896853.0,
722,454142,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL6 release at 1 uM/mL after 24 hrs by ELISA,Other,19896853.0,
723,454144,3,4,,104234229,5743,Unspecified,,,,,Cytotoxicity against human THP1 cells assessed as CCK8 release at 1 uM/mL after 24 hrs by ELISA,Other,19896853.0,
724,455986,3,5,,104234229,5743,Unspecified,,,,,Permeability across human Caco-2 cells,Other,19734051.0,
725,457538,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha release at 1 uM by ELISA,Other,20056549.0,
726,458284,3,3,,104234229,5743,Active,,,,,"Antiinflammatory activity in human CKLF1-electroporated transfected mouse assessed as decrease in infiltration of inflammatory cells at 2 mg/kg, po",Other,20099827.0,
727,458288,3,4,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in human CKLF1-electroporated transfected mouse assessed as WBC count in per microL of bronchoalveolar lavage fluid at 2 mg/kg, po",Other,20099827.0,
728,458291,3,4,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in human CKLF1-electroporated transfected mouse assessed as eosinophils in bronchoalveolar lavage fluid at 2 mg/kg, po",Other,20099827.0,
729,458299,3,3,,104234229,5743,Active,,,,,"Antiinflammatory activity in human CKLF1-electroporated transfected mouse assessed as decrease in collagen deposition at 2 mg/kg, po",Other,20099827.0,
730,459145,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha release at 1 uM preincubated for 30 mins before LPS challenge by ELISA,Other,20064725.0,
731,459147,3,4,,104234229,5743,Unspecified,,,,,Toxicity against human CCK8 cells assessed as cell growth,Other,20064725.0,
732,459149,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL6 release at 1 uM preincubated for 30 mins before LPS challenge by ELISA,Other,20064725.0,
733,460594,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha release at 1 uM after 24 hrs by ELISA,Other,20138527.0,
734,460595,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL6 release at 1 uM after 24 hrs by ELISA,Other,20138527.0,
735,460596,3,4,,104234229,5743,Unspecified,,,,,Cytotoxicity against human THP1 cells assessed as CCK8 release at 1 uM after 24 hrs by ELISA,Other,20138527.0,
736,463079,1,2,,56314873,5743,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
737,463079,1,2,,56320685,5743,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
738,463082,1,1,,56314873,5743,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
739,463082,1,1,,56320685,5743,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
740,463104,1,2,,56314873,5743,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
741,463104,1,2,,56320685,5743,Inactive,,,,,uHTS identification of small molecule activators of the adaptive arm of the Unfolded Protein response via a luminescent-based reporter assay,Screening,,
742,463111,1,1,,56320685,5743,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
743,463141,1,2,,56314873,5743,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
744,463141,1,2,,56320685,5743,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
745,463165,1,1,,56320685,5743,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
746,463190,1,2,,56314873,5743,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
747,463190,1,2,,56320685,5743,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay,Screening,,
748,463195,1,2,,56314873,5743,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
749,463195,1,2,,56320685,5743,Inactive,285809906.0,856395.0,,,uHTS identification of small molecule inhibitors of tim10 yeast via a luminescent assay,Screening,,
750,463210,1,2,,56314873,5743,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
751,463210,1,2,,56320685,5743,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
752,463212,1,1,,56314873,5743,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
753,463212,1,1,,56320685,5743,Inactive,285814664.0,855751.0,,,uHTS identification of small molecule inhibitors of tim23-1 yeast via a luminescent assay,Screening,,
754,463254,1,1,,56314873,5743,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
755,463254,1,1,,56320685,5743,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
756,467424,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human PBMC assessed as inhibition of 10 ng/ml LPS-induced TNFalpha release at 1.3 uM pretreated 24 hrs before inducer-challenge measured 24 hrs after LPS addition by ELISA,Other,19835377.0,
757,467425,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human PBMC assessed as inhibition of 10 ng/ml LPS-induced TNFalpha release at 5.1 uM pretreated 24 hrs before inducer-challenge measured 24 hrs after LPS addition by ELISA,Other,19835377.0,
758,467612,3,6,,104234229,5743,Unspecified,,,,,Fraction unbound in human plasma,Other,19586686.0,
759,467613,5,3,,104234229,5743,Unspecified,,,,,Volume of distribution at steady state in human,Other,19586686.0,
760,469716,6,1,,104234229,5743,Active,,,0.0072,EC50,Agonist activity at glucocorticoid receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay,Confirmatory,19863083.0,
761,473408,7,5,,104234229,5743,Active,121069.0,2908.0,0.0114,IC50,Displacement of fluoromone from human glucocorticoid receptor LBD assessed as reduction of maximum polarization by fluorescence polarization assay relative to control,Confirmatory,20334371.0,
762,473409,7,5,,104234229,5743,Unspecified,121069.0,2908.0,,Ki,Displacement of [3H]DEX from human glucocorticoid receptor,Confirmatory,20334371.0,
763,473411,3,10,,104234229,5743,Unspecified,121069.0,2908.0,,,Displacement of fluoromone from human glucocorticoid receptor LBD at 1 uM assessed as reduction of maximum polarization by fluorescence polarization assay relative to control,Other,20334371.0,
764,473415,3,10,,104234229,5743,Unspecified,121069.0,2908.0,,,Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL-1-alpha-induced IL6 expression after 24 hrs by ELISA,Other,20334371.0,
765,473491,3,3,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in mouse assessed as inhibition of phorbol ester-induced ear edema at 1 mg/ear,Other,20188549.0,
766,475024,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in LPS-stimulated human THP1 cells assessed as inhibition of TNFalpha formation at 1 uM pretreated 30 mins before LPS challenge measured after 24 hrs by ELISA,Other,20207143.0,
767,476929,3,3,,104234229,5743,Unspecified,,,,,Human intestinal absorption in po dosed human,Other,20022146.0,
768,478062,6,2,,104234229,5743,Active,,,0.019,Kd,Binding affinity to glucocorticoid receptor,Confirmatory,20355713.0,
769,480591,3,10,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human fibroblast assessed as inhibition of IL-1-beta-induced IL6 production at 100 nM treated 1 hr before IL1-beta challenge measured after 24 hrs by transrepression assay,Other,20427184.0,
770,480592,3,10,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human fibroblast assessed as inhibition of IL-1-beta-induced IL6 production at 2 nM treated 1 hr before IL1-beta challenge measured after 24 hrs by transrepression assay,Other,20427184.0,
771,481439,3,4,,104234229,5743,Unspecified,,,,,Absolute bioavailability in human,Other,20373811.0,
772,481442,3,6,,104234229,5743,Unspecified,,,,,Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells,Other,20373811.0,
773,483905,5,2,,104234229,5743,Active,,,0.0006309999999999999,IC50,Antiinflammatory activity in human primary synovial fibroblasts assessed as inhibition of IL1-induced IL6 release after 18 hrs by MSD technology,Confirmatory,20469868.0,
774,483906,5,2,,104234229,5743,Active,,,0.0005009999999999999,IC50,Antiinflammatory activity in human primary synovial fibroblasts assessed as inhibition of IL1-induced IL8 release after 18 hrs by MSD technology,Confirmatory,20469868.0,
775,483907,5,2,,104234229,5743,Active,,,0.00031600000000000004,IC50,Antiinflammatory activity in human primary synovial fibroblasts assessed as inhibition of IL1-induced MMP1 release after 18 hrs by MSD technology,Confirmatory,20469868.0,
776,483908,3,4,,104234229,5743,Unspecified,,,,,Toxicity in human skeletal muscle cells assessed as increase in glutamine synthase mRNA level after 18 hrs by PCR,Other,20469868.0,
777,483909,3,4,,104234229,5743,Unspecified,,,,,Toxicity in human hepatocytes assessed as increase in PEPCK mRNA level after 18 hrs by PCR,Other,20469868.0,
778,483920,3,4,,104234229,5743,Active,,,,,"Plasma concentration in mouse bearing mouse NIH-3T3 cells integrated with MMTV reporter gene at 10 mg/kg, po after 1 hr",Other,20469868.0,
779,483921,3,6,,104234229,5743,Unspecified,,,,,"Relative plasma concentration in mouse assessed as ratio of plasma concentration in mouse at 10 mg/kg, po to IC50 for NF-kappaB transrepression activity in A549 cells expressing MMTV reporter gene",Other,20469868.0,
780,483922,3,4,,104234229,5743,Active,,,,,"Fraction unbound in mouse plasma bearing mouse NIH-3T3 cells integrated with MMTV reporter gene at 10 mg/kg, po after 1 hr",Other,20469868.0,
781,483923,3,6,,104234229,5743,Unspecified,,,,,"Relative fraction unbound in mouse assessed as ratio of fraction unbound in mouse at 10 mg/kg, po to IC50 for NF-kappaB transrepression activity in A549 cells expressing MMTV reporter gene",Other,20469868.0,
782,483924,3,4,,104234229,5743,Active,,,,,"Plasma concentration in mouse bearing mouse NIH-3T3 cells integrated with MMTV reporter gene at 1 mg/kg, po after 1 hr",Other,20469868.0,
783,483925,3,6,,104234229,5743,Unspecified,,,,,"Relative plasma concentration in mouse assessed as ratio of plasma concentration in mouse at 1 mg/kg, po to IC50 for NF-kappaB transrepression activity in A549 cells expressing MMTV reporter gene",Other,20469868.0,
784,483926,3,4,,104234229,5743,Active,,,,,"Fraction unbound in mouse plasma bearing mouse NIH-3T3 cells integrated with MMTV reporter gene at 1 mg/kg, po after 1 hr",Other,20469868.0,
785,483927,3,6,,104234229,5743,Unspecified,,,,,"Relative fraction unbound in mouse assessed as ratio of fraction unbound in mouse at 1 mg/kg, po to IC50 for NF-kappaB transrepression activity in A549 cells expressing MMTV reporter gene",Other,20469868.0,
786,483928,3,4,,104234229,5743,Active,,,,,"Plasma concentration in mouse bearing mouse NIH-3T3 cells integrated with MMTV reporter gene at 0.1 mg/kg, po after 1 hr",Other,20469868.0,
787,483929,3,6,,104234229,5743,Unspecified,,,,,"Relative plasma concentration in mouse assessed as ratio of plasma concentration in mouse at 0.1 mg/kg, po to IC50 for NF-kappaB transrepression activity in A549 cells expressing MMTV reporter gene",Other,20469868.0,
788,483930,3,4,,104234229,5743,Active,,,,,"Fraction unbound in mouse plasma bearing mouse NIH-3T3 cells integrated with MMTV reporter gene at 0.1 mg/kg, po after 1 hr",Other,20469868.0,
789,483931,3,6,,104234229,5743,Unspecified,,,,,"Relative fraction unbound in mouse assessed as ratio of fraction unbound in mouse at 0.1 mg/kg, po to IC50 for NF-kappaB transrepression activity in A549 cells expressing MMTV reporter gene",Other,20469868.0,
790,483932,3,4,,104234229,5743,Active,,,,,"Plasma concentration in mouse bearing mouse NIH-3T3 cells integrated with MMTV reporter gene at 0.01 mg/kg, po after 1 hr",Other,20469868.0,
791,483933,3,6,,104234229,5743,Unspecified,,,,,"Relative plasma concentration in mouse assessed as ratio of plasma concentration in mouse at 0.01 mg/kg, po to IC50 for NF-kappaB transrepression activity in A549 cells expressing MMTV reporter gene",Other,20469868.0,
792,483934,3,4,,104234229,5743,Active,,,,,"Fraction unbound in mouse plasma bearing mouse NIH-3T3 cells integrated with MMTV reporter gene at 0.01 mg/kg, po after 1 hr",Other,20469868.0,
793,483935,3,6,,104234229,5743,Unspecified,,,,,"Relative fraction unbound in mouse assessed as ratio of fraction unbound in mouse at 0.01 mg/kg, po to IC50 for NF-kappaB transrepression activity in A549 cells expressing MMTV reporter gene",Other,20469868.0,
794,483940,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of IL1-induced circulating IL6 release in mouse at 10 mg/kg, po",Other,20469868.0,
795,483941,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of IL1-induced circulating IL6 release in mouse at 1 mg/kg, po",Other,20469868.0,
796,483942,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of IL1-induced circulating IL6 release in mouse at 0.1 mg/kg, po",Other,20469868.0,
797,483943,3,3,,104234229,5743,Unspecified,,,,,"Inhibition of IL1-induced circulating IL6 release in mouse at 0.01 mg/kg, po",Other,20469868.0,
798,483945,4,3,,104234229,5743,Unspecified,,,,,Inhibition of IL1-induced circulating IL6 release in po dosed mouse,Other,20469868.0,
799,485270,1,1,,56314873,5743,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
800,485270,1,1,,56320685,5743,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
801,485272,1,1,,56314873,5743,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
802,485272,1,1,,56320685,5743,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
803,485273,2,1,,56314873,5743,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
804,485273,2,1,,56320685,5743,Inactive,4507793.0,7334.0,,,uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay,Screening,,
805,485275,1,3,,56314873,5743,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
806,485275,1,3,,56320685,5743,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
807,485281,1,1,,26752876,5743,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
808,485281,1,1,,26752877,5743,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
809,485290,1,1,,17389945,5743,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
810,485290,1,1,,26752876,5743,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
811,485290,1,1,,26752877,5743,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
812,485290,1,1,,56314873,5743,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
813,485294,1,1,,56314873,5743,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
814,485294,1,1,,56320685,5743,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
815,485297,1,1,,56314873,5743,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
816,485297,1,1,,56320685,5743,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
817,485298,1,1,,56314873,5743,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
818,485298,1,1,,56320685,5743,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
819,485313,1,2,,56314873,5743,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
820,485313,1,2,,56320685,5743,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
821,485317,1,2,,56314873,5743,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
822,485317,1,2,,56320685,5743,Inactive,54112432.0,2671.0,,,HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS,Screening,,
823,485341,1,1,,56314873,5743,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
824,485341,1,1,,56320685,5743,Inactive,119389684.0,,,Potency,qHTS Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
825,485344,1,1,,56314873,5743,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
826,485344,1,1,,56320685,5743,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists,Screening,,
827,485346,1,1,,56314873,5743,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
828,485346,1,1,,56314873,5743,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
829,485346,1,1,,56320685,5743,Inactive,88702791.0,4194.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
830,485346,1,1,,56320685,5743,Inactive,89993689.0,4193.0,,,uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.,Screening,,
831,485347,1,2,,56314873,5743,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
832,485347,1,2,,56320685,5743,Inactive,4503385.0,1813.0,,,HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators,Screening,,
833,485349,1,1,,56314873,5743,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
834,485349,1,1,,56320685,5743,Inactive,71902540.0,472.0,,Potency,qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia,Confirmatory,,
835,485350,1,2,,99300936,5743,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
836,485353,2,1,,56314873,5743,Inactive,30124074.0,1489680.0,,,qHTS of Yeast-based Assay for SARS-CoV PLP,Confirmatory,,
837,485358,1,1,,56314873,5743,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
838,485358,1,1,,56320685,5743,Inactive,4503385.0,1813.0,,,HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists,Screening,,
839,485360,1,1,,56314873,5743,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
840,485360,1,1,,56320685,5743,Inactive,117938328.0,26013.0,,Potency,qHTS Assay for the Inhibitors of L3MBTL1,Confirmatory,,
841,485364,1,1,,56314873,5743,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
842,485364,1,1,,56320685,5743,Inactive,15149312.0,8345881.0,,Potency,qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins,Confirmatory,,
843,485367,1,2,,56314873,5743,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
844,485367,1,2,,56320685,5743,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
845,486249,3,5,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha secretion at 10 uM treated 30 mins before LPS challenge measured after 24 hrs by ELISA relative to control,Other,20171758.0,
846,486250,3,5,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL-6 secretion at 10 uM treated 30 mins before LPS challenge measured after 24 hrs by ELISA relative to control,Other,20171758.0,
847,486251,3,5,,104234229,5743,Unspecified,,,,,Cytotoxicity against human CCK8 cells at 10 uM,Other,20171758.0,
848,488837,1,1,,56314873,5743,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
849,488837,1,1,,56320685,5743,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
850,488839,1,1,,56314873,5743,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
851,488839,1,1,,56314873,5743,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
852,488839,1,1,,56320685,5743,Inactive,20072248.0,8851.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
853,488839,1,1,,56320685,5743,Inactive,48146199.0,1020.0,,,Development of CDK5 inhibitors   Measured in Biochemical System Using Plate Reader - 2083-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
854,488847,1,3,,56314873,5743,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
855,488847,1,3,,56320685,5743,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
856,488862,1,1,,56314873,5743,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
857,488862,1,1,,56320685,5743,Inactive,,,,,Inhibitors of Prion Protein 5' UTR mRNA Measured in Cell-Based System Using Plate Reader - 2078-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
858,488890,1,2,,56314873,5743,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
859,488890,1,2,,56320685,5743,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
860,488895,1,2,,56314873,5743,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
861,488895,1,2,,56320685,5743,Inactive,90111653.0,948321.0,,,High Throughput Screen for Tat Transport Inhibitors Measured in Microorganism System Using Plate Reader - 2093-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
862,488896,1,1,,56314873,5743,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
863,488896,1,1,,56320685,5743,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
864,488899,1,1,,56314873,5743,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
865,488899,1,1,,56320685,5743,Inactive,40807040.0,4286.0,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
866,488922,1,2,,56320685,5743,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
867,488965,1,2,,56314873,5743,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
868,488965,1,2,,56320685,5743,Inactive,218891639.0,,,,Fluorescent Biochemical Primary HTS to Identify Inhibitors of P. aeruginosa PvdQ acylase Measured in Biochemical System Using Plate Reader and Imaging Combination - 2091-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
869,488966,1,1,,56314873,5743,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
870,488966,1,1,,56320685,5743,Inactive,,,,IC50,Primary and Confirmatory Screening for Inhibitors of Bacterial Capsule Biogenesis,Confirmatory,,
871,488975,1,2,,56320685,5743,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
872,488977,1,2,,56320685,5743,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
873,489030,2,1,,56314873,5743,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
874,489030,2,1,,56320685,5743,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of inhibitors of Apaf-1,Screening,,
875,489031,2,1,,56314873,5743,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
876,489031,2,1,,56320685,5743,Inactive,187952397.0,317.0,,,uHTS Fluorescent assay for identification of activators of Apaf-1,Screening,,
877,490940,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha production at 1 uM treated 30 mins before LPS challenge measured after 24 hrs by ELISA relative to control,Other,20430485.0,
878,490941,3,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL-6 production at 1 uM treated 30 mins before LPS challenge measured after 24 hrs by ELISA relative to control,Other,20430485.0,
879,490942,3,4,,104234229,5743,Unspecified,,,,,Cytotoxicity against human CCK8 cells at 1 uM,Other,20430485.0,
880,492947,1,1,,56314873,5743,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
881,492947,1,1,,56320685,5743,Inactive,4501969.0,154.0,,Potency,qHTS assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
882,492953,1,1,,56314873,5743,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
883,492953,1,1,,56320685,5743,Inactive,296080766.0,5049.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)",Screening,,
884,492956,1,1,,56314873,5743,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
885,492956,1,1,,56320685,5743,Inactive,4758878.0,5051.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet activating factor acetylhydrolase 2 (PAFAH2),Screening,,
886,492972,1,1,,56314873,5743,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
887,492972,1,1,,56320685,5743,Inactive,225543099.0,5050.0,,,"Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1B, catalytic subunit 3 (PAFAH1B3)",Screening,,
888,493005,1,1,,56314873,5743,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
889,493005,1,1,,56320685,5743,Inactive,5454140.0,7251.0,,Potency,qHTS Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
890,493008,1,1,,56314873,5743,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
891,493008,1,1,,56314873,5743,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
892,493008,1,1,,56314873,5743,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
893,493008,1,1,,56314873,5743,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
894,493008,1,1,,56320685,5743,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
895,493008,1,1,,56320685,5743,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
896,493008,1,1,,56320685,5743,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
897,493008,1,1,,56320685,5743,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
898,493011,1,1,,56314873,5743,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
899,493011,1,1,,56320685,5743,Inactive,21955158.0,200315.0,,,uHTS identification of APOBEC3A DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
900,493012,1,1,,56314873,5743,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
901,493012,1,1,,56320685,5743,Inactive,13399304.0,60489.0,,,uHTS identification of APOBEC3G DNA Deaminase Inhibitors via a fluorescence-based single-stranded DNA deaminase assay,Screening,,
902,493014,1,1,,56314873,5743,Inactive,,,,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
903,493014,1,1,,56320685,5743,Inconclusive,,,0.0041,Potency,qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
904,493033,1,2,,99300936,5743,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
905,493036,1,2,,56314873,5743,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
906,493036,1,2,,56320685,5743,Inactive,110611243.0,4923.0,,,Image-Based HTS for Selective Agonists for NTR1,Screening,,
907,493056,1,1,,56314873,5743,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
908,493056,1,1,,56320685,5743,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers,Screening,,
909,493083,1,1,,56320685,5743,Inactive,62740231.0,15499.0,,AC50_uM,HSF-1 induced GFP reporter and Doxycycline induced RFP reporter Measured in Cell-Based System Using Plate Reader - 2038-03_Inhibitor_DoseNoFile_CherryPick_Activity_Set3,Confirmatory,,
910,493084,1,1,,56314873,5743,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
911,493084,1,1,,56320685,5743,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.,Screening,,
912,493085,1,1,,56320685,5743,Inactive,62740231.0,15499.0,,AC50_uM,HSF-1 induced GFP reporter and Doxycycline induced RFP reporter Measured in Cell-Based System Using Plate Reader - 2038-03_Inhibitor_DoseNoFile_CherryPick_Internal-Standard_Set3,Confirmatory,,
913,493087,1,1,,56314873,5743,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
914,493087,1,1,,56320685,5743,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE),Screening,,
915,493091,1,1,,56314873,5743,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
916,493091,1,1,,56320685,5743,Inactive,10864009.0,58190.0,,,uHTS Colorimetric assay for identification of inhibitors of Scp-1,Screening,,
917,493098,1,1,,56314873,5743,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
918,493098,1,1,,56320685,5743,Inactive,37187860.0,1235.0,,,uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay,Screening,,
919,493131,1,1,,56314873,5743,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
920,493131,1,1,,56320685,5743,Inactive,6679827.0,14282.0,,,Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01_Activator_SinglePoint_HTS_Activity,Screening,,
921,493160,1,1,,56314873,5743,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
922,493160,1,1,,56320685,5743,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing  I (HKDC1),Screening,,
923,493187,1,2,,56314873,5743,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
924,493187,1,2,,56320685,5743,Inactive,156151420.0,80201.0,,,uHTS Fluorescent assay for identification of activators of hexokinase domain containing  I (HKDC1),Screening,,
925,493244,1,1,,56314873,5743,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
926,493244,1,1,,56314873,5743,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
927,493244,1,1,,56314873,5743,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
928,493244,1,1,,56314873,5743,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
929,493244,1,1,,56320685,5743,Inactive,1927.0,100037999.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
930,493244,1,1,,56320685,5743,Inactive,4507615.0,7134.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
931,493244,1,1,,56320685,5743,Inactive,48255881.0,7139.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
932,493244,1,1,,56320685,5743,Inactive,151101270.0,7137.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF),Screening,,
933,496817,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
934,496818,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
935,496819,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
936,496820,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
937,496821,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
938,496823,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
939,496824,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
940,496825,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
941,496826,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
942,496827,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
943,496828,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
944,496829,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
945,496830,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
946,496831,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
947,496832,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
948,497005,4,2,,104234229,5743,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
949,497377,2,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity against human THP1 cells assessed as inhibition of LPS-induced TNFalpha release at 1 uM after 24 hrs,Other,20638287.0,
950,497378,2,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity against human THP1 cells assessed as inhibition of LPS-induced IL6 release at 1 uM after 24 hrs,Other,20638287.0,
951,497379,2,4,,104234229,5743,Unspecified,,,,,Cytotoxicity against human CCK8 cells at 1 uM,Other,20638287.0,
952,499645,2,5,,104234229,5743,Unspecified,,,,,"Antiallergic activity in C57BL/6 mouse assessed as reduction of HDM/CRA-induced chitinase activity in bronchoalveolar lavage fluid at 10 mg/kg, ip administered once daily",Other,20666458.0,
953,500076,3,3,,104234229,5743,Active,,,,,Immunomodulatory activity in ip dosed mouse lung assessed as reduction in inhibition of ovalbumin-induced intense cell filtration,Other,20681573.0,
954,500077,2,4,,104234229,5743,Active,,,,,Immunomodulatory activity in ip dosed mouse lung assessed as reduction of eosinophils in bronchoalveolar lavage fluid,Other,20681573.0,
955,500080,2,10,,104234229,5743,Inactive,121069.0,2908.0,,,Induction of nuclear translocation of YFP-fused GRalpha in human COS7 cells,Other,20681573.0,
956,503305,2,5,,104234229,5743,Unspecified,,,,,Antiproliferative activity against human PC3 cells at 500 nM after 120 hrs by MTT assay relative to DMSO,Other,16680159.0,
957,504326,1,2,,56314873,5743,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
958,504326,1,2,,56314873,5743,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
959,504326,1,2,,56320685,5743,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
960,504326,1,2,,56320685,5743,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
961,504327,1,1,,26752876,5743,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
962,504327,1,1,,26752877,5743,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
963,504327,1,1,,56314873,5743,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
964,504327,1,1,,56320685,5743,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
965,504329,1,1,,56314873,5743,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
966,504329,1,1,,56320685,5743,Inactive,227977143.0,23308111.0,,IC50,Discovery of Small Molecule Probes for H1N1 Influenza NS1A,Confirmatory,,
967,504332,1,1,,26752876,5743,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
968,504332,1,1,,56314873,5743,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
969,504332,1,1,,56320685,5743,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
970,504333,1,1,,56314873,5743,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
971,504333,1,1,,56320685,5743,Inactive,6683500.0,29994.0,,Potency,qHTS Assay for Inhibitors of BAZ2B,Confirmatory,,
972,504339,1,1,,56314873,5743,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
973,504339,1,1,,56320685,5743,Inactive,162330054.0,,,Potency,qHTS Assay for Inhibitors of JMJD2A-Tudor Domain,Confirmatory,,
974,504357,1,1,,56314873,5743,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
975,504357,1,1,,56314873,5743,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
976,504357,1,1,,56320685,5743,Inactive,63477962.0,4985.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
977,504357,1,1,,56320685,5743,Inactive,117940060.0,4988.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors,Screening,,
978,504406,1,1,,56314873,5743,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
979,504406,1,1,,56320685,5743,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
980,504408,2,1,,56320685,5743,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
981,504411,1,1,,56314873,5743,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
982,504411,1,1,,56320685,5743,Inactive,218931251.0,221955.0,,,"Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)",Screening,,
983,504414,1,1,,56314873,5743,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
984,504414,1,1,,56314873,5743,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
985,504414,1,1,,56320685,5743,Inactive,9966877.0,57120.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
986,504414,1,1,,56320685,5743,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with Cer CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
987,504423,1,1,,56314873,5743,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
988,504423,1,1,,56320685,5743,Inactive,312275222.0,,,,C-LANA FP assay Measured in Biochemical System Using Plate Reader - 2117-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
989,504441,1,1,,56320685,5743,Inactive,6978787.0,25255.0,,,Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
990,504444,1,1,,56314873,5743,Active,224028257.0,4780.0,0.0052,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
991,504444,1,1,,56320685,5743,Active,224028257.0,4780.0,0.0046,Potency,Nrf2 qHTS screen for inhibitors,Confirmatory,,
992,504454,1,3,,56314873,5743,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
993,504454,1,3,,56320685,5743,Inactive,4501969.0,154.0,,,HTS for Beta-2AR agonists via FAP method,Screening,,
994,504462,1,1,,56314873,5743,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
995,504462,1,1,,56320685,5743,Inactive,47132611.0,23192.0,,,uHTS fluorescent assay for identification of inhibitors of ATG4B,Screening,,
996,504466,1,1,,56314873,5743,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
997,504466,1,1,,56320685,5743,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
998,504467,1,1,,56314873,5743,Inactive,116283940.0,79915.0,,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
999,504467,1,1,,56320685,5743,Inconclusive,116283940.0,79915.0,15.8489,Potency,qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
1000,504490,1,2,,56314873,5743,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1001,504490,1,2,,56320685,5743,Inactive,13177715.0,408.0,,,Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling,Screening,,
1002,504523,1,1,,56314873,5743,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1003,504523,1,1,,56314873,5743,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1004,504523,1,1,,56320685,5743,Inactive,45269145.0,9817.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1005,504523,1,1,,56320685,5743,Inactive,224028257.0,4780.0,,,Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2   Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1006,504558,1,1,,56314873,5743,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1007,504558,1,1,,56320685,5743,Inactive,23893668.0,3783750.0,,,Inhibitors of Epstein-Barr LMP1 inducible NF-kappaB luciferase reporter Measured in Cell-Based System Using Plate Reader - 2122-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1008,504577,2,2,,56314873,5743,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1009,504577,2,2,,56320685,5743,Inactive,6325022.0,855842.0,,,HTS of Small Molecules that Regulate V-ATPase Proton Transport in Yeast using pHLuorin,Screening,,
1010,504582,2,1,,56314873,5743,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1011,504582,2,1,,56320685,5743,Inactive,124809271.0,811941.0,,,In vivo-based yeast HTS to detect compounds rescuing yeast growth/survival of Plasmodium Falciparum HSP40-mediated toxicity Measured in Whole Organism System Using Plate Reader - 2120-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1012,504621,1,1,,56314873,5743,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1013,504621,1,1,,56320685,5743,Inactive,124809506.0,811999.0,,,Anti-Malarial Hsp90 Inhibitors Measured in Microorganism System Using Plate Reader - 2121-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1014,504634,1,1,,56314873,5743,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1015,504634,1,1,,56320685,5743,Inactive,13236497.0,3361.0,,,Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1016,504648,1,1,,56314873,5743,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1017,504648,1,1,,56320685,5743,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: counterscreen for cytotoxicity,Confirmatory,,
1018,504651,1,1,,56314873,5743,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1019,504651,1,1,,56320685,5743,Inactive,4503383.0,1812.0,,,Potentiators of Human D1 Dopamine Receptor: qHTS,Screening,,
1020,504652,1,1,,56320685,5743,Inactive,4503383.0,1812.0,,,Antagonist of Human D 1 Dopamine Receptor: qHTS,Screening,,
1021,504660,1,1,,56314873,5743,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1022,504660,1,1,,56320685,5743,Inactive,4503383.0,1812.0,,,Allosteric Agonists of the Human D1 Dopamine Receptor: qHTS,Screening,,
1023,504690,1,3,,56314873,5743,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1024,504690,1,3,,56320685,5743,Inactive,12381848.0,,,,uHTS identification of small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay,Screening,,
1025,504692,2,2,,56314873,5743,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1026,504692,2,2,,56320685,5743,Inactive,13236497.0,3361.0,,,Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A),Screening,,
1027,504700,1,1,,56314873,5743,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1028,504700,1,1,,56314873,5743,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1029,504700,1,1,,56320685,5743,Inactive,46909587.0,5567.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1030,504700,1,1,,56320685,5743,Inactive,47132585.0,5577.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R2B (PKA-R2B) complex,Screening,,
1031,504706,1,1,,56314873,5743,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1032,504706,1,1,,56320685,5743,Inactive,23491729.0,7157.0,,Potency,qHTS assay for re-activators of p53 using a Luc reporter,Confirmatory,,
1033,504707,1,1,,56314873,5743,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1034,504707,1,1,,56314873,5743,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1035,504707,1,1,,56320685,5743,Inactive,6755076.0,18749.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1036,504707,1,1,,56320685,5743,Inactive,115496662.0,615074.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex,Screening,,
1037,504720,1,1,,56314873,5743,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1038,504720,1,1,,56320685,5743,Inactive,16130689.0,947252.0,,,uHTS identification of MazEF TA System activators  via a fluorescence-based single-stranded RNase assay,Screening,,
1039,504734,1,1,,56314873,5743,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1040,504734,1,1,,56320685,5743,Inactive,194068499.0,54106.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.,Screening,,
1041,504766,2,1,,56314873,5743,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1042,504766,2,1,,56320685,5743,Inactive,5016090.0,190.0,,,"Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)",Screening,,
1043,504775,1,1,,56314873,5743,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1044,504775,1,1,,56320685,5743,Inactive,14389423.0,20778.0,,,HTS using DiI-HDL to assay lipid transfer in ldlA[SR-BI] cells Measured in Cell-Based System Using Plate Reader - 2085-01_Activator_SinglePoint_HTS_Activity,Screening,,
1045,504803,1,1,,56314873,5743,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1046,504803,1,1,,56320685,5743,Inactive,121945198.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the HTRA serine peptidase 1 (HTRA1),Screening,,
1047,504810,1,2,,56314873,5743,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1048,504812,1,2,,56314873,5743,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
1049,504832,1,1,,56314873,5743,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1050,504832,1,1,,56320685,5743,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
1051,504834,1,1,,56314873,5743,Inconclusive,,,10.4179,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1052,504834,1,1,,56320685,5743,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
1053,504842,1,1,,56314873,5743,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1054,504842,1,1,,56320685,5743,Inactive,4090929.0,10576.0,,Potency,Inhibitors of TCP-1 ring complex (TRiC) of Methanococcus maripaludis (MmCpn): qHTS,Confirmatory,,
1055,504845,1,1,,26752876,5743,Inconclusive,86301163.0,5999.0,0.0238,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1056,504845,1,1,,56314873,5743,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1057,504845,1,1,,56320685,5743,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
1058,504847,1,1,,26752876,5743,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1059,504847,1,1,,26752877,5743,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1060,504847,1,1,,56314873,5743,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1061,504847,1,1,,56320685,5743,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
1062,504884,1,2,,56314873,5743,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1063,504884,1,2,,56320685,5743,Inactive,115347926.0,1175052.0,,,Inhibitors of Y. pestis Topo-I using cleavage product accumulation Measured in Biochemical System Using Plate Reader - 2123-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1064,504891,1,1,,56314873,5743,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1065,504891,1,1,,56320685,5743,Inactive,5453898.0,5300.0,,Potency,qHTS Assay to Find Inhibitors of Pin1,Confirmatory,,
1066,504894,1,1,,56314873,5743,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1067,504894,1,1,,56320685,5743,Inactive,553160.0,,,Potency,Activators of T cell receptors: qHTS campaign,Confirmatory,,
1068,504937,1,2,,56314873,5743,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1069,504937,1,2,,56320685,5743,Inactive,179095.0,6609.0,,Potency,Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS,Confirmatory,,
1070,507145,3,4,,104234229,5743,Active,,,,,Cytotoxicity against human HeLa cells assessed as inhibition of DNA replication by imaging analysis,Other,18066055.0,
1071,507146,3,4,,104234229,5743,Active,,,,,Inhibition of mitosis in human HeLa cells by imaging analysis,Other,18066055.0,
1072,511563,2,3,,104234229,5743,Unspecified,,,,,"Protection against SEB-induced toxicity in C3H/HeJ mouse assessed as lethality at 1.2 mg/kg, in administered at 5 hrs after SEB challenge followed by 5 mg/kg, ip infusion after 24 to 96 hrs of SEB exposure",Other,20086156.0,
1073,515514,5,1,,104234229,5743,Active,,,0.0034,IC50,Binding affinity to glucocorticoid receptor expressed in baculovirus-infected insect cells using tetramethylrhodamine labeled Dexamethasone by fluorescence polarization microplate assay,Confirmatory,20735001.0,
1074,515515,5,1,,104234229,5743,Unspecified,,,2.0,IC50,Binding affinity to progesterone receptor expressed in baculovirus-infected insect cells using tetramethylrhodamine labeled RU-486 by fluorescence polarization microplate assay,Confirmatory,20735001.0,
1075,515516,5,1,,104234229,5743,Active,,,0.033,IC50,Binding affinity to mineralocorticoid receptor expressed in baculovirus-infected insect cells using tetramethylrhodamine labeled Dexamethasone by fluorescence polarization microplate assay,Confirmatory,20735001.0,
1076,515517,6,5,,104234229,5743,Active,121069.0,2908.0,0.0005099999999999999,IC50,Transrepression activity at glucocorticoid receptor in HFF assessed as inhibition of IL-1-induced IL-6 production after 18 to 24 hrs by ELISA,Confirmatory,20735001.0,
1077,516371,7,5,,104234229,5743,Active,121069.0,2908.0,0.01259,IC50,Binding affinity to human recombinant glucocorticoid receptor expressed in baculovirus infected Sf9 cells,Confirmatory,20727743.0,
1078,516372,7,5,,104234229,5743,Unspecified,90110048.0,5241.0,1.0,IC50,Binding affinity to human recombinant progesterone receptor expressed in baculovirus infected Sf9 cells,Confirmatory,20727743.0,
1079,516373,7,5,,104234229,5743,Unspecified,126885.0,4306.0,1.0,IC50,Binding affinity to human recombinant mineralocorticoid receptor expressed in baculovirus infected Sf9 cells,Confirmatory,20727743.0,
1080,516374,7,5,,104234229,5743,Unspecified,1018618719.0,367.0,1.0,IC50,Binding affinity to human recombinant androgen receptor expressed in baculovirus infected Sf9 cells,Confirmatory,20727743.0,
1081,516375,7,5,,104234229,5743,Active,121069.0,2908.0,0.00251,IC50,Transrepression activity at glucocorticoid receptor-mediated antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL-8 production,Confirmatory,20727743.0,
1082,516377,7,5,,104234229,5743,Active,121069.0,2908.0,0.00158,IC50,Transrepression activity at glucocorticoid receptor-mediated antiinflammatory activity in human HeLa cells assessed as inhibition of TPA-induced collagenase promoter activity by luciferase reporter gene assay,Confirmatory,20727743.0,
1083,516378,6,5,,104234229,5743,Active,121069.0,2908.0,0.007940000000000001,EC50,Transactivation activity at glucocorticoid receptor in human HeLa cells assessed as induction of MMTV promoter activity by luciferase reporter gene assay,Confirmatory,20727743.0,
1084,517026,5,6,,104234229,5743,Active,121069.0,2908.0,15.8489,EC50,Agonist activity at glucocorticoid receptor-LBD in human U2OS cells transfected with Gal4-DBD assessed as increase of transactivation activity after 18 hrs by luciferase reporter gene assay,Confirmatory,20812681.0,
1085,517033,5,6,,104234229,5743,Active,121069.0,2908.0,0.000508,IC50,Antagonist activity at glucocorticoid receptor-LBD in human U2OS cells transfected with Gal4-DBD assessed as inhibition of transactivation activity after 18 hrs by luciferase reporter gene assay,Confirmatory,20812681.0,
1086,532000,1,3,,104234229,5743,Inactive,,,,,Bactericidal activity against kanamycin-resistant Pseudomonas aeruginosa PAO1 up to 50 uM after 3 hrs by time-kill assay,Other,20308375.0,
1087,532238,2,3,,104234229,5743,Unspecified,,,,,Cytotoxicity against human neutrophil assessed as effect on cell viability up to 20 uM after 12 hrs by microscopy,Other,20308375.0,
1088,532240,2,6,,104234229,5743,Active,,,,,Induction of CFP-tagged glucocorticoid receptor nuclear localization expressed in BAEC at 0.01 to 1 uM after 1 hr by luminescence assay,Other,20308375.0,
1089,537733,2,3,,104234229,5743,Active,,,,,Binding affinity to Candida albicans CaCdr1p expressed in yeast AD1-8u,Other,20739103.0,
1090,537734,5,2,,104234229,5743,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaMdr1p by agar disk diffusion assay,Other,20739103.0,
1091,537735,2,3,,104234229,5743,Inactive,,,,,Binding affinity to Candida albicans CaMdr1p expressed in yeast AD1-8u,Other,20739103.0,
1092,537736,5,2,,104234229,5743,Unspecified,,,,,Antifungal activity against yeast AD1-8u expressing Candida albicans CaCdr1p by agar disk diffusion assay,Other,20739103.0,
1093,540209,4,3,,104234229,5743,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
1094,540210,4,3,,104234229,5743,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
1095,540211,2,5,,104234229,5743,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
1096,540212,4,3,,104234229,5743,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
1097,540213,4,3,,104234229,5743,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
1098,540253,1,1,,56314873,5743,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1099,540253,1,1,,56314873,5743,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1100,540253,1,1,,56314873,5743,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1101,540253,1,1,,56320685,5743,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1102,540253,1,1,,56320685,5743,Inactive,5453555.0,5901.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1103,540253,1,1,,56320685,5743,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation,Confirmatory,,
1104,540263,1,1,,56314873,5743,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1105,540263,1,1,,56314873,5743,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1106,540263,1,1,,56320685,5743,Inactive,5031833.0,10073.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1107,540263,1,1,,56320685,5743,Inactive,19923142.0,3837.0,,Potency,qHTS Assay for Inhibitors of Rango (Ran-regulated importin-beta cargo) - Importin beta complex formation,Confirmatory,,
1108,540267,1,1,,56314873,5743,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1109,540267,1,1,,56320685,5743,Inactive,,,,,Small Molecules that selectively kill Giardia lamblia: qHTS,Screening,,
1110,540275,1,1,,56314873,5743,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
1111,540275,1,1,,56320685,5743,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1,Screening,,
1112,540277,1,1,,56314873,5743,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
1113,540277,1,1,,56320685,5743,Inactive,74315350.0,7442.0,,,HTS Assay for Compounds that Act as Potentiators of the Vanilloid Receptor 1,Screening,,
1114,540295,1,1,,56314873,5743,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1115,540295,1,1,,56320685,5743,Inactive,119508433.0,4160.0,,,TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R,Screening,,
1116,540303,1,1,,56314873,5743,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1117,540303,1,1,,56314873,5743,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1118,540303,1,1,,56314873,5743,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1119,540303,1,1,,56320685,5743,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1120,540303,1,1,,56320685,5743,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1121,540303,1,1,,56320685,5743,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation,Confirmatory,,
1122,540308,1,1,,56314873,5743,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1123,540308,1,1,,56320685,5743,Inactive,119508433.0,4160.0,,,Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R,Screening,,
1124,540317,1,1,,56314873,5743,Inactive,187960037.0,10951.0,,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1125,540317,1,1,,56320685,5743,Inactive,187960037.0,10951.0,100.0,Potency,HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
1126,540336,1,1,,56314873,5743,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1127,540336,1,1,,56314873,5743,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1128,540336,1,1,,56320685,5743,Inactive,68474550.0,3639678.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1129,540336,1,1,,56320685,5743,Inactive,68488893.0,3646682.0,,,Rtt109/Vps75 Measured in Biochemical System Using Plate Reader - 2106-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1130,540364,1,2,,56314873,5743,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1131,540364,1,2,,56320685,5743,Inactive,,2395.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter,Screening,,
1132,566275,6,5,,104234229,5743,Active,121069.0,2908.0,0.005,IC50,Inhibition of human glucocorticoid receptor,Confirmatory,20875743.0,
1133,568215,6,2,,104234229,5743,Active,,,0.01259,IC50,Displacement of fluorescent-labelled Dexamethasone from glucocorticoid receptor,Confirmatory,21257309.0,
1134,568216,5,6,,104234229,5743,Active,121069.0,2908.0,0.001,IC50,Agonist activity at glucocorticoid receptor in human A549 cells by NF-kappaB transrepression assay,Confirmatory,21257309.0,
1135,568217,2,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in human A549 cells by NFkappaB transrepression assay relative to Dexamethasone,Other,21257309.0,
1136,568218,5,6,,104234229,5743,Active,121069.0,2908.0,0.00398,IC50,Agonist activity at GR in human A549 cells transfected with luciferase gene linked to MMTV promoter assessed as luciferase transactivation activity,Confirmatory,21257309.0,
1137,568219,2,11,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at GR in human A549 cells transfected with luciferase gene linked to MMTV promoter assessed as luciferase transactivation activity relative to Dexamethasone,Other,21257309.0,
1138,568366,4,2,,104234229,5743,Active,,,0.86,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production treated 2 hrs before LPS challenge measured after 18 hrs by griess reaction,Confirmatory,21288727.0,
1139,578355,6,5,,104234229,5743,Active,1169883.0,24413.0,0.022000000000000002,IC50,Displacement of [3H]dexamethasone from Sprague-Dawley rat GR by liquid scintillation counting,Confirmatory,21349712.0,
1140,578564,4,2,,104234229,5743,Active,,,0.8,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method,Confirmatory,21353543.0,
1141,578565,4,2,,104234229,5743,Active,,,0.01,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion after 18 hrs,Confirmatory,21353543.0,
1142,578569,2,4,,104234229,5743,Active,,,,,Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as nitrite level at 10 uM after 24 hrs by Griess method,Other,21353543.0,
1143,578571,1,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as TNF-alpha level at 10 uM after 18 hrs,Other,21353543.0,
1144,587910,3,5,,104234229,5743,Active,,,,,Immunomodulatory activity in human HMC1 cells assessed as inhibition of phorbol 12-myristate 13-acetate/A23187-stimulated IL1-beta secretion treated 1 hr prior to 30 mins phorbol 12-myristate 13-acetate/A23187 challenge by Western blotting analysis,Other,21302967.0,
1145,588209,2,3,,104234229,5743,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
1146,588210,2,4,,104234229,5743,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
1147,588211,2,3,,104234229,5743,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
1148,588212,2,3,,104234229,5743,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
1149,588213,2,3,,104234229,5743,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
1150,588214,2,3,,104234229,5743,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
1151,588215,2,3,,104234229,5743,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
1152,588216,2,3,,104234229,5743,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
1153,588217,2,3,,104234229,5743,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
1154,588218,2,3,,104234229,5743,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
1155,588219,2,3,,104234229,5743,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
1156,588334,1,1,,56314873,5743,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1157,588334,1,1,,56320685,5743,Inactive,,,,,MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Activator_SinglePoint_HTS_Activity,Screening,,
1158,588335,1,1,,56314873,5743,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1159,588335,1,1,,56320685,5743,Inactive,,,,,Counterscreen for inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis: Absorbance-based biochemical high throughput Glycerophosphate Dehydrogenase-Triosephosphate Isomerase (GDH-TPI) full deck assay to identify assay artifacts,Screening,,
1160,588342,1,1,,56314873,5743,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
1161,588342,1,1,,56320685,5743,Inactive,160794.0,,,Potency,qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for miR-21 project),Confirmatory,,
1162,588352,1,2,,56314873,5743,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1163,588352,1,2,,56320685,5743,Inactive,32307126.0,8202.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 3 (SRC3; NCOA3),Screening,,
1164,588354,1,1,,56314873,5743,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1165,588354,1,1,,56320685,5743,Inactive,22538455.0,8648.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1),Screening,,
1166,588358,1,2,,56314873,5743,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1167,588358,1,2,,56320685,5743,Inactive,,,,,HTS to Find Inhibitors of Pathogenic Pemphigus Antibodies,Screening,,
1168,588391,1,1,,56320685,5743,Inactive,14790033.0,5034.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of Protein Disulfide Isomerase Measured in Biochemical System Using Plate Reader - 2137-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1169,588405,1,1,,56314873,5743,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1170,588405,1,1,,56320685,5743,Inactive,78486550.0,171071.0,,,HTS Assay for Peg3 Promoter Inhibitors,Screening,,
1171,588413,1,2,,56314873,5743,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1172,588413,1,2,,56320685,5743,Inactive,6009644.0,14632.0,,,uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay,Screening,,
1173,588436,1,1,,56314873,5743,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1174,588436,1,1,,56320685,5743,Inactive,,,,,"Cholera Quorum: HTS for inducers of light production in the absence ofautoinducers using BH1578 (luxS deficient, cqsA deficient) Measured in Microorganism System Using Plate Reader - 2132-01_Agonist_SinglePoint_HTS_Activity",Screening,,
1175,588453,1,1,,56314873,5743,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1176,588453,1,1,,56320685,5743,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1177,588456,1,1,,56314873,5743,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1178,588456,1,1,,56320685,5743,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
1179,588458,1,1,,56314873,5743,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1180,588458,1,1,,56320685,5743,Inactive,4503351.0,1786.0,,,uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay,Screening,,
1181,588473,1,1,,56314873,5743,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1182,588473,1,1,,56314873,5743,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1183,588473,1,1,,56320685,5743,Inactive,30219.0,1393.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1184,588473,1,1,,56320685,5743,Inactive,38349113.0,1395.0,,,uHTS identification of agonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1185,588475,1,2,,56314873,5743,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1186,588475,1,2,,56314873,5743,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1187,588475,1,2,,56320685,5743,Inactive,30219.0,1393.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1188,588475,1,2,,56320685,5743,Inactive,38349113.0,1395.0,,,uHTS identification of antagonists of the CRF-binding protein and CRF-R2 receptor complex,Screening,,
1189,588478,1,2,,124801160,5743,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1190,588478,1,2,,125231101,5743,Inactive,4877999.0,51377.0,,,"A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37",Other,,
1191,588489,1,1,,56314873,5743,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1192,588489,1,1,,56320685,5743,Inactive,46367787.0,26986.0,,,uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay,Screening,,
1193,588492,1,1,,56314873,5743,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1194,588492,1,1,,56320685,5743,Inactive,,,,,uHTS identification of small molecule modulators of myocardial damage,Screening,,
1195,588493,1,2,,56314873,5743,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1196,588493,1,2,,56320685,5743,Inactive,16306916.0,10213.0,,,uHTS identification of inhibitors of Rpn11 in a Fluorescent Polarization assay,Screening,,
1197,588497,1,2,,56314873,5743,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1198,588497,1,2,,56314873,5743,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1199,588497,1,2,,56314873,5743,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1200,588497,1,2,,56320685,5743,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,16604538.0,
1201,588497,1,2,,56320685,5743,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20035615.0,
1202,588497,1,2,,56320685,5743,Inactive,168184763.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set",Screening,20938917.0,
1203,588499,1,3,,56314873,5743,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1204,588499,1,3,,56314873,5743,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1205,588499,1,3,,56314873,5743,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1206,588499,1,3,,56320685,5743,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,16604538.0,
1207,588499,1,3,,56320685,5743,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20035615.0,
1208,588499,1,3,,56320685,5743,Inactive,148378801.0,5185061.0,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set",Screening,20938917.0,
1209,588501,1,2,,56314873,5743,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1210,588501,1,2,,56314873,5743,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1211,588501,1,2,,56314873,5743,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1212,588501,1,2,,56320685,5743,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,16604538.0,
1213,588501,1,2,,56320685,5743,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20035615.0,
1214,588501,1,2,,56320685,5743,Inactive,21392848.0,,,,"High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set",Screening,20938917.0,
1215,588511,1,2,,56320685,5743,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
1216,588513,1,1,,17389945,5743,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1217,588513,1,1,,26752878,5743,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
1218,588514,1,1,,17389945,5743,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1219,588514,1,1,,26752878,5743,Inactive,348019627.0,2099.0,,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
1220,588515,1,1,,17389945,5743,Inconclusive,124375976.0,367.0,0.3162,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1221,588515,1,1,,26752878,5743,Inconclusive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
1222,588516,1,1,,17389945,5743,Inconclusive,124375976.0,367.0,1.122,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1223,588516,1,1,,26752878,5743,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
1224,588519,1,2,,99300936,5743,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
1225,588526,1,1,,17389945,5743,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1226,588526,1,1,,26752878,5743,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
1227,588527,1,1,,17389945,5743,Inactive,325495553.0,9971.0,,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1228,588527,1,1,,26752878,5743,Inconclusive,325495553.0,9971.0,0.0035,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
1229,588532,1,1,,17389945,5743,Inconclusive,311348376.0,2908.0,0.0035,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1230,588532,1,1,,26752878,5743,Active,311348376.0,2908.0,0.0158,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
1231,588533,1,1,,17389945,5743,Inconclusive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1232,588533,1,1,,26752878,5743,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
1233,588534,1,1,,17389945,5743,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1234,588534,1,1,,26752878,5743,Inactive,216409690.0,5467.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1235,588535,1,1,,17389945,5743,Inconclusive,216409690.0,5467.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1236,588535,1,1,,26752878,5743,Inconclusive,216409690.0,5467.0,0.0178,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
1237,588536,1,1,,17389945,5743,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1238,588536,1,1,,26752878,5743,Inactive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1239,588537,1,1,,17389945,5743,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1240,588537,1,1,,26752878,5743,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
1241,588541,1,1,,17389945,5743,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1242,588541,1,1,,26752878,5743,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
1243,588543,1,1,,17389945,5743,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1244,588543,1,1,,26752878,5743,Inactive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
1245,588544,1,1,,17389945,5743,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1246,588544,1,1,,26752878,5743,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
1247,588545,1,1,,17389945,5743,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1248,588545,1,1,,26752878,5743,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
1249,588546,1,1,,17389945,5743,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1250,588546,1,1,,26752878,5743,Inactive,325495497.0,6256.0,,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
1251,588547,1,1,,17389945,5743,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1252,588547,1,1,,26752878,5743,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
1253,588549,1,1,,56314873,5743,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1254,588549,1,1,,56320685,5743,Inactive,1781172.0,,,,Fluorescence polarization to screen for inhibitor that competite the binding of FadD28 to bisubstrate Measured in Biochemical System Using Plate Reader - 2147-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1255,588579,1,1,,26752876,5743,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1256,588579,1,1,,26752877,5743,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1257,588579,1,1,,56314873,5743,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1258,588579,1,1,,56320685,5743,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
1259,588590,1,1,,56314873,5743,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1260,588590,1,1,,56320685,5743,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
1261,588591,1,1,,56314873,5743,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1262,588591,1,1,,56320685,5743,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
1263,588621,1,1,,56314873,5743,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1264,588621,1,1,,56320685,5743,Inactive,90652859.0,84867.0,,,uHTS identification of small molecule inhibitors of Striatal-Enriched Phosphatase via a fluorescence intensity assay,Screening,,
1265,588627,1,1,,56320685,5743,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
1266,588664,1,2,,56314873,5743,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1267,588664,1,2,,56314873,5743,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1268,588664,1,2,,56320685,5743,Inactive,62362414.0,25.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1269,588664,1,2,,56320685,5743,Inactive,68989256.0,9610.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)",Screening,,
1270,588674,1,2,,56314873,5743,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1271,588674,1,2,,56320685,5743,Inactive,,,,,Schnurri-3 Inhibitors: specific inducers of adult bone formation Measured in Cell-Based System Using Plate Reader - 2134-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1272,588675,1,1,,56320685,5743,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
1273,588676,1,1,,56320685,5743,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
1274,588689,1,1,,56314873,5743,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1275,588689,1,1,,56320685,5743,Inactive,219689243.0,,,IC50,Primary and Confirmatory Screening for Flavivirus Genomic Capping Enzyme Inhibition,Confirmatory,,
1276,588692,2,1,,56314873,5743,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1277,588692,2,1,,56320685,5743,Inactive,,,,,Luciferase Reporter Cell Based HTS to identify inhibitors of N-linked Glycosylation Measured in Cell-Based System Using Plate Reader - 2146-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1278,588726,1,2,,56314873,5743,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1279,588726,1,2,,56320685,5743,Inactive,15607504.0,886474.0,,,Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis,Screening,,
1280,588727,1,1,,56314873,5743,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1281,588727,1,1,,56320685,5743,Inactive,,,,IC50,"A Cell-Based Confirmatory Screen for Compounds that Inhibit VEEV, TC-83",Confirmatory,,
1282,588795,1,1,,56314873,5743,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1283,588795,1,1,,56320685,5743,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
1284,588812,1,1,,17389945,5743,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1285,588812,1,1,1.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1286,588812,1,1,2.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1287,588812,1,1,3.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1288,588812,1,1,4.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1289,588812,1,1,5.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1290,588812,1,1,6.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1291,588812,1,1,7.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1292,588812,1,1,8.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1293,588812,1,1,9.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1294,588812,1,1,10.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1295,588812,1,1,11.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1296,588812,1,1,12.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1297,588812,1,1,13.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1298,588812,1,1,14.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1299,588812,1,1,15.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1300,588812,1,1,16.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1301,588812,1,1,17.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1302,588812,1,1,18.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1303,588812,1,1,19.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1304,588812,1,1,20.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1305,588812,1,1,21.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1306,588812,1,1,22.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1307,588812,1,1,23.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1308,588812,1,1,24.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1309,588812,1,1,25.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1310,588812,1,1,26.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1311,588812,1,1,27.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1312,588812,1,1,28.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1313,588812,1,1,29.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1314,588812,1,1,30.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1315,588812,1,1,31.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1316,588812,1,1,32.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1317,588812,1,1,33.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1318,588812,1,1,34.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1319,588812,1,1,35.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1320,588812,1,1,36.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1321,588812,1,1,37.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1322,588812,1,1,38.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1323,588812,1,1,39.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1324,588812,1,1,40.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1325,588812,1,1,41.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1326,588812,1,1,42.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1327,588812,1,1,43.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1328,588812,1,1,44.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1329,588812,1,1,45.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1330,588812,1,1,46.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1331,588812,1,1,47.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1332,588812,1,1,48.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1333,588812,1,1,49.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1334,588812,1,1,50.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1335,588812,1,1,51.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1336,588812,1,1,52.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1337,588812,1,1,53.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1338,588812,1,1,54.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1339,588812,1,1,55.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1340,588812,1,1,56.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1341,588812,1,1,57.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1342,588812,1,1,58.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1343,588812,1,1,59.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1344,588812,1,1,60.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1345,588812,1,1,61.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1346,588812,1,1,62.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1347,588812,1,1,63.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1348,588812,1,1,64.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1349,588812,1,1,65.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1350,588812,1,1,66.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1351,588812,1,1,67.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1352,588812,1,1,68.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1353,588812,1,1,69.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1354,588812,1,1,70.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1355,588812,1,1,71.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1356,588812,1,1,72.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1357,588812,1,1,73.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1358,588812,1,1,74.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1359,588812,1,1,75.0,17389945,5743,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1360,588812,1,1,76.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1361,588812,1,1,77.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1362,588812,1,1,78.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1363,588812,1,1,79.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1364,588812,1,1,80.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1365,588812,1,1,81.0,17389945,5743,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
1366,588813,1,1,,17389945,5743,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1367,588813,1,1,1.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1368,588813,1,1,2.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1369,588813,1,1,3.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1370,588813,1,1,4.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1371,588813,1,1,5.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1372,588813,1,1,6.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1373,588813,1,1,7.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1374,588813,1,1,8.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1375,588813,1,1,9.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1376,588813,1,1,10.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1377,588813,1,1,11.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1378,588813,1,1,12.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1379,588813,1,1,13.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1380,588813,1,1,14.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1381,588813,1,1,15.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1382,588813,1,1,16.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1383,588813,1,1,17.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1384,588813,1,1,18.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1385,588813,1,1,19.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1386,588813,1,1,20.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1387,588813,1,1,21.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1388,588813,1,1,22.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1389,588813,1,1,23.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1390,588813,1,1,24.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1391,588813,1,1,25.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1392,588813,1,1,26.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1393,588813,1,1,27.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1394,588813,1,1,28.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1395,588813,1,1,29.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1396,588813,1,1,30.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1397,588813,1,1,31.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1398,588813,1,1,32.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1399,588813,1,1,33.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1400,588813,1,1,34.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1401,588813,1,1,35.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1402,588813,1,1,36.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1403,588813,1,1,37.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1404,588813,1,1,38.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1405,588813,1,1,39.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1406,588813,1,1,40.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1407,588813,1,1,41.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1408,588813,1,1,42.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1409,588813,1,1,43.0,17389945,5743,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1410,588813,1,1,44.0,17389945,5743,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1411,588813,1,1,45.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1412,588813,1,1,46.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1413,588813,1,1,47.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1414,588813,1,1,48.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1415,588813,1,1,49.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1416,588813,1,1,50.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1417,588813,1,1,51.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1418,588813,1,1,52.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1419,588813,1,1,53.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1420,588813,1,1,54.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1421,588813,1,1,55.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1422,588813,1,1,56.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1423,588813,1,1,57.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1424,588813,1,1,58.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1425,588813,1,1,59.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1426,588813,1,1,60.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1427,588813,1,1,61.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1428,588813,1,1,62.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1429,588813,1,1,63.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1430,588813,1,1,64.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1431,588813,1,1,65.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1432,588813,1,1,66.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1433,588813,1,1,67.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1434,588813,1,1,68.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1435,588813,1,1,69.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1436,588813,1,1,70.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1437,588813,1,1,71.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1438,588813,1,1,72.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1439,588813,1,1,73.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1440,588813,1,1,74.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1441,588813,1,1,75.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1442,588813,1,1,76.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1443,588813,1,1,77.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1444,588813,1,1,78.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1445,588813,1,1,79.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1446,588813,1,1,80.0,17389945,5743,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1447,588813,1,1,81.0,17389945,5743,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
1448,588814,1,3,,56314873,5743,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1449,588814,1,3,,56320685,5743,Inactive,37622910.0,1128.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)",Screening,,
1450,588819,1,4,,56314873,5743,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1451,588819,1,4,,56320685,5743,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).,Screening,,
1452,588827,1,1,,56320685,5743,Inactive,62740231.0,15499.0,,AC50_uM,HSF-1 induced GFP reporter and Doxycycline induced RFP reporter Measured in Cell-Based System Using Plate Reader - 2038-03_Inhibitor_Dose_CherryPick_Activity_Set4,Confirmatory,,
1453,588832,1,1,,56314873,5743,Inactive,7300964.0,,,,Hedgehog Measured in Biochemical System Using Plate Reader - 2070-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1454,588834,2,1,,17389945,5743,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
1455,588847,1,1,,56320685,5743,Inactive,2190535.0,,52.0,AC50_uM,Luciferase Inhibition Counter Screen Measured in Biochemical System Using Plate Reader - 2038-06_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1456,588850,1,1,,56314873,5743,Active,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1457,588850,1,1,,56320685,5743,Active,90421313.0,1080.0,,,uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1458,588852,1,3,,56314873,5743,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1459,588852,1,3,,56320685,5743,Inactive,37622910.0,1128.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1),Screening,,
1460,588855,1,1,,56314873,5743,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1461,588855,1,1,,56320685,5743,Inactive,18418623.0,4088.0,,Potency,qHTS for Inhibitors of TGF-b,Confirmatory,,
1462,588856,1,1,,56314873,5743,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1463,588856,1,1,,56320685,5743,Inactive,,,,Potency,qHTS for Inhibitors of TGF-b: Cytotox Counterscreen,Confirmatory,,
1464,589039,1,10,,104234229,5743,Unspecified,116241312.0,1576.0,,,"Clinically relevant substrates of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
1465,589050,1,10,,104234229,5743,Unspecified,308153612.0,1548.0,,,"Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP2A6",Other,,
1466,589056,1,10,,104234229,5743,Unspecified,116241312.0,1576.0,,,"Clinically relevant inducers of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
1467,589397,1,4,,104234229,5743,Active,,,0.02,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma induced NO production after 24 hrs by Griess reaction,Confirmatory,21361338.0,
1468,592681,1,4,,104234229,5743,Unspecified,,,,,Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis,Other,21458999.0,
1469,601264,1,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in rat Polymorphonuclear leukocyte assessed as inhibition of LPS-induced nitric oxide production at 5 uM,Other,21473609.0,
1470,602123,1,1,,56314873,5743,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1471,602123,1,1,,56320685,5743,Inactive,16128424.0,945085.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Escherichia coli DNA-binding ATP-dependent protease La (eLon),Screening,,
1472,602141,1,1,,56314873,5743,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1473,602141,1,1,,56320685,5743,Inactive,,,,,uHTS determination of small molecule cytotoxicity in a fluorescence assay to identify cystic fibrosis induced NFkb Inhibitors,Screening,,
1474,602162,1,1,,56314873,5743,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1475,602162,1,1,,56320685,5743,Inactive,9955963.0,10058.0,,,Flow Cytometric HTS Screen for inhibitors of the ABC transporter ABCB6 for MLPCN Compound Set,Screening,,
1476,602163,1,1,,56314873,5743,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1477,602163,1,1,,56320685,5743,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA),Screening,,
1478,602179,1,2,,56314873,5743,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1479,602179,1,2,,56320685,5743,Inactive,89573979.0,3417.0,,Potency,qHTS for Inhibitors of mutant isocitrate dehydrogenase 1 (IDH1): qHTS,Confirmatory,,
1480,602229,1,1,,56314873,5743,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1481,602229,1,1,,56320685,5743,Inactive,216409728.0,10002.0,,,"Luminescence-based cell-based high throughput primary screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3)",Screening,,
1482,602233,1,1,,56314873,5743,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1483,602233,1,1,,56320685,5743,Inactive,115503961.0,4357161.0,,Potency,qHTS Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
1484,602244,1,2,,56314873,5743,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1485,602244,1,2,,56320685,5743,Inactive,5730106.0,10663.0,,,uHTS identification of CXCR6 Inhibitors in a B-arrestin luminescence assay,Screening,,
1486,602247,1,2,,56314873,5743,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1487,602247,1,2,,56320685,5743,Inactive,,,,,Full deck counterscreen for positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1488,602248,1,2,,56314873,5743,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1489,602248,1,2,,56320685,5743,Inactive,,,,,Full deck counterscreen for agonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective activators and assay artifacts using the parental CHOK1 cell line,Screening,,
1490,602250,1,2,,56314873,5743,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1491,602250,1,2,,56320685,5743,Inactive,,,,,Full deck counterscreen for antagonists of the human M1 muscarinic receptor (CHRM1): Fluorescence-based cell-based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental CHOK1 cell line,Screening,,
1492,602252,1,1,,56314873,5743,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1493,602252,1,1,,56314873,5743,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1494,602252,1,1,,56320685,5743,Inactive,62868213.0,57120.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1495,602252,1,1,,56320685,5743,Inactive,90421313.0,1080.0,,,Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1496,602261,1,1,,56314873,5743,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1497,602261,1,1,,56320685,5743,Inactive,41872631.0,2194.0,,,uHTS identification of small molecule inhibitors of  the thioesterase domain of fatty acid synthase via a fluorescence intensity assay,Screening,,
1498,602266,1,1,,56320685,5743,Inactive,62740231.0,15499.0,,AC50_uM,Quantitative-PCR analysis for transcription inhibition of HSF-1 target gene Hsp90aa Measured in Cell-Based System Using RT-PCR - 2038-08_Inhibitor_Dose_CherryPick_Activity,Confirmatory,,
1499,602274,1,2,,56314873,5743,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1500,602274,1,2,,56320685,5743,Inactive,,,,,uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells,Screening,,
1501,602281,1,1,,56314873,5743,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1502,602281,1,1,,56314873,5743,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1503,602281,1,1,,56320685,5743,Inactive,31542303.0,51099.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1504,602281,1,1,,56320685,5743,Inactive,116292172.0,440503.0,,,"Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the lipase co-activator protein, abhydrolase domain containing 5 (ABHD5) with perilipin-5 (MLDP; PLIN5)",Screening,,
1505,602310,1,2,,56314873,5743,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1506,602310,1,2,,56320685,5743,Inactive,13399304.0,60489.0,,Potency,qHTS for Inhibitors of Vif-A3G Interactions: qHTS,Confirmatory,,
1507,602313,1,1,,56314873,5743,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1508,602313,1,1,,56320685,5743,Inactive,22907044.0,200316.0,,Potency,qHTS for Inhibitors of Vif-A3F Interactions: qHTS,Confirmatory,,
1509,602314,1,2,,99300936,5743,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
1510,602329,1,1,,56314873,5743,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1511,602329,1,1,,56320685,5743,Inactive,216548193.0,8438.0,,,Identification of inhibitors of RAD54 Measured in Biochemical System Using Plate Reader - 2159-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1512,602332,1,1,,26752876,5743,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1513,602332,1,1,,26752877,5743,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1514,602332,1,1,,56314873,5743,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1515,602332,1,1,,56320685,5743,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
1516,602340,1,2,,56314873,5743,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1517,602340,1,2,,56320685,5743,Inactive,,,,,HTS for suppressors of simvastatin-induced mytoxicity in differentiated C2C12 cells Measured in Cell-Based System Using Plate Reader - 2112-01_Suppressor_SinglePoint_HTS_Activity,Screening,,
1518,602342,2,1,,56314873,5743,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1519,602342,2,1,,56320685,5743,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1520,602346,1,1,,56314873,5743,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1521,602346,1,1,,56320685,5743,Inactive,9629361.0,155459.0,,,Identification of VIF Inhibitors Measured in Cell-Based System Using Imaging - 2108-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1522,602363,1,1,,56314873,5743,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1523,602363,1,1,,56320685,5743,Inactive,,,,,Whole cell Yeast HTS to identify compounds modulating the fidelity of the start codon recognition in eukaryotes. Measured in Whole Organism System Using Plate Reader - 2155-01_Other_SinglePoint_HTS_Activity,Screening,,
1524,602393,1,1,,56314873,5743,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1525,602393,1,1,,56320685,5743,Inactive,291463269.0,20586.0,,,Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1526,602396,1,2,,56314873,5743,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1527,602396,1,2,,56320685,5743,Inactive,4504343.0,2494.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2),Screening,,
1528,602399,1,2,,56314873,5743,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1529,602399,1,2,,56320685,5743,Inactive,15927174.0,,,,uHTS identification of inhibitors of NadD in a Colorimetric assay,Screening,,
1530,602405,1,1,,56314873,5743,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1531,602405,1,1,,56320685,5743,Inactive,75495260.0,,,,PgID: DNTB colorimetric HTS to detect inhibitor of PgID Measured in Biochemical System Using Plate Reader - 2164-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1532,602410,1,1,,56314873,5743,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1533,602410,1,1,,56320685,5743,Inactive,11093520.0,3777.0,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3,Screening,,
1534,602429,1,1,,56314873,5743,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1535,602429,1,1,,56320685,5743,Inactive,1762973.0,7341.0,,,uHTS identification of SUMO1-mediated protein-protein interactions,Screening,,
1536,602438,1,1,,56314873,5743,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1537,602438,1,1,,56320685,5743,Inactive,160877737.0,,,,uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay,Screening,,
1538,602440,1,1,,56314873,5743,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1539,602440,1,1,,56320685,5743,Inactive,262118306.0,123228.0,,,uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8),Screening,,
1540,602449,1,2,,56314873,5743,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1541,602449,1,2,,56320685,5743,Inactive,,,,,uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay,Screening,,
1542,602472,1,1,,56314873,5743,Inactive,90421313.0,1080.0,,,Single concentration confirmation of uHTS hits for cystic fibrosis induced NFkb Inhibitors in a fluoresence assay,Screening,,
1543,602481,1,1,,56314873,5743,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1544,602481,1,1,,56320685,5743,Inactive,378544807.0,,,,Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1545,603439,1,5,,104234229,5743,Unspecified,,,,,Inhibition of LPS-induced nitric oxide production in C57BL/6J mouse peritoneal macrophages at 10 uM after 24 hrs by Griess reaction,Other,21469695.0,
1546,604795,4,2,,104234229,5743,Active,,,0.0011,Ki,Displacement of GS-red from GRapha by fluorescence polarization assay,Confirmatory,21073190.0,
1547,604797,5,5,,104234229,5743,Active,121069.0,2908.0,0.0025,EC50,Transrepression activity of glucocorticoid receptor in human A549 cells expressing AP-1 assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay,Confirmatory,21073190.0,
1548,604799,5,5,,104234229,5743,Active,121069.0,2908.0,0.0042,EC50,Transactivation activity of glucocorticoid receptor ligand binding domain expressed in human NP-1 Hela cells co-expressing GAL4 DNA binding domain by luciferase reporter gene assay,Confirmatory,21073190.0,
1549,604800,5,5,,104234229,5743,Active,121069.0,2908.0,0.0011,EC50,Transrepression activity of glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay,Confirmatory,21073190.0,
1550,604854,5,5,,104234229,5743,Active,121069.0,2908.0,0.005,EC50,Transactivation activity at glucocorticoid receptor in human 13D3/Huh7 cells assessed as induction of tyrosine aminotransferase activity after 24 hrs,Confirmatory,21073190.0,
1551,609789,1,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha production at 1 uM treated 30 mins before LPS challenge measured after 24 hrs by ELISA,Other,21737269.0,
1552,609817,1,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced IL6 production at 1 uM treated 30 mins before LPS challenge measured after 24 hrs by ELISA,Other,21737269.0,
1553,610928,1,4,,104234229,5743,Unspecified,,,,,Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide mRNA expression at 10 uM after 24 hrs by RT-PCR relative to control,Other,21598928.0,
1554,612358,1,4,,104234229,5743,Active,,,,,Inhibition of LPS-induced TNFalpha production in mouse RAW264.7 cells pre-incubated for 30 mins before LPS challenge measured 6 hrs post LPS challenge by ELISA,Other,21775152.0,
1555,612359,1,4,,104234229,5743,Active,,,,,Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 20 mins before LPS challenge measured 18 hrs post LPS challenge by Griess method,Other,21775152.0,
1556,616800,1,5,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in knockout-transgenic sickle cell mouse monocytes assessed as inhibition of LPS-induced TNFalpha production at 1 uM administered 30 mins before LPS challenge measured after 24 hrs by ELISA,Other,21766854.0,
1557,620568,1,5,,104234229,5743,Active,,,,,Antiinflammatory activity in human monocytes assessed as inhibition of LPS-induced COX2 expression at 5 uM after 20 hrs using rabbit polyclonal antibody IgG by SDS-PAGE analysis,Other,21843935.0,
1558,623674,1,4,,104234229,5743,Inactive,,,,,"Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in mechanical hyperalgesia at 2 mg/kg, ip administered 40 mins before CFA challenge measured after 2 to 6 hrs",Other,21939182.0,
1559,623681,1,4,,104234229,5743,Inactive,,,,,"Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in paw edema at 2 mg/kg, ip administered 40 mins before CFA challenge measured after 2 hrs",Other,21939182.0,
1560,623682,1,4,,104234229,5743,Inactive,,,,,"Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in paw edema at 2 mg/kg, ip administered 40 mins before CFA challenge measured after 4 hrs",Other,21939182.0,
1561,623683,1,4,,104234229,5743,Inactive,,,,,"Antinociceptive activity against Freund's complete adjuvant-induced paw inflammation in mouse assessed as reduction in paw edema at 2 mg/kg, ip administered 40 mins before CFA challenge measured after 6 hrs",Other,21939182.0,
1562,623687,1,5,,104234229,5743,Active,,,,,"Inhibition of IL1-beta production in Freund's complete adjuvant-induced mouse at 2 mg/kg, ip administered 40 mins before CFA challenge measured after 2 hrs by ELISA",Other,21939182.0,
1563,623690,1,4,,104234229,5743,Active,,,,,"Inhibition of TNF-alpha production in Freund's complete adjuvant-induced mouse at 2 mg/kg, ip administered 40 mins before CFA challenge measured after 2 hrs by ELISA",Other,21939182.0,
1564,623870,1,1,,56320685,5743,Inactive,2702319.0,405.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1565,623870,1,1,,56320685,5743,Inactive,5454102.0,10460.0,,,ARNT-TAC3: AlphaScreen HTS to detect disruption of ARNT/TAC3 interactions Measured in Biochemical System Using Plate Reader - 2158-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1566,623877,1,1,,56314873,5743,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1567,623877,1,1,,56320685,5743,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A),Screening,,
1568,623901,1,1,,56314873,5743,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1569,623901,1,1,,56320685,5743,Inactive,,,,,Small molecule inhibitors of miR122  Measured in Cell-Based System Using Plate Reader - 2144-01_Activator_SinglePoint_HTS_Activity,Screening,,
1570,624037,1,3,,56314873,5743,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1571,624037,1,3,,56320685,5743,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1572,624038,1,3,,56314873,5743,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1573,624038,1,3,,56320685,5743,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1574,624040,1,3,,56314873,5743,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1575,624040,1,3,,56320685,5743,Inactive,7108336.0,1133.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)",Screening,,
1576,624101,1,2,,85787759,5743,Inactive,62203298.0,3417.0,,,Development of  IDH1/2 inhibitors (CTD2project) Measured in Biochemical System Using Plate Reader - 2107-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1577,624125,1,4,,56314873,5743,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1578,624125,1,4,,56320685,5743,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1579,624126,1,3,,56314873,5743,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1580,624126,1,3,,56320685,5743,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1581,624127,1,2,,56314873,5743,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1582,624127,1,2,,56320685,5743,Inactive,52426748.0,1132.0,,,"Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)",Screening,,
1583,624137,1,1,,85787759,5743,Inactive,881546.0,3400.0,,,SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity,Screening,,
1584,624156,1,1,,85787759,5743,Inactive,,,,,Fluorescence Cell-Based Primary  HTS to Identify Reactive Oxygen Species Inducers in Cancer Cells Measured in Cell-Based System Using Plate Reader and Imaging Combination - 2044-01_Activator_SinglePoint_HTS_Activity,Screening,,
1585,624168,1,1,,56314873,5743,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1586,624168,1,1,,56320685,5743,Inactive,47678551.0,9215.0,,,uHTS identification of small molecule activators of alpha dystroglycan glycosylation,Screening,,
1587,624169,1,1,,56314873,5743,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1588,624169,1,1,,56320685,5743,Inactive,27753985.0,15558.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A),Screening,,
1589,624170,1,1,,56314873,5743,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1590,624170,1,1,,56320685,5743,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
1591,624171,1,1,,56314873,5743,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1592,624171,1,1,,56320685,5743,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators,Confirmatory,,
1593,624172,1,1,,56314873,5743,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1594,624172,1,1,,56320685,5743,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
1595,624173,1,3,,56314873,5743,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1596,624173,1,3,,56320685,5743,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
1597,624178,1,1,,56314873,5743,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1598,624178,1,1,,56320685,5743,Unspecified,179095.0,6609.0,,Potency,qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate,Confirmatory,,
1599,624202,1,1,,56314873,5743,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1600,624202,1,1,,56320685,5743,Inactive,1698399.0,672.0,,Potency,qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression,Confirmatory,,
1601,624204,1,2,,56314873,5743,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1602,624204,1,2,,56320685,5743,Inactive,7657550.0,,,,"uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay",Screening,,
1603,624246,1,1,,56314873,5743,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1604,624246,1,1,,56320685,5743,Inactive,343478176.0,2078.0,,Potency,qHTS for Small Molecule Inhibitors of the ERG Ets/DNA interaction,Confirmatory,,
1605,624256,1,2,,56314873,5743,Inconclusive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1606,624256,1,2,,56320685,5743,Inconclusive,,3205.0,,,HTS to identify compounds that promote myeloid differentiation with MLPCN compound set,Screening,,
1607,624260,1,1,,85787759,5743,Inactive,109633019.0,7468.0,,,NSD2 Inhibitors Measured in Biochemical System Using Plate Reader - 2115-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1608,624263,1,1,,56314873,5743,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1609,624263,1,1,,56314873,5743,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1610,624263,1,1,,56320685,5743,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1611,624263,1,1,,56320685,5743,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
1612,624267,1,2,,56314873,5743,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1613,624267,1,2,,56314873,5743,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1614,624267,1,2,,56320685,5743,Inactive,4506537.0,8767.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1615,624267,1,2,,56320685,5743,Inactive,119603173.0,64127.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2),Screening,,
1616,624268,1,3,,56314873,5743,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1617,624268,1,3,,56320685,5743,Inactive,71746704.0,3662741.0,,,Luminescence-based biochemical primary high throughput screening assay to identify inhibitors of Trypanosoma brucei methionyl tRNA synthetase (MetRS),Screening,,
1618,624288,1,1,,56314873,5743,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1619,624288,1,1,,56320685,5743,Inactive,52000961.0,2778.0,,Potency,"qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS",Confirmatory,,
1620,624296,1,1,,56314873,5743,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1621,624296,1,1,,56320685,5743,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
1622,624297,1,1,,56314873,5743,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1623,624297,1,1,,56320685,5743,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
1624,624304,1,2,,56314873,5743,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1625,624304,1,2,,56320685,5743,Inactive,25148072.0,177343.0,,,uHTS identification of SKN-1 Inhibitors in a fluoresence assay,Screening,,
1626,624330,1,2,,56314873,5743,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1627,624330,1,2,,56320685,5743,Inactive,21361397.0,29127.0,,IC50,Discovery of small molecule inhibitors of the oncogenic and cytokinetic protein MgcRacGAP -  Primary and Confirmatory Screens,Confirmatory,,
1628,624349,1,2,,92308949,5743,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1629,624349,1,2,,121362596,5743,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
1630,624352,1,1,,56314873,5743,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1631,624352,1,1,,56320685,5743,Inactive,40254439.0,2034.0,,,uHTS identification of HIF-2a Inhibitors in a luminesence assay,Screening,,
1632,624354,1,1,,56314873,5743,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1633,624354,1,1,,56320685,5743,Inactive,224494019.0,8795.0,,,uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay,Screening,,
1634,624377,1,1,,56320686,5743,Inactive,351542238.0,50807.0,,,"Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)",Screening,,
1635,624414,1,1,,56314873,5743,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1636,624414,1,1,,56320685,5743,Inactive,10092597.0,57192.0,,,qHTS for Agonists of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1637,624415,1,2,,56314873,5743,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1638,624415,1,2,,56320685,5743,Inactive,10092597.0,57192.0,,,qHTS for Inhibitors of the Human Mucolipin Transient Receptor Potential 1 (TRPML1),Screening,,
1639,624416,1,1,,56320686,5743,Inactive,9629363.0,155971.0,,,"TRFRET-based biochemical primary high throughput screening assay to identify small molecules that bind to the HIV-1-gp120 binding antibody, PG9",Screening,,
1640,624417,1,1,,56314873,5743,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1641,624417,1,1,,56320685,5743,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode),Confirmatory,,
1642,624418,1,1,,56314873,5743,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1643,624418,1,1,,56320685,5743,Inactive,,,,Potency,qHTS of GLP-1 Receptor Inverse Agonists: Cytotox Screen,Confirmatory,,
1644,624463,1,1,,56314873,5743,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1645,624463,1,1,,56320685,5743,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists,Other,,
1646,624464,1,1,,56314873,5743,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1647,624464,1,1,,56320685,5743,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators,Other,,
1648,624465,1,1,,56314873,5743,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1649,624465,1,1,,56320685,5743,Inactive,4503385.0,1813.0,,,Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists,Other,,
1650,624466,1,3,,56320686,5743,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1651,624467,1,1,,56320686,5743,Inactive,21264324.0,134864.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human trace amine associated receptor 1 (TAAR1),Screening,,
1652,624483,1,1,,56314873,5743,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1653,624483,1,1,,56320685,5743,Inactive,,,,,Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease,Screening,,
1654,624622,3,1,,104234229,5743,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
1655,624623,3,1,,104234229,5743,Unspecified,238054374.0,5243.0,,,Apparent permeability (Papp) from basolateral to apical side determined in MDR1-MDCKII cells,Other,11602674.0,
1656,624626,1,9,,104234229,5743,Unspecified,238054374.0,5243.0,,,Ratio of apparent permeability from basolateral to apical side over apical to basolateral side determined in MDR1-MDCKII cells,Other,11602674.0,
1657,624628,1,9,,104234229,5743,Unspecified,238054374.0,5243.0,,,Drug-stimulated Pgp ATPase activity ratio determined in MDR1-Sf9 cell membranes with test compound at a concentration of 20uM,Other,11602674.0,
1658,624629,1,9,,104234229,5743,Unspecified,238054374.0,5243.0,,,Inhibition of Pgp expressed in MDR1-MDCKII cells measured by calcein-AM assay,Other,11602674.0,
1659,625144,5,5,,104234229,5743,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
1660,625145,4,7,,104234229,5743,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
1661,625146,5,5,,104234229,5743,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
1662,625147,4,7,,104234229,5743,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1663,625148,4,7,,104234229,5743,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1664,625149,4,7,,104234229,5743,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
1665,625150,5,5,,104234229,5743,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
1666,625151,4,7,,104234229,5743,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1667,625152,4,7,,104234229,5743,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1668,625153,4,7,,104234229,5743,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1669,625154,4,7,,104234229,5743,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1670,625155,4,7,,104234229,5743,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
1671,625156,1,9,,104234229,5743,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
1672,625157,6,2,,104234229,5743,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
1673,625158,3,4,,104234229,5743,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
1674,625159,5,5,,104234229,5743,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
1675,625160,1,9,,104234229,5743,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
1676,625161,4,7,,104234229,5743,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
1677,625162,4,7,,104234229,5743,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1678,625163,4,7,,104234229,5743,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
1679,625164,1,6,,104234229,5743,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
1680,625165,3,4,,104234229,5743,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1681,625166,3,4,,104234229,5743,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
1682,625167,5,5,,104234229,5743,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
1683,625168,4,7,,104234229,5743,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
1684,625169,1,6,,104234229,5743,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
1685,625170,3,4,,104234229,5743,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
1686,625171,4,7,,104234229,5743,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
1687,625172,4,7,,104234229,5743,Active,75071465.0,,23.291999999999998,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
1688,625173,5,5,,104234229,5743,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
1689,625174,5,5,,104234229,5743,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
1690,625175,5,5,,104234229,5743,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
1691,625176,1,9,,104234229,5743,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
1692,625177,5,5,,104234229,5743,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1693,625178,5,5,,104234229,5743,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
1694,625179,1,9,,104234229,5743,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
1695,625180,5,5,,104234229,5743,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1696,625181,5,5,,104234229,5743,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1697,625182,5,5,,104234229,5743,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
1698,625183,5,5,,104234229,5743,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
1699,625184,5,5,,104234229,5743,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1700,625185,5,5,,104234229,5743,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1701,625186,5,5,,104234229,5743,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1702,625187,5,5,,104234229,5743,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
1703,625188,1,9,,104234229,5743,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
1704,625189,1,7,,104234229,5743,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
1705,625190,4,5,,104234229,5743,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
1706,625191,4,7,,104234229,5743,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1707,625192,4,7,,104234229,5743,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
1708,625193,5,5,,104234229,5743,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
1709,625194,4,7,,104234229,5743,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
1710,625195,4,7,,104234229,5743,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
1711,625196,5,6,,104234229,5743,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
1712,625197,3,4,,104234229,5743,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
1713,625198,4,7,,104234229,5743,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1714,625199,4,7,,104234229,5743,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1715,625200,4,7,,104234229,5743,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
1716,625201,4,7,,104234229,5743,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
1717,625202,4,7,,104234229,5743,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
1718,625203,4,7,,104234229,5743,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
1719,625204,4,7,,104234229,5743,Unspecified,48429211.0,153.0,,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1720,625205,4,7,,104234229,5743,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
1721,625206,4,7,,104234229,5743,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
1722,625207,4,7,,104234229,5743,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1723,625208,5,5,,104234229,5743,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
1724,625209,4,7,,104234229,5743,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
1725,625210,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
1726,625211,1,6,,104234229,5743,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
1727,625212,3,4,,104234229,5743,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
1728,625213,4,7,,104234229,5743,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
1729,625214,1,9,,104234229,5743,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
1730,625215,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
1731,625216,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
1732,625217,4,7,,104234229,5743,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1733,625218,4,7,,104234229,5743,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
1734,625219,3,4,,104234229,5743,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
1735,625220,4,7,,104234229,5743,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
1736,625221,4,7,,104234229,5743,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
1737,625222,4,7,,104234229,5743,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
1738,625223,4,7,,104234229,5743,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
1739,625224,3,4,,104234229,5743,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
1740,625225,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
1741,625226,4,7,,104234229,5743,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
1742,625227,4,7,,104234229,5743,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
1743,625228,4,7,,104234229,5743,Active,113832.0,24208.0,24.555999999999997,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
1744,625229,5,5,,104234229,5743,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
1745,625230,1,6,,104234229,5743,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
1746,625231,4,7,,104234229,5743,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
1747,625232,1,9,,104234229,5743,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
1748,625233,4,7,,104234229,5743,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
1749,625234,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
1750,625235,4,7,,104234229,5743,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
1751,625236,5,5,,104234229,5743,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
1752,625237,4,7,,104234229,5743,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
1753,625238,4,7,,104234229,5743,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
1754,625239,4,7,,104234229,5743,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
1755,625240,1,9,,104234229,5743,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
1756,625241,4,7,,104234229,5743,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
1757,625242,4,7,,104234229,5743,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
1758,625243,5,5,,104234229,5743,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1759,625244,5,5,,104234229,5743,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
1760,625245,5,5,,104234229,5743,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1761,625246,1,9,,104234229,5743,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
1762,625247,5,5,,104234229,5743,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1763,625248,5,5,,104234229,5743,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1764,625249,5,5,,104234229,5743,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1765,625250,5,5,,104234229,5743,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
1766,625251,5,5,,104234229,5743,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
1767,625252,4,7,,104234229,5743,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
1768,625253,4,7,,104234229,5743,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1769,625254,4,7,,104234229,5743,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1770,625255,4,7,,104234229,5743,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
1771,625256,4,7,,104234229,5743,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
1772,625257,4,7,,104234229,5743,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
1773,625258,4,7,,104234229,5743,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1774,625259,4,7,,104234229,5743,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
1775,625260,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
1776,625261,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
1777,625262,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
1778,625263,4,7,,104234229,5743,Active,121069.0,2908.0,0.00806,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
1779,625264,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
1780,625265,1,6,,104234229,5743,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
1781,625266,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
1782,625267,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
1783,625268,4,2,,104234229,5743,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1784,625268,4,2,,104234229,5743,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1785,625268,4,2,,104234229,5743,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1786,625268,4,2,,104234229,5743,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
1787,625269,4,7,,104234229,5743,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
1788,625270,4,7,,104234229,5743,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
1789,625271,5,5,,104234229,5743,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
1790,625272,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
1791,625273,4,6,,104234229,5743,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
1792,625274,1,6,,104234229,5743,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
1793,625275,3,4,,104234229,5743,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
1794,625277,1,3,,104234229,5743,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI,Other,21624500.0,
1795,625279,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
1796,625280,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
1797,625281,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
1798,625282,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
1799,625283,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
1800,625284,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
1801,625285,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
1802,625286,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
1803,625287,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
1804,625288,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
1805,625289,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
1806,625290,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
1807,625291,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
1808,625292,1,3,,104234229,5743,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
1809,626140,4,5,,104234229,5743,Active,121069.0,2908.0,0.003,IC50,Displacement of tetramethylrhodamine-labeled Dexamethasone from human recombinant glucocorticoid receptor expressed in baculovirus infected insect cells by fluorescence polarization assay,Confirmatory,21963986.0,
1810,626141,4,5,,104234229,5743,Unspecified,90110048.0,5241.0,2.0,IC50,Displacement of tetramethylrhodamine-labeled RU-486 from human recombinant progesterone receptor expressed in baculovirus infected insect cells by fluorescence polarization assay,Confirmatory,21963986.0,
1811,626142,4,5,,104234229,5743,Active,126885.0,4306.0,0.033,IC50,Displacement of tetramethylrhodamine-labeled Dexamethasone from human recombinant mineralocorticoid receptor expressed in baculovirus infected insect cells by fluorescence polarization assay,Confirmatory,21963986.0,
1812,626146,2,6,,104234229,5743,Active,121069.0,2908.0,0.0005099999999999999,IC50,Agonist activity at glucocorticoid receptor in HFF assessed as inhibition of IL1-induced IL-6 production after 18 to 24 hrs,Confirmatory,21963986.0,
1813,626200,4,5,,104234229,5743,Active,121069.0,2908.0,0.0018,EC50,Transactivation activity of glucocorticoid receptor in HFF assessed as induction of aromatase activity by measuring beta-estradiol activity after 18 to 24 hrs by ELISA,Confirmatory,21963986.0,
1814,626202,2,6,,104234229,5743,Active,121069.0,2908.0,0.017,EC50,Agonist activity at glucocorticoid receptor in human HeLa cells transfected with luciferase gene linked to MMTV promoter assessed as luciferase transactivation activity,Confirmatory,21963986.0,
1815,626476,4,5,,104234229,5743,Active,1169883.0,24413.0,0.022000000000000002,IC50,Displacement of [3H]Dex from glucocorticoid receptor in Sprague-Dawley rat liver after 2 hrs by liquid scintillation counting,Confirmatory,21944856.0,
1816,626817,1,4,,104234229,5743,Active,,,0.0069,EC50,Antiinflammatory activity in human whole blood assessed as inhibition of LPS-induced TNFalpha production after overnight incubation by ELISA,Confirmatory,21899328.0,
1817,626821,1,4,,104234229,5743,Active,,,0.0051,EC50,Antiinflammatory activity in human whole blood assessed as inhibition of IL-1beta-induced IL-8 production after overnight incubation by ELISA,Confirmatory,21899328.0,
1818,628386,1,4,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in BALB/c mouse model assessed as inhibition of ovalbumin-induced eosinophil accumulation in bronchoalveolar lavage fluid at 1 mg/kg, ip administered 1 hr prior to and 7 hrs after ovalbumin challenge for 3 days measured 8 hrs after final dose by cell counting",Other,21916510.0,
1819,628411,1,3,,104234229,5743,Active,,,,,"Antiinflammatory activity in BALB/c mouse contact hypersensitivity model assessed as inhibition of FITC-mediated ear swelling at 5 mg/kg, iv administered 1 hr prior to and 7 hrs after the FITC-challenge measured 24 hrs after final dose",Other,21916510.0,
1820,639529,1,4,,104234229,5743,Unspecified,,,,,"Antihypersensitivity against TNCB-induced contact hypersensitivity in BALB/c mouse ear assessed as inhibition of edema at 0.025 mg/ear applied tropically after 30 mins, 24 hrs and 48 hrs of TNCB challenge measured after 24 hrs relative to control",Other,21469692.0,
1821,639532,1,4,,104234229,5743,Unspecified,,,,,"Antihypersensitivity against TNCB-induced contact hypersensitivity in BALB/c mouse ear assessed as inhibition of edema at 0.025 mg/ear applied tropically after 30 mins, 24 hrs and 48 hrs of TNCB challenge measured after 72 hrs relative to control",Other,21469692.0,
1822,639575,1,4,,104234229,5743,Active,,,,,Antihypersensitivity activity against TNCB-induced atopic dermatitis in BALB/c mouse ear assessed as inhibition of ear thickness at 0.025 mg/ear applied topically three times per week 30 min TNCB post challenge measured up to 25 days,Other,21469692.0,
1823,639578,1,4,,104234229,5743,Unspecified,,,,,Antihypersensitivity activity against TNCB-induced acute contact hypersensitivity in BALB/c mouse ear assessed as inhibition of neutrophil infiltration by measuring MPO activity at 0.025 mg/ear measured after 24 to 72 hrs relative to control,Other,21469692.0,
1824,639579,1,4,,104234229,5743,Unspecified,,,,,Antihypersensitivity activity against TNCB-induced acute contact hypersensitivity in BALB/c mouse ear assessed as inhibition of neutrophil infiltration by measuring MPO activity at 0.025 mg/ear measured after 22 days of repeated application of TNCB relative to control,Other,21469692.0,
1825,639584,1,4,,104234229,5743,Unspecified,,,,,Antihypersensitivity activity against TNCB-induced contact hypersensitivity in BALB/c mouse ear assessed as decrease cytokines levels at 0.025 mg/ear measured at 24 hrs by ELISA relative to control,Other,21469692.0,
1826,639590,1,4,,104234229,5743,Unspecified,,,,,Antihypersensitivity activity against TNCB-induced contact hypersensitivity in BALB/c mouse ear assessed as decreased COX2 expression at 0.025 mg/ear after at 24 hrs by Western blotting relative to control,Other,21469692.0,
1827,639591,1,4,,104234229,5743,Unspecified,,,,,Antihypersensitivity activity against TNCB-induced contact hypersensitivity in BALB/c mouse ear assessed as decreased COX2 expression at 0.025 mg/ear after at 72 hrs by Western blotting relative to control,Other,21469692.0,
1828,639626,1,4,,104234229,5743,Unspecified,,,,,Antihypersensitivity activity against TNCB-induced contact hypersensitivity in BALB/c mouse ear assessed as inhibition of MMP9 production at 0.025 mg/ear measured at 24 hrs by Western blot analysis relative to control,Other,21469692.0,
1829,639627,1,4,,104234229,5743,Unspecified,,,,,Antihypersensitivity activity against TNCB-induced contact hypersensitivity in BALB/c mouse ear assessed as inhibition of MMP9 production at 0.025 mg/ear measured at 72 hrs by Western blot analysis relative to control,Other,21469692.0,
1830,651548,1,1,,85787759,5743,Inactive,21361095.0,2146.0,,,EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1831,651550,1,1,,56314873,5743,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1832,651550,1,1,,56320685,5743,Inactive,60391226.0,207.0,,,HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen,Screening,,
1833,651560,1,1,,56314873,5743,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1834,651560,1,1,,56320685,5743,Inactive,1709543.0,52.0,,,"uHTS identification of small molecule inhibitors of Low Molecular Weight Protein Tyrosine Phosphatase, LMPTP, via a fluorescence intensity assay",Screening,,
1835,651572,1,2,,56320686,5743,Active,21489979.0,246310.0,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1836,651582,1,1,,56320685,5743,Inactive,,,,,uHTS identification of small molecule Triacylglycerol inhbitors in a fluoresence assay,Screening,,
1837,651602,1,1,,56320686,5743,Inactive,16130723.0,947287.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1838,651602,1,1,,56320686,5743,Inactive,16130724.0,947286.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1839,651602,1,1,,56320686,5743,Inactive,16130726.0,947294.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of RecBCD (with phage),Screening,,
1840,651608,1,1,,56320686,5743,Inactive,21489979.0,246310.0,,,Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of ADP-ribosylation factor GTPase activating protein 1 (ARFGAP1),Screening,,
1841,651610,2,1,,56320686,5743,Inactive,,,,,HIV entry: Env-mediated Cell Fusion Measured in Cell-Based System Using Plate Reader - 7013-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1842,651631,4,1,,144207320,5743,Inconclusive,269849759.0,7157.0,0.2468,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
1843,651632,4,1,,144207320,5743,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
1844,651633,4,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
1845,651634,4,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
1846,651635,1,3,,56314873,5743,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1847,651635,1,3,,56320685,5743,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
1848,651636,1,1,,56314873,5743,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1849,651636,1,1,,56320685,5743,Inactive,4826706.0,1880.0,,,uHTS identification of small molecule antagonists of the EBI2 receptor via a luminescent beta-arrestin assay,Screening,,
1850,651640,1,1,,56320686,5743,Inactive,,,,,DENV2 CPE-Based HTS Measured in Cell-Based and Microorganism Combination System Using Plate Reader - 2149-01_Other_SinglePoint_HTS_Activity,Screening,,
1851,651644,1,1,,56314873,5743,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1852,651644,1,1,,56320685,5743,Inactive,28872817.0,155807.0,,Potency,qHTS Assay for Inhibitors of the HIV-1 protein Vpr,Confirmatory,,
1853,651647,1,1,,56314873,5743,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1854,651647,1,1,,56320685,5743,Inactive,4826834.0,4323.0,,,uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay,Screening,,
1855,651654,1,1,,56314873,5743,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1856,651654,1,1,,56320685,5743,Inactive,,,,,HTS for the detection of C. neoformans cell lysis via adenylate kinase (AK) release Measured in Microorganism System Using Plate Reader - 2162-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1857,651658,1,1,,56320686,5743,Inactive,10190672.0,27006.0,,,Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1858,651661,2,1,,56320686,5743,Inactive,,,,,Luminescence Cell-Based Primary HTS to identify inhibitors of the oncoprotein EWS/Fli transcriptional activity Measured in Cell-Based System Using Plate Reader - 7014-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1859,651687,1,1,,56314873,5743,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1860,651687,1,1,,56320685,5743,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1861,651699,1,1,,56314873,5743,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1862,651699,1,1,,56314873,5743,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1863,651699,1,1,,56320685,5743,Inactive,4502169.0,8883.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1864,651699,1,1,,56320685,5743,Inactive,4507791.0,9040.0,,,uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay,Screening,,
1865,651702,1,2,,56314873,5743,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1866,651702,1,2,,56320685,5743,Inactive,,,,,Flow Cytometric HTS Screening for Inhibitors of Lytic Granule Exocytosis with MLPCN Compound Library,Screening,,
1867,651704,2,1,,56320686,5743,Inactive,156104889.0,4300.0,,,Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1868,651710,1,1,,56320686,5743,Inactive,109637798.0,5893.0,,,FRET-based HTS for detection of RAD52 Inhibitors Measured in Biochemical System Using Plate Reader - 7018-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
1869,651711,2,1,,56320686,5743,Inactive,2501205.0,10130.0,,,Turbidometric Biochemical  Primary HTS  to identify inhibitors of ERp5 Measured in Biochemical System Using Plate Reader - 7002-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1870,651718,1,2,,56320686,5743,Inactive,73586699.0,281312.0,,,Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA),Screening,,
1871,651719,1,2,,56320686,5743,Inactive,4503907.0,8484.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the Galanin Receptor 3 (GalR3),Screening,,
1872,651723,1,1,,56314873,5743,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1873,651723,1,1,,56320685,5743,Inactive,,,,,MLPCN PGC1a Modulators Measured in Cell-Based System Using Plate Reader - 2139-01_Activator_SinglePoint_HTS_Activity,Screening,,
1874,651724,1,1,,56314873,5743,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1875,651724,1,1,,56320685,5743,Inactive,1730321.0,5932.0,,,qHTS Assay for Inhibitors of the CtBP/E1A Interaction,Screening,,
1876,651725,1,1,,56314873,5743,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1877,651725,1,1,,56320685,5743,Inactive,1246761.0,6495.0,,,qHTS Assay for Inhibitors of the Six1/Eya2 Interaction,Screening,,
1878,651741,1,1,,17389945,5743,Active,20149576.0,4780.0,42.1632,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1879,651741,1,1,,26752878,5743,Inactive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1880,651743,1,1,,17389945,5743,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1881,651743,1,1,,26752878,5743,Inactive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
1882,651749,1,1,,17389945,5743,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1883,651749,1,1,,26752878,5743,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
1884,651751,1,1,,17389945,5743,Active,5702233.0,84385.0,14.1254,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1885,651751,1,1,,26752878,5743,Active,5702233.0,84385.0,6.3096,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
1886,651754,1,1,,17389945,5743,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
1887,651755,1,1,,17389945,5743,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
1888,651757,1,1,,17389945,5743,Inactive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
1889,651758,1,1,,17389945,5743,Inconclusive,186368.0,3576.0,,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
1890,651768,1,2,,56314873,5743,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1891,651768,1,2,,56320685,5743,Inactive,3719421.0,7486.0,,Potency,qHTS for Inhibitors of WRN Helicase,Confirmatory,,
1892,651777,1,1,,17389945,5743,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1893,651777,1,1,,26752878,5743,Inactive,51095037.0,196.0,,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
1894,651778,1,1,,17389945,5743,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1895,651778,1,1,,26752878,5743,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
1896,651800,1,1,,56320686,5743,Inactive,2358024.0,6955.0,,,Fluorescence-based biochemical primary high throughput assay to identify inhibitors of T-cell receptor (TCR)-CD3 interaction using a TAMRA-labeled TCR probe,Screening,,
1897,651802,1,1,,17389945,5743,Inactive,49066040.0,6097.0,,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1898,651819,1,1,,56314873,5743,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1899,651819,1,1,,56320685,5743,Inactive,83758679.0,153562.0,,,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity,Screening,,
1900,651820,1,1,,56314873,5743,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1901,651820,1,1,,56320685,5743,Inactive,,,,Potency,qHTS Assay for Inhibitors of Hepatitis C Virus (HCV),Confirmatory,,
1902,651821,2,4,,56320686,5743,Inactive,,,,,Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind r(CAG) RNA repeats,Screening,,
1903,651828,1,2,,92308949,5743,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1904,651828,1,2,,121362596,5743,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
1905,651838,1,1,,17389945,5743,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1906,651838,1,1,,26752878,5743,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1907,651838,1,1,1.0,17389945,5743,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1908,651838,1,1,1.0,26752878,5743,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1909,651838,1,1,2.0,17389945,5743,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1910,651838,1,1,2.0,26752878,5743,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1911,651838,1,1,3.0,17389945,5743,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1912,651838,1,1,3.0,26752878,5743,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1913,651838,1,1,4.0,17389945,5743,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1914,651838,1,1,4.0,26752878,5743,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1915,651838,1,1,5.0,17389945,5743,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1916,651838,1,1,5.0,26752878,5743,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1917,651838,1,1,6.0,17389945,5743,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1918,651838,1,1,6.0,26752878,5743,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1919,651838,1,1,7.0,17389945,5743,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1920,651838,1,1,7.0,26752878,5743,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1921,651838,1,1,8.0,17389945,5743,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1922,651838,1,1,8.0,26752878,5743,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
1923,651957,1,1,,56320686,5743,Inactive,5729858.0,10499.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2),Screening,,
1924,651958,1,1,,56320686,5743,Inactive,76364066.0,2943075.0,,,Fluorescence-based biochemical high throughput screening primary assay to identify inhibitors of Crimean-Congo Hemorrhagic Fever (CCHF) viral ovarian tumor domain protease (vOTU): Pep-AMC substrate,Screening,,
1925,651965,1,1,,56314873,5743,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1926,651965,1,1,,56320685,5743,Inactive,2668494.0,,,Potency,qHTS Assay for Activators of ClpP,Confirmatory,,
1927,651999,1,1,,56314873,5743,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1928,651999,1,1,,56320685,5743,Inactive,38027923.0,10987.0,,,"uHTS identification of small molecule inhibitors of Csn-mediated Deneddylation of Cullin-Ring Ligases, vis a fluorescence polarization assay",Screening,,
1929,652010,1,1,,56320686,5743,Inactive,5016090.0,190.0,,,"Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1",Screening,,
1930,652017,1,1,,56320686,5743,Inactive,119579215.0,6595.0,,,"Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)",Screening,,
1931,652025,1,1,,56314873,5743,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1932,652025,1,1,,56320685,5743,Inactive,7110653.0,16183.0,,Potency,qHTS of IL-2 Activators,Confirmatory,,
1933,652039,1,1,,56320686,5743,Inactive,21327705.0,5650.0,,,Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen,Screening,,
1934,652048,1,2,,56314873,5743,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1935,652048,1,2,,56320685,5743,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
1936,652051,1,1,,56314873,5743,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1937,652051,1,1,,56320685,5743,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
1938,652054,1,1,,56314873,5743,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1939,652054,1,1,,56320685,5743,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Antagonist: qHTS,Screening,,
1940,652067,1,4,,56320686,5743,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. contortus (hcDAF-12),Screening,,
1941,652104,1,1,,56314873,5743,Inactive,20140568.0,23435.0,,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1942,652104,1,1,,56320685,5743,Inconclusive,20140568.0,23435.0,35.4813,Potency,qHTS of TDP-43 Inhibitors,Confirmatory,,
1943,652105,1,1,,56314873,5743,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1944,652105,1,1,,56320685,5743,Inactive,18266879.0,5305.0,,Potency,qHTS for Inhibitors of phosphatidylinositol 5-phosphate 4-kinase (PI5P4K),Confirmatory,,
1945,652106,1,1,,56314873,5743,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1946,652106,1,1,,56320685,5743,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
1947,652115,1,1,,56320686,5743,Inactive,38258652.0,23408.0,,,MLPCN SirT-5 Measured in Biochemical System Using Imaging - 7044-01_Inhibitor_SinglePoint_HTS_Activity_Set5,Screening,,
1948,652126,1,3,,56320686,5743,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite S. stercoralis (ssDAF-12),Screening,,
1949,652154,1,1,,56320686,5743,Inactive,998701.0,7849.0,,,HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1950,652162,2,1,,56320686,5743,Inactive,126698238.0,4914074.0,,,C. difficile toxins: HTS for inhibitors of TcdB glycohydrolase activity Measured in Biochemical System Using Plate Reader - 7074-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1951,652163,1,1,,56320686,5743,Inactive,47496637.0,6275.0,,,S100A4: HTS Measured in Biochemical System Using Plate Reader - 7045-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1952,652197,1,1,,56320686,5743,Inactive,21315078.0,51752.0,,,MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
1953,652257,1,1,,56320686,5743,Inactive,32425330.0,3276.0,,,Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1),Screening,,
1954,658655,1,3,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human PMA-stimulated THP1 cells assessed as inhibition of LPS-induced TNFalpha production at 1 uM treated 30 mins before LPS challenge measured after 24 hrs by ELISA,Other,22520258.0,
1955,658657,1,3,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human PMA-stimulated THP1 cells assessed as inhibition of LPS-induced IL-6 production at 1 uM treated 30 mins before LPS challenge measured after 24 hrs by ELISA,Other,22520258.0,
1956,662759,1,2,,104234229,5743,Active,,,,,"Antiinflammatory activity in LPS-induced mouse assessed as decrease in cellular infiltration into BAL fluid at 100 mg/kg, ip administered 3 hrs prior LPS challenge relative to control",Other,22595173.0,
1957,662760,1,2,,104234229,5743,Active,,,,,"Antiinflammatory activity in LPS-induced mouse assessed as decrease in TNFalpha secretion at 100 mg/kg, ip administered 3 hrs prior LPS challenge relative to control",Other,22595173.0,
1958,663988,2,2,,104234229,5743,Active,,,0.98,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 2 hrs before LPS challenge measured after 18 hrs by Griess method,Confirmatory,22537362.0,
1959,664333,1,2,,104234229,5743,Unspecified,,,,,"Antiarthritic activity in B10/R3 mouse immunized with bovine type2 collagen in Freund's complete adjuvant assessed as inhibition of increase in clinical arthritic scores at 0.1 mg/kg, po administered bid for 10 days measured for 10 days",Other,22339472.0,
1960,664573,2,3,,104234229,5743,Active,,,0.0023,IC50,Antiinflammatory activity in rat polymorphonuclear leukocytes assessed as inhibition of LPS-stimulated nitric oxide production after 20 mins by Griess method,Confirmatory,22506620.0,
1961,664752,2,2,,104234229,5743,Active,,,0.47,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated nitric oxide production pretreated for 2 hrs before LPS challenge measured after 18 hrs by Griess method,Confirmatory,22372956.0,
1962,666240,1,4,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in ovalbumin-sensitised Balb/c mouse assessed as reduction in ovalbumin-induced eosinophil count in bronchoalveolar lavage fluid at 1 mg/kg, ip administered 1 hr before and 7 hrs after ovalbumin challenge measured after 8 hrs by haemocytometeric analysis",Other,24900359.0,
1963,668008,1,4,,104234229,5743,Unspecified,,,,,"Ex vivo induction of CYP-isozymes in Sprague-Dawley rat liver microsomes at 80 mg/kg, po bid for 3 days relative to control",Other,22497764.0,
1964,668011,1,4,,104234229,5743,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as changes in liver weight at 80 mg/kg, po bid for 3 days relative to control",Other,22497764.0,
1965,668014,1,3,,104234229,5743,Unspecified,,,,,"Toxicity in Sprague-Dawley rat assessed as changes in microsomal protein level at 80 mg/kg, po bid for 3 days relative to control",Other,22497764.0,
1966,673089,1,4,,104234229,5743,Active,,,,,"Antiinflammatory activity in BALB/c mouse assessed as reduction in LPS-induced neutrophil accumulation in bronchoalveolar lung fluid at 0.5 mg, it administered 1 hr prior to LPS-challenge and measured after 8 hrs relative to vehicle treated control",Other,22738635.0,
1967,676828,1,3,,104234229,5743,Active,,,,,Antiinflammatory activity in human A549 cells assessed as inhibition of IL-1beta-induced mPGES1 expression at 1 uM treated 30 mins prior to IL-1beta challenge measured after 48 hrs by Western blot analysis relative to control,Other,22795900.0,
1968,678712,1,8,,104234229,5743,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
1969,678713,1,8,,104234229,5743,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
1970,678714,1,8,,104234229,5743,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1971,678715,1,8,,104234229,5743,Active,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
1972,678716,1,8,,104234229,5743,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
1973,678717,1,8,,104234229,5743,Active,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
1974,678721,1,5,,104234229,5743,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
1975,678722,1,5,,104234229,5743,Unspecified,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
1976,678833,1,8,,104234229,5743,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in mdr1a-expressing LLC-PK1 cell,Other,7560060.0,
1977,678990,1,8,,104234229,5743,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: Western blot, primary hepatocytes",Other,11323161.0,
1978,678991,1,8,,104234229,5743,Unspecified,3219824.0,25303.0,,,TP_TRANSPORTER: Northern blot from primary hepatocytes,Other,11323161.0,
1979,679056,1,8,,104234229,5743,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: Western in vivo, kidney of SD rat",Other,9929003.0,
1980,679274,1,9,,104234229,5743,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (apical to basal) of Dexamethasone at a concentration of 24.7 nM in MDR1-expressing LLC-PK1 cells,Other,11785684.0,
1981,679342,1,8,,104234229,5743,Unspecified,239938877.0,18671.0,,,TP_TRANSPORTER: increase in brain concentration in mdr1a(-/-) mouse,Other,7560060.0,
1982,680031,1,8,,104234229,5743,Unspecified,1171882.0,6579.0,,,"TP_TRANSPORTER: inhibition of DHEAS uptake (DHEAS: 5 uM, Dexamethasone: 100 uM) in Xenopus laevis oocytes",Other,9539145.0,
1983,680126,1,8,,104234229,5743,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells,Other,7560060.0,
1984,680445,1,8,,104234229,5743,Unspecified,1171883.0,50572.0,,,"TP_TRANSPORTER: inhibition of Ouabain uptake (Ouabain: 100 uM, Dexamethasone: 100 uM) in Xenopus laevis oocytes",Other,8786566.0,
1985,680874,1,8,,104234229,5743,Unspecified,1170902.0,24646.0,,,"TP_TRANSPORTER: Western blot, primary hepatocytes",Other,8845310.0,
1986,681061,1,8,,104234229,5743,Unspecified,1170902.0,24646.0,,,TP_TRANSPORTER: Northern blot from primary hepatocytes,Other,8845310.0,
1987,681119,3,6,,104234229,5743,Unspecified,239938877.0,18671.0,50.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1a-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1988,681120,1,8,,104234229,5743,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in Caco-2 cells,Other,12699389.0,
1989,681121,1,8,,104234229,5743,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing MDCKII cells,Other,11602674.0,
1990,681122,3,6,,104234229,5743,Unspecified,238054374.0,5243.0,50.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in MDR1-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1991,681128,3,6,,104234229,5743,Unspecified,126927.0,18669.0,50.0,IC50,TP_TRANSPORTER: inhibition of Calcein-AM efflux in Mdr1b-expressing LLC-PK1 cells,Confirmatory,12699389.0,
1992,681136,1,8,,104234229,5743,Unspecified,27735248.0,80899.0,,,TP_TRANSPORTER: inhibition of Taurocholate uptake in OAT-K2-expressing MDCK cells,Other,10101033.0,
1993,681164,2,8,,104234229,5743,Unspecified,238054374.0,5243.0,,Km,TP_TRANSPORTER: ATP hydrolysis in membrane fraction from High Five (BTI-TN5B1-4) cells,Confirmatory,11785684.0,
1994,681167,1,8,,104234229,5743,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: Northern blot from LS174T cell,Other,11297522.0,
1995,681337,1,8,,104234229,5743,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: Western blot, HK-2 cells",Other,12387747.0,
1996,681354,1,8,,104234229,5743,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: transepithelial transport in MDR1-expressing LLC-PK1 cells,Other,14661924.0,
1997,681385,1,8,,104234229,5743,Unspecified,238054374.0,5243.0,,,TP_TRANSPORTER: RT-PCR in HK-2 cell,Other,12387747.0,
1998,681477,1,7,,104234229,5743,Unspecified,81911503.0,,,,"TP_TRANSPORTER: Western blot, primary hepatocytes",Other,8101494.0,
1999,681484,1,7,,104234229,5743,Unspecified,81911503.0,,,,"TP_TRANSPORTER: Western in vivo, kidney of SD rat",Other,9929003.0,
2000,681492,1,7,,104234229,5743,Unspecified,81911503.0,,,,TP_TRANSPORTER: Northern blot from primary hepatocytes,Other,8101494.0,
2001,681606,2,7,,104234229,5743,Unspecified,1171883.0,50572.0,,Km,TP_TRANSPORTER: uptake in Xenopus laevis oocytes,Confirmatory,8786566.0,
2002,681737,1,8,,104234229,5743,Unspecified,12585136.0,83569.0,,,TP_TRANSPORTER: Northern blot from primary hepatocytes,Other,11557128.0,
2003,681738,1,8,,104234229,5743,Unspecified,12585136.0,83569.0,,,TP_TRANSPORTER: Northern blot in vivo rat,Other,11557128.0,
2004,682041,1,8,,104234229,5743,Unspecified,3219824.0,25303.0,,,"TP_TRANSPORTER: Western in vivo, liver of SD rat",Other,9929003.0,
2005,682136,1,8,,104234229,5743,Unspecified,3914190.0,170698.0,,,"TP_TRANSPORTER: Western in vivo SD rat, liver",Other,11752118.0,
2006,686940,1,1,,56320686,5743,Inactive,14149746.0,7026.0,,,Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of COUP-TFII (NR2F2),Screening,,
2007,686964,1,1,,56320686,5743,Inactive,21595776.0,8932.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of 5-meCpG-binding domain protein 2 (MBD2)-DBD binding to methylated oligonucleotide,Screening,,
2008,686970,1,2,,56314873,5743,Inactive,49168486.0,3417.0,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2009,686970,1,2,,56320685,5743,Inconclusive,49168486.0,3417.0,0.0103,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line,Confirmatory,,
2010,686971,1,2,,56314873,5743,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2011,686971,1,2,,56320685,5743,Inactive,,,,Potency,qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line,Confirmatory,,
2012,686978,1,1,,26752876,5743,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2013,686978,1,1,,56314873,5743,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2014,686978,1,1,,56320685,5743,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
2015,686979,1,1,,26752876,5743,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2016,686979,1,1,,56314873,5743,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2017,686979,1,1,,56320685,5743,Inconclusive,79154014.0,55775.0,0.0206,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
2018,686992,2,1,,56320686,5743,Inactive,187960042.0,6401.0,,,Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity,Screening,,
2019,686996,1,1,,56320686,5743,Inactive,13325293.0,839.0,,,VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2,Screening,,
2020,687014,1,1,,56320686,5743,Inactive,71987181.0,181263.0,,,Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12).,Screening,,
2021,687016,1,1,,56320686,5743,Inactive,115430235.0,29128.0,,,Counterscreen for inhibitors of 5-meCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide,Screening,,
2022,687408,1,2,,104234229,5743,Active,,,,,"Antinociceptive activity in Swiss mouse inflammatory pain model assessed as reduction in mechanical hyperalgesia at 2 mg/kg, sc dosed 45 mins before complete Freund's adjuvant dosing measured 4 to 24 hrs post complete Freund's adjuvant challenge by electronic pressure-meter test",Other,21417376.0,
2023,687411,1,2,,104234229,5743,Active,,,,,"Antinociceptive activity in Swiss mouse inflammatory pain model assessed as reduction in paw withdrawal response at 2 mg/kg, sc dosed once daily for 7 days dosed 45 mins before complete Freund's adjuvant dosing measured post complete Freund's adjuvant challenge",Other,21417376.0,
2024,687413,1,2,,104234229,5743,Active,,,,,"Antinociceptive activity in Swiss mouse inflammatory pain model assessed as reduction in paw edema at 2 mg/kg, sc dosed once daily for 7 days dosed 45 mins before complete Freund's adjuvant dosing measured post complete Freund's adjuvant challenge",Other,21417376.0,
2025,687415,1,2,,104234229,5743,Active,,,,,"Antinociceptive activity in Swiss mouse inflammatory pain model assessed as reduction in hyperalgesia at 0.5 mg/kg, sc dosed once daily for 7 days dosed 45 mins before carrageenan dosing measured 3 hrs post carrageenan challenge",Other,21417376.0,
2026,687421,1,2,,104234229,5743,Active,,,,,"Inhibition of complete Freund's adjuvant-induced IL-1beta production in Swiss mouse at 2 mg/kg, sc dosed 45 mins before complete Freund's adjuvant dosing measured up to 24 hrs post complete Freund's adjuvant challenge by ELISA",Other,21417376.0,
2027,687422,1,2,,104234229,5743,Active,,,,,"Inhibition of complete Freund's adjuvant-induced TNFalpha production in Swiss mouse at 2 mg/kg, sc dosed 45 mins before complete Freund's adjuvant dosing measured up to 2 hrs post complete Freund's adjuvant challenge by ELISA",Other,21417376.0,
2028,687427,1,2,,104234229,5743,Active,,,,,"Inhibition of complete Freund's adjuvant-induced neutrophil migration to paw tissue in Swiss mouse at 2 mg/kg, sc dosed 45 mins before complete Freund's adjuvant dosing measured 3 to 4 hrs post complete Freund's adjuvant challenge by myeloperoxidase kinetic colorimetric assay",Other,21417376.0,
2029,687428,1,2,,104234229,5743,Active,,,,,"Inhibition of carrageenan-induced neutrophil migration to paw tissue in Swiss mouse at 2 mg/kg, sc dosed 45 mins before carrageenan dosing measured 3 to 4 hrs post complete Freund's adjuvant challenge by myeloperoxidase kinetic colorimetric assay",Other,21417376.0,
2030,688610,1,5,,104234229,5743,Unspecified,121069.0,2908.0,,,Activation of GR transfected in HEK293 cells assessed as fold signal induction at 2.5 uM after 18 hrs by firefly luciferase reporter gene-based luminescence assay,Other,21800856.0,
2031,691200,1,2,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human PMA-activated THP1 cells assessed as inhibition of LPS-induced TNFalpha production at 1 uM incubated for 30 mins prior to LPS-challenge measured after 24 hrs by ELISA relative to control,Other,22981334.0,
2032,691202,1,2,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human PMA-activated THP1 cells assessed as inhibition of LPS-induced IL6 production at 1 uM incubated for 30 mins prior to LPS-challenge measured after 24 hrs by ELISA relative to control,Other,22981334.0,
2033,695747,1,2,,104234229,5743,Unspecified,,,,,"Antiarthritic activity in BALB/c mouse type 2 collagen antibody-induced arthritis model assessed as inhibition of disease burden at 3 mg/kg, po qd for 14 days measured on day 20 relative to control",Other,22682057.0,
2034,695888,1,2,,104234229,5743,Active,,,,,"Antiarthritic activity in BALB/c mouse type 2 collagen antibody-induced arthritis model assessed as physiological disease-modifying affect at 3 mg/kg, po qd for 14 days measured on day 20 relative to control",Other,22682057.0,
2035,695891,1,2,,104234229,5743,Unspecified,,,,,"Toxicity in BALB/c mouse type 2 collagen antibody-induced arthritis model assessed as change in body weight at 3 mg/kg, po qd for 14 days measured on day 20",Other,22682057.0,
2036,696173,1,2,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-stimulated TNFalpha production at 1 uM incubated for 30 mins prior to LPS-challenge measured 24 hrs post LPS-challenge by ELISA,Other,23026000.0,
2037,696175,1,2,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-stimulated IL-6 production at 1 uM incubated for 30 mins prior to LPS-challenge measured 24 hrs post LPS-challenge by ELISA,Other,23026000.0,
2038,699539,1,7,,104234229,5743,Unspecified,12643959.0,10599.0,,,Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting,Other,22541068.0,
2039,699540,1,7,,104234229,5743,Unspecified,27734563.0,28234.0,,,Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2040,699541,1,7,,104234229,5743,Unspecified,313104012.0,11309.0,,,Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting,Other,22541068.0,
2041,719931,1,2,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in LPS-induced COPD BALB/c mouse model assessed as reduction in pulmonary neutrophilia at 0.3 mg/kg, ip qd",Other,22924688.0,
2042,720504,1,1,,56314873,5743,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2043,720504,1,1,,56320685,5743,Inactive,21359873.0,5347.0,,Potency,qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen,Confirmatory,,
2044,720508,1,1,,56320686,5743,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2045,720509,1,1,,56320686,5743,Inactive,28373962.0,,,,Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )],Screening,,
2046,720511,1,1,,56320686,5743,Inactive,89348172.0,1080.0,,,Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity,Screening,,
2047,720516,2,1,,144207320,5743,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
2048,720522,1,1,,56314873,5743,Inactive,122893032.0,,,Potency,Nrf2 qHTS screen for inhibitors: Purified Fluc Biochemical Counterscreen for Hit Validation,Confirmatory,,
2049,720522,1,1,,56320685,5743,Inactive,122893032.0,,,Potency,Nrf2 qHTS screen for inhibitors: Purified Fluc Biochemical Counterscreen for Hit Validation,Confirmatory,,
2050,720523,1,1,,56314873,5743,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: A549 ARE-Fluc Cytotoxicity Counterscreen for Hit Validation,Confirmatory,,
2051,720523,1,1,,56320685,5743,Inactive,,,,Potency,Nrf2 qHTS screen for inhibitors: A549 ARE-Fluc Cytotoxicity Counterscreen for Hit Validation,Confirmatory,,
2052,720524,1,1,,56314873,5743,Active,224028257.0,4780.0,0.0065,Potency,Nrf2 qHTS screen for inhibitors: Nrf2 A549 ARE-Fluc Confirmation Assay for Hit Validation,Confirmatory,,
2053,720524,1,1,,56320685,5743,Active,224028257.0,4780.0,0.0052,Potency,Nrf2 qHTS screen for inhibitors: Nrf2 A549 ARE-Fluc Confirmation Assay for Hit Validation,Confirmatory,,
2054,720532,1,1,,26752876,5743,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2055,720532,1,1,,26752877,5743,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
2056,720533,1,1,,26752876,5743,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2057,720533,1,1,,26752877,5743,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
2058,720542,1,2,,56314873,5743,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2059,720542,1,2,,56320685,5743,Inactive,23496270.0,810891.0,,Potency,qHTS for Inhibitors of AMA1-RON; Towards Development of Antimalarial Drug Lead: Primary Screen,Confirmatory,,
2060,720543,1,1,,56320686,5743,Inactive,326937491.0,105501.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of alpha/beta hydrolase domain containing 4 (ABHD4).,Screening,,
2061,720551,1,2,,56314873,5743,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2062,720551,1,2,,56320685,5743,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS,Confirmatory,,
2063,720552,2,1,,144207320,5743,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
2064,720553,1,2,,56314873,5743,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2065,720553,1,2,,56320685,5743,Inactive,342840031.0,3757.0,,Potency,qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS,Confirmatory,,
2066,720554,1,3,,121362596,5743,Inactive,52423132.0,3087402.0,,,Inhibition of the Burkholderia mallei acyl-homoserine lactone synthase BmaI1,Other,,
2067,720579,2,1,,26752876,5743,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2068,720579,2,1,,56314873,5743,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2069,720579,2,1,,56320685,5743,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
2070,720580,1,1,,26752876,5743,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2071,720580,1,1,,56314873,5743,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2072,720580,1,1,,56320685,5743,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
2073,720582,1,1,,56320686,5743,Inactive,2393947.0,102.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.,Screening,,
2074,720596,1,1,,56320686,5743,Inactive,4506113.0,5621.0,,,TRFRET-based cell-based primary high throughput screening assay to identify inhibitors of cell surface Prion Protein (PRPC),Screening,,
2075,720634,2,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
2076,720635,2,1,,144207320,5743,Inconclusive,,,17.4745,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
2077,720636,1,1,,17389945,5743,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2078,720636,1,1,,26752878,5743,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
2079,720637,2,1,,144207320,5743,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
2080,720641,1,2,,92308949,5743,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
2081,720647,1,2,,56320686,5743,Inactive,,,,,Bursicon-induced LGR2 mediated cAMP production in LGR-2/CRE6x-Luciferase co-transfected HEK293 cells Inhibition,Screening,,
2082,720648,1,1,,56320686,5743,Inactive,73747889.0,6868.0,,,QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.,Screening,,
2083,720652,1,1,,17389945,5743,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2084,720653,1,1,,17389945,5743,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2085,720653,1,1,,26752878,5743,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
2086,720659,1,1,,17389945,5743,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2087,720659,1,1,,26752878,5743,Inconclusive,325495557.0,8856.0,50.1187,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
2088,720674,2,2,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
2089,720675,2,2,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
2090,720678,2,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
2091,720679,2,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
2092,720680,2,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
2093,720681,2,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
2094,720682,2,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
2095,720683,2,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
2096,720684,2,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
2097,720685,2,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
2098,720686,2,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
2099,720687,2,2,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
2100,720691,4,1,,144207320,5743,Active,311348376.0,2908.0,0.0025,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2101,720692,3,1,,144207320,5743,Inconclusive,311348376.0,2908.0,0.0079,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
2102,720693,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
2103,720700,1,4,,56320686,5743,Inactive,223459640.0,5335.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).,Screening,,
2104,720702,1,1,,56320686,5743,Inactive,23510348.0,51567.0,,,Epi Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of human tyrosyl-DNA phosphodiesterase 2 (TDP2),Screening,,
2105,720704,1,4,,56320686,5743,Inactive,148745659.0,5331.0,,,Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).,Screening,,
2106,720707,1,2,,56314873,5743,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2107,720707,1,2,,56320685,5743,Inactive,317373593.0,10411.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2108,720708,1,2,,56314873,5743,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2109,720708,1,2,,56320685,5743,Inactive,32171491.0,11069.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 2 (EPAC2): primary screen,Confirmatory,,
2110,720709,1,2,,56314873,5743,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2111,720709,1,2,,56320685,5743,Inactive,317373593.0,10411.0,,Potency,qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen,Confirmatory,,
2112,720711,1,2,,56314873,5743,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2113,720711,1,2,,56320685,5743,Inactive,32171491.0,11069.0,,Potency,qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 4 (EPAC2): primary screen,Confirmatory,,
2114,720717,1,3,,92308949,5743,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2115,720717,1,3,,92310024,5743,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
2116,720719,2,1,,144207320,5743,Active,311348376.0,2908.0,0.00378085,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2117,720725,2,1,,144207320,5743,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
2118,721753,1,6,,104234229,5743,Unspecified,74731723.0,55244.0,,,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells at 20 uM after 1.5 mins by fluorescence assay,Other,23241029.0,
2119,721754,2,5,,104234229,5743,Unspecified,74731723.0,55244.0,500.0,IC50,Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay,Confirmatory,23241029.0,
2120,724393,1,2,,104234229,5743,Active,,,0.001,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-5 production after 48 hrs,Confirmatory,23199485.0,
2121,724394,1,2,,104234229,5743,Active,,,0.0055,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-10 production after 48 hrs,Confirmatory,23199485.0,
2122,724395,1,2,,104234229,5743,Active,,,0.0035,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-3 production after 48 hrs,Confirmatory,23199485.0,
2123,724396,1,2,,104234229,5743,Active,,,0.0036,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-2 production after 48 hrs,Confirmatory,23199485.0,
2124,724397,1,2,,104234229,5743,Unspecified,,,0.2,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced MCP-1 production after 24 hrs,Confirmatory,23199485.0,
2125,724398,1,2,,104234229,5743,Active,,,0.0012,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-13 production after 24 hrs,Confirmatory,23199485.0,
2126,724399,1,2,,104234229,5743,Active,,,0.0024,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IP-10 production after 24 hrs,Confirmatory,23199485.0,
2127,724400,1,2,,104234229,5743,Active,,,0.0009199999999999999,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-4 production after 24 hrs,Confirmatory,23199485.0,
2128,724401,1,2,,104234229,5743,Active,,,0.0076,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IFNgamma production after 24 hrs,Confirmatory,23199485.0,
2129,724402,1,2,,104234229,5743,Active,,,0.13,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced MIP1alpha production after 6 hrs,Confirmatory,23199485.0,
2130,724403,1,2,,104234229,5743,Active,,,0.08800000000000001,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-8 production after 6 hrs,Confirmatory,23199485.0,
2131,724404,1,2,,104234229,5743,Active,,,0.08199999999999999,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-6 production after 6 hrs,Confirmatory,23199485.0,
2132,724405,1,2,,104234229,5743,Active,,,0.0061,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced TNFalpha production after 6 hrs,Confirmatory,23199485.0,
2133,724406,1,2,,104234229,5743,Active,,,0.0094,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of PHA-induced IL-1beta production after 6 hrs,Confirmatory,23199485.0,
2134,724407,1,2,,104234229,5743,Active,,,0.00047000000000000004,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced GM-CSF production after 48 hrs,Confirmatory,23199485.0,
2135,724408,1,2,,104234229,5743,Active,,,0.0041,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced IL-12p70 production after 48 hrs,Confirmatory,23199485.0,
2136,724409,1,2,,104234229,5743,Active,,,0.0021,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced IL-1beta production after 48 hrs,Confirmatory,23199485.0,
2137,724410,1,2,,104234229,5743,Active,,,0.0019,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of anti-CD3-induced TNFalpha production after 48 hrs,Confirmatory,23199485.0,
2138,724411,1,2,,104234229,5743,Active,,,0.066,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced MIP1alpha production after 6 hrs,Confirmatory,23199485.0,
2139,724412,1,2,,104234229,5743,Active,,,0.07200000000000001,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 production after 6 hrs,Confirmatory,23199485.0,
2140,724413,1,2,,104234229,5743,Active,,,0.01,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha production after 6 hrs,Confirmatory,23199485.0,
2141,724414,1,2,,104234229,5743,Active,,,0.055,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-6 production after 6 hrs,Confirmatory,23199485.0,
2142,724415,2,5,,104234229,5743,Active,121069.0,2908.0,0.0097,EC50,Inhibition of glucocorticoid receptor in human H13 cells assessed as inhibition of glucocorticoid-induced cell proliferation after 3 hrs by [3H]-thymidine incorporation assay,Confirmatory,23199485.0,
2143,724416,2,5,,104234229,5743,Active,121069.0,2908.0,0.0125,EC50,Displacement of [3H]-dexamethasone human glucocorticoid receptor alpha expressed in 293 MSR cells after 60 mins by scintillation counting,Confirmatory,23199485.0,
2144,724417,2,5,,104234229,5743,Active,121069.0,2908.0,0.0037,EC50,Binding affinity to glucocorticoid receptor (unknown origin) by fluorescence polarization competitive binding assay,Confirmatory,23199485.0,
2145,724418,1,2,,104234229,5743,Active,,,0.013999999999999999,EC50,Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta production after 6 hrs,Confirmatory,23199485.0,
2146,724423,1,2,,104234229,5743,Inactive,,,,,Drug uptake in mouse J774A1 cells at 10 uM after 3 hrs by LC-MS/MS method,Other,23199485.0,
2147,724424,1,2,,104234229,5743,Inactive,,,,,Drug uptake in mouse J774A1 cells assessed as compound retention at 10 uM after 3 hrs by LC-MS/MS method,Other,23199485.0,
2148,725919,1,6,,104234229,5743,Active,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor (unknown origin) expressed in human HCT116 cells co-expressing GRE at 20 to 40 uM after 24 hrs by luciferase reporter gene assay,Other,23276449.0,
2149,726799,1,6,,104234229,5743,Inactive,62906901.0,5970.0,,,Inhibition of NF-kappaB p65 activation in HSV1 KOS infected human IOBA-NHC cells assessed as reduction of NF-kappaB p65 translocation at 40 uM after 24 hrs by indirect immunofluorescence assay,Other,23219855.0,
2150,726800,1,6,,104234229,5743,Inactive,62906901.0,5970.0,,,Inhibition of NF-kappaB p65 activation in HSV1 KOS infected human HCLE cells assessed as reduction of NF-kappaB p65 translocation at 40 uM after 24 hrs by indirect immunofluorescence assay,Other,23219855.0,
2151,726801,1,6,,104234229,5743,Unspecified,417926.0,19697.0,,,Effect on NF-kappaB p65 activation in LPS-stimulated mouse J774A.1 cells assessed as NF-kappaB p65 translocation at 40 uM after 24 hrs by indirect immunofluorescence assay,Other,23219855.0,
2152,726808,1,6,,104234229,5743,Active,62906901.0,5970.0,,,Inhibition of NF-kappaB p65-mediated TNFalpha release in HSV1 KOS infected human IOBA-NHC cells at 40 uM after 24 hrs by ELISA,Other,23219855.0,
2153,726809,1,6,,104234229,5743,Active,62906901.0,5970.0,,,Inhibition of NF-kappaB p65-mediated IL-6 release in HSV1 KOS infected human IOBA-NHC cells at 40 uM after 24 hrs by ELISA,Other,23219855.0,
2154,726810,1,6,,104234229,5743,Active,62906901.0,5970.0,,,Inhibition of NF-kappaB p65-mediated IL-8 release in HSV1 KOS infected human IOBA-NHC cells at 40 uM after 24 hrs by ELISA,Other,23219855.0,
2155,726811,1,6,,104234229,5743,Active,62906901.0,5970.0,,,Inhibition of NF-kappaB p65-mediated IL-8 release in HSV1 KOS infected human HCLE cells at 40 uM after 24 hrs by ELISA,Other,23219855.0,
2156,729607,1,2,,104234229,5743,Unspecified,,,,,Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells at 5 uM,Other,23268606.0,
2157,729895,1,2,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL6 release at 10 uM incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay relative to control,Other,23411072.0,
2158,729897,1,2,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL1-beta release at 100 uM incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay relative to control,Other,23411072.0,
2159,729898,1,2,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced TNFalpha release at 100 uM incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay relative to control,Other,23411072.0,
2160,729900,1,2,,104234229,5743,Active,,,0.0095,IC50,Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced IL1-beta release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay,Confirmatory,23411072.0,
2161,729901,1,2,,104234229,5743,Active,,,0.017,IC50,Antiinflammatory activity in human PBMCs assessed as inhibition of LPS-induced TNFalpha release incubated for 15 mins prior to LPS challenge measured after 24 hrs by HTRF assay,Confirmatory,23411072.0,
2162,733140,1,2,,104234229,5743,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as reversal in LPS-induced weight loss at 20 mg/kg, ip administered for 5 days prior to LPS-challenge measured from day 9 to 11 relative to control",Other,23373965.0,
2163,733149,1,2,,104234229,5743,Inactive,,,,,"Antiinflammatory activity in ICR mouse assessed as reversal in LPS-induced weight loss at 20 mg/kg, ip administered for 5 days prior to LPS-challenge measured up to day 8 relative to control",Other,23373965.0,
2164,733151,1,2,,104234229,5743,Active,,,,,"Antiinflammatory activity in ICR mouse assessed as protection against LPS-induced sepsis at 20 mg/kg, ip administered for 5 days prior to LPS-challenge measured after 2 hrs",Other,23373965.0,
2165,733175,1,2,,104234229,5743,Active,,,1.43,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Griess method,Confirmatory,23373965.0,
2166,733176,1,2,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 50 uM incubated for 2 hrs prior to LPS-challenge measured after 24 hrs by Griess method,Other,23373965.0,
2167,743012,3,1,,144207320,5743,Inconclusive,,,0.22,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
2168,743014,3,1,,144207320,5743,Active,,,0.5526,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
2169,743015,3,1,,144207320,5743,Active,,,55.2593,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
2170,743033,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
2171,743035,2,1,,144207320,5743,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2172,743036,2,1,,144207320,5743,Inconclusive,124375976.0,367.0,5.5762,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
2173,743040,3,1,,144207320,5743,Active,124375976.0,367.0,0.0078,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2174,743041,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
2175,743042,3,1,,144207320,5743,Inactive,124375976.0,367.0,0.006999999999999999,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
2176,743053,2,1,,144207320,5743,Active,124375976.0,367.0,1.9285400000000001,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2177,743054,2,1,,144207320,5743,Inconclusive,124375976.0,367.0,0.00372415,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
2178,743063,2,1,,144207320,5743,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
2179,743064,3,1,,144207320,5743,Inconclusive,,,27.6952,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
2180,743065,3,1,,144207320,5743,Inconclusive,399498506.0,24831.0,31.0746,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2181,743066,3,1,,144207320,5743,Inactive,399498506.0,24831.0,15.5742,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
2182,743067,2,1,,144207320,5743,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
2183,743069,2,1,,144207320,5743,Inactive,348019627.0,2099.0,0.0063,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2184,743074,2,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
2185,743075,2,1,,144207320,5743,Inactive,348019627.0,2099.0,0.2795,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
2186,743077,2,1,,144207320,5743,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2187,743078,2,1,,144207320,5743,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
2188,743079,3,1,,144207320,5743,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2189,743080,3,1,,144207320,5743,Inconclusive,348019627.0,2099.0,0.0196,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
2190,743081,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
2191,743083,3,1,,144207320,5743,Inactive,119597822.0,1588.0,0.0055,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
2192,743084,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
2193,743085,3,1,,144207320,5743,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
2194,743086,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
2195,743091,2,1,,144207320,5743,Inconclusive,348019627.0,2099.0,0.00875801,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
2196,743094,3,1,,144207320,5743,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2197,743122,2,1,,144207320,5743,Inconclusive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
2198,743126,1,1,,56320686,5743,Inactive,119580345.0,50487.0,,,QFRET-based biochemical high throughput primary assay to identify inhibitors of human group III secreted phospholipase A2 enzyme (HGIII-sPLA2),Screening,,
2199,743139,2,1,,144207320,5743,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
2200,743140,2,1,,144207320,5743,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2201,743191,3,1,,144207320,5743,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
2202,743194,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
2203,743199,2,1,,144207320,5743,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
2204,743202,4,1,,144207320,5743,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
2205,743203,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
2206,743209,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
2207,743210,4,1,,144207320,5743,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
2208,743211,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2209,743212,3,1,,144207320,5743,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2210,743213,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
2211,743215,3,1,,144207320,5743,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
2212,743217,3,1,,144207320,5743,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2213,743218,3,1,,144207320,5743,Inconclusive,,,2.2199,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2214,743219,3,1,,144207320,5743,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
2215,743220,3,1,,144207320,5743,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
2216,743221,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
2217,743222,3,1,,144207320,5743,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2218,743223,3,1,,144207320,5743,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
2219,743224,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2220,743225,3,1,,144207320,5743,Inconclusive,,,17.6335,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
2221,743226,2,1,,144207320,5743,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2222,743227,2,1,,144207320,5743,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
2223,743228,3,1,,144207320,5743,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
2224,743238,1,1,,56320686,5743,Inactive,,,,,High Content Cell-Based Imaging Primary HTS to Identify Small Molecules Involved in X-Chromosome Reactivation and Reprogramming Measured in Cell-Based System Using Imaging - 7015-01_Activator_SinglePoint_HTS_Activity_Set2,Screening,,
2225,743239,2,1,,144207320,5743,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2226,743240,2,1,,144207320,5743,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
2227,743241,2,1,,144207320,5743,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2228,743242,2,1,,144207320,5743,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
2229,743247,1,2,,56320686,5743,Inactive,,,,,Inhibition of Alexa 488-Fibronectin deposition #on AH1F cell monolayers Measured in Cell-Based System Using Plate Reader - 7059-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2230,743255,1,1,,56314873,5743,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2231,743255,1,1,,56320685,5743,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Primary Screen,Confirmatory,,
2232,743266,1,2,,56314873,5743,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2233,743266,1,2,,56320685,5743,Inactive,296080761.0,5745.0,,Potency,qHTS of PTHR Inhibitors: Primary Screen,Confirmatory,,
2234,743268,1,1,,172080768,5743,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-labeled substrate oligonucliotide bound to E. coli SSB,Screening,,
2235,743269,1,1,,56320686,5743,Inactive,2853980.0,,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2236,743269,1,1,,56320686,5743,Inactive,6708281.0,11168.0,,,TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration,Screening,,
2237,743270,1,1,,172080768,5743,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening  assay of the NIH Clinical Collections to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
2238,743271,1,1,,172080768,5743,Inactive,,,,,Biochemical high throughput counterscreening assay of the NIH Clinical Collection for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence polarization based assay to identify compounds that can displace E. coli single stranded binding protein,Screening,,
2239,743272,1,1,,172080768,5743,Inactive,,,,,Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors of the NIH Clinical Collection: a biochemical high-throughput screening assay to identify compounds that cause fluorescent interference,Screening,,
2240,743279,1,2,,56320685,5743,Inactive,10835145.0,3553.0,,,qHTS for Inhibitors of Inflammasome Signaling:  IL-1-beta AlphaLISA Primary Screen,Screening,,
2241,743287,1,1,,56320686,5743,Inactive,,,,,Luminescent GLuc Reporter Gene Assay Primary HTS to Identify Small Molecule Activator of Glucose Dependent Insulin Secretion Measured in Cell-Based System Using Plate Reader - 7055-01_Activator_SinglePoint_HTS_Activity,Screening,,
2242,743288,1,1,,17389945,5743,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2243,743288,1,1,,26752878,5743,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
2244,743292,1,1,,17389945,5743,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2245,743292,1,1,,26752878,5743,Inactive,,,,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
2246,743344,1,1,,174007382,5743,Inactive,,,13.3244,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
2247,743345,1,1,,174007382,5743,Inactive,,,0.0266,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
2248,743346,1,1,,174007382,5743,Inactive,,,8.4071,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
2249,743347,1,1,,174007382,5743,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
2250,743397,1,1,,56320686,5743,Inactive,,,,,HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2251,743398,1,1,,56320686,5743,Inactive,,,,,Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01_Activator_SinglePoint_HTS_Activity,Screening,,
2252,751222,1,2,,104234229,5743,Unspecified,,,,,Antiproliferative activity against rat IEC-18 cells at 10 uM after 24 hrs by MTT assay,Other,23758110.0,
2253,751224,1,1,,104234229,5743,Unspecified,,,,,Wound healing activity in rat IEC-18 cells assessed as reduction of cell migration at 10 uM after 24 hrs relative to control,Other,23758110.0,
2254,751677,2,3,,104234229,5743,Active,121069.0,2908.0,,IC50,Displacement of [3H]Dexamethasone from glucocorticoid receptor in human HeLaS3 cells after 2 hrs,Confirmatory,23403082.0,
2255,751742,1,5,,104234229,5743,Unspecified,121069.0,2908.0,,,Displacement of [3H]Dexamethasone from glucocorticoid receptor in human HeLaS3 cells at 10 uM after 2 hrs relative to control,Other,23403082.0,
2256,751844,2,3,,104234229,5743,Active,121069.0,2908.0,,IC50,Binding affinity to human glucocorticoid receptor by radioligand displacement assay,Confirmatory,23466604.0,
2257,752207,2,3,,104234229,5743,Active,121069.0,2908.0,0.0025,IC50,Binding affinity to human glucocorticoid receptor by radioligand displacement assay,Confirmatory,23582449.0,
2258,768881,1,3,,104234229,5743,Unspecified,,,,,Cytotoxicity against human THP1 cells assessed as cell viability at 1 ug/ml after 24 hrs by CCK-8 assay,Other,,
2259,768883,1,3,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in LPS-stimulated human THP1 cells assessed as inhibition of IL-6 release at 1 ug/ml after 24 hrs by ELISA relative to control,Other,,
2260,768885,1,3,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in LPS-stimulated human THP1 cells assessed as inhibition of TNFalpha release at 1 ug/ml after 24 hrs by ELISA relative to control,Other,,
2261,770011,2,3,,104234229,5743,Active,121069.0,2908.0,0.0045,EC50,Transactivation activity at glucocorticoid receptor ligand binding domain (unknown origin) expressed in human Hela cells co-expressing GAL4 DNA binding domain assessed as NP-1-stimulated GRE activation by luciferase reporter gene assay,Confirmatory,23916594.0,
2262,770014,2,3,,104234229,5743,Active,121069.0,2908.0,0.0011,EC50,Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL1beta-stimulated NFkappaB-dependent E-selectin transcription by luciferase reporter gene assay,Confirmatory,23916594.0,
2263,770016,2,3,,104234229,5743,Active,121069.0,2908.0,0.0025,EC50,Transrepression activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-stimulated AP1 response element by luciferase reporter gene assay,Confirmatory,23916594.0,
2264,770017,2,3,,104234229,5743,Active,121069.0,2908.0,0.0012,Ki,Binding affinity to glucocorticoid receptor (unknown origin) by fluorescence assay,Confirmatory,23916594.0,
2265,770291,2,3,,104234229,5743,Active,121069.0,2908.0,0.0045,EC50,Transactivation of glucocorticoid receptor ligand binding domain (unknown origin) transfected in human HeLa cells assessed as activation of NP-1 by GAL4 luciferase reporter gene assay,Confirmatory,23953070.0,
2266,770294,2,3,,104234229,5743,Active,121069.0,2908.0,0.0025,EC50,Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activation by luciferase reporter gene assay,Confirmatory,23953070.0,
2267,770295,2,3,,104234229,5743,Active,121069.0,2908.0,0.0011,EC50,Agonist activity at glucocorticoid receptor in human A549 cells assessed as inhibition of IL-1beta-induced NF-kappaB dependent E-selectin activation by luciferase reporter gene assay,Confirmatory,23953070.0,
2268,770296,2,3,,104234229,5743,Active,121069.0,2908.0,0.0012,Ki,Binding affinity to glucocorticoid receptor (unknown origin) by fluorescence polarization assay,Confirmatory,23953070.0,
2269,771527,1,5,,104234229,5743,Active,121069.0,2908.0,0.0042,EC50,Transactivation of GR-LBD expressed in human HeLa cells co-expressing GAL4-DBD by luciferase reporter gene assay,Confirmatory,24011644.0,
2270,771529,2,3,,104234229,5743,Active,121069.0,2908.0,0.0025,EC50,Transrepression of glucocorticoid receptor in human A549 cells assessed as inhibition of PMA-induced AP-1 activity by luciferase reporter gene assay,Confirmatory,24011644.0,
2271,771530,2,3,,104234229,5743,Active,121069.0,2908.0,0.0011,Ki,Binding affinity to glucocorticoid receptor-LBD (unknown origin) by fluorescence polarization assay,Confirmatory,24011644.0,
2272,779463,1,1,,104234229,5743,Active,,,,,"Antiinflammatory activity in ovalbumin-sensitized Balb/c mouse asthma model model assessed as reduction of goblet cell hyperplasia in lungs at 1 mg/kg, po by PAS staining",Other,24054491.0,
2273,779466,1,1,,104234229,5743,Active,,,,,"Antiinflammatory activity in ovalbumin-sensitized Balb/c mouse asthma model model assessed as reduction of eosinophils, neutrophils, lymphocytes, and macrophages level in BAL fluid at 1 mg/kg, po",Other,24054491.0,
2274,779469,1,1,,104234229,5743,Active,,,,,"Antiinflammatory activity in ovalbumin-sensitized Balb/c mouse asthma model model assessed as reduction in methacholine-induced airway hyperresponsiveness at 1 mg/kg, po",Other,24054491.0,
2275,909383,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/6,Other,,
2276,909384,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/6,Other,,
2277,909385,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/6,Other,,
2278,909386,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/7,Other,,
2279,909387,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/7,Other,,
2280,909388,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/7,Other,,
2281,909389,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/7,Other,,
2282,909826,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/7,Other,,
2283,909827,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/7,Other,,
2284,909828,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/7,Other,,
2285,909829,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/7,Other,,
2286,909830,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/7,Other,,
2287,909831,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/7,Other,,
2288,909832,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/7,Other,,
2289,909833,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/7,Other,,
2290,909834,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/7,Other,,
2291,909835,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/7,Other,,
2292,909836,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/7,Other,,
2293,909837,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/7,Other,,
2294,909838,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/7,Other,,
2295,909839,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/7,Other,,
2296,909840,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/7,Other,,
2297,909841,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/7,Other,,
2298,909842,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/7,Other,,
2299,909843,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/8,Other,,
2300,909844,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/8,Other,,
2301,909845,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/8,Other,,
2302,909846,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/8,Other,,
2303,909847,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/8,Other,,
2304,909848,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/8,Other,,
2305,909849,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/8,Other,,
2306,909850,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/8,Other,,
2307,909851,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/8,Other,,
2308,909852,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/8,Other,,
2309,909853,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/8,Other,,
2310,909854,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/8,Other,,
2311,909855,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/8,Other,,
2312,909856,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/8,Other,,
2313,909857,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/8,Other,,
2314,909858,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/8,Other,,
2315,909859,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/8,Other,,
2316,909860,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/8,Other,,
2317,909861,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/8,Other,,
2318,909862,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/8,Other,,
2319,909863,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/8,Other,,
2320,909864,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/9,Other,,
2321,909865,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/9,Other,,
2322,909866,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/9,Other,,
2323,911693,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/9,Other,,
2324,911694,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/9,Other,,
2325,911695,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/9,Other,,
2326,911696,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/9,Other,,
2327,911697,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/9,Other,,
2328,911698,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/9,Other,,
2329,911699,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/9,Other,,
2330,911700,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/9,Other,,
2331,911701,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/9,Other,,
2332,911702,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/9,Other,,
2333,911703,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/9,Other,,
2334,911704,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/9,Other,,
2335,911705,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/9,Other,,
2336,911706,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/9,Other,,
2337,911707,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/9,Other,,
2338,911708,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/9,Other,,
2339,911709,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/9,Other,,
2340,911710,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/9,Other,,
2341,911711,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/10,Other,,
2342,911712,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/10,Other,,
2343,911713,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/10,Other,,
2344,911714,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/10,Other,,
2345,911715,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/10,Other,,
2346,911716,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/10,Other,,
2347,911717,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/10,Other,,
2348,911718,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/10,Other,,
2349,911719,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/10,Other,,
2350,911720,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/10,Other,,
2351,911721,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/10,Other,,
2352,911722,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/10,Other,,
2353,911723,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/10,Other,,
2354,911724,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/10,Other,,
2355,911725,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/10,Other,,
2356,911726,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/10,Other,,
2357,911727,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/10,Other,,
2358,911728,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/10,Other,,
2359,911729,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/10,Other,,
2360,911730,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/10,Other,,
2361,911731,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/10,Other,,
2362,911732,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/11,Other,,
2363,911733,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/11,Other,,
2364,911734,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/11,Other,,
2365,911735,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/11,Other,,
2366,911736,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/11,Other,,
2367,912109,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/11,Other,,
2368,912110,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/11,Other,,
2369,912111,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/11,Other,,
2370,912112,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/11,Other,,
2371,913530,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/11,Other,,
2372,913531,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/11,Other,,
2373,913532,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/11,Other,,
2374,913533,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/11,Other,,
2375,913534,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/11,Other,,
2376,913535,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/11,Other,,
2377,913536,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/11,Other,,
2378,913537,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/11,Other,,
2379,913538,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/11,Other,,
2380,913539,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/11,Other,,
2381,913540,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/11,Other,,
2382,913541,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/11,Other,,
2383,913542,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/12,Other,,
2384,913543,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/12,Other,,
2385,913544,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/12,Other,,
2386,913545,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/12,Other,,
2387,913546,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/12,Other,,
2388,913547,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/12,Other,,
2389,913548,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/12,Other,,
2390,913549,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/12,Other,,
2391,913550,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/12,Other,,
2392,913551,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/12,Other,,
2393,913552,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/12,Other,,
2394,913553,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/12,Other,,
2395,913554,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/12,Other,,
2396,913555,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/12,Other,,
2397,913556,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/12,Other,,
2398,913557,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/12,Other,,
2399,913558,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/12,Other,,
2400,913559,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/12,Other,,
2401,913560,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/12,Other,,
2402,913561,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/12,Other,,
2403,913562,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/12,Other,,
2404,913563,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/13,Other,,
2405,913564,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/13,Other,,
2406,913942,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/13,Other,,
2407,913943,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/13,Other,,
2408,913944,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/13,Other,,
2409,913945,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/13,Other,,
2410,913946,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/13,Other,,
2411,913947,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/13,Other,,
2412,913948,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/13,Other,,
2413,913949,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/13,Other,,
2414,913950,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/13,Other,,
2415,913951,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/13,Other,,
2416,913952,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/13,Other,,
2417,913953,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/13,Other,,
2418,913954,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/13,Other,,
2419,914848,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/5,Other,,
2420,914849,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/5,Other,,
2421,914850,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/5,Other,,
2422,914851,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/5,Other,,
2423,914852,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/5,Other,,
2424,914853,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/5,Other,,
2425,915303,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/5,Other,,
2426,915304,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/5,Other,,
2427,915305,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/5,Other,,
2428,915306,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/5,Other,,
2429,915307,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/5,Other,,
2430,915308,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/5,Other,,
2431,915309,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/5,Other,,
2432,915310,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/5,Other,,
2433,915311,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/5,Other,,
2434,915312,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/5,Other,,
2435,915313,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/5,Other,,
2436,915314,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/5,Other,,
2437,915315,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/5,Other,,
2438,915316,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/5,Other,,
2439,915317,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/6,Other,,
2440,915318,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/6,Other,,
2441,915319,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/6,Other,,
2442,915320,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/6,Other,,
2443,915321,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/6,Other,,
2444,915322,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/6,Other,,
2445,915323,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/6,Other,,
2446,915324,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/6,Other,,
2447,915325,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/6,Other,,
2448,915326,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/6,Other,,
2449,915327,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/6,Other,,
2450,915328,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/6,Other,,
2451,915329,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/6,Other,,
2452,915330,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/6,Other,,
2453,915331,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/6,Other,,
2454,915332,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/6,Other,,
2455,915333,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/6,Other,,
2456,915334,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/6,Other,,
2457,915347,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/5,Other,,
2458,915368,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/13,Other,,
2459,915369,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/13,Other,,
2460,915370,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/13,Other,,
2461,915371,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/13,Other,,
2462,915372,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/13,Other,,
2463,915373,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/13,Other,,
2464,915374,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/14,Other,,
2465,915375,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/14,Other,,
2466,915376,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/14,Other,,
2467,915377,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/14,Other,,
2468,915378,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/14,Other,,
2469,915379,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/14,Other,,
2470,915380,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/14,Other,,
2471,915381,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/14,Other,,
2472,915382,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/14,Other,,
2473,915383,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/14,Other,,
2474,915384,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/14,Other,,
2475,915385,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/14,Other,,
2476,915386,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/14,Other,,
2477,915387,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/14,Other,,
2478,915388,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/14,Other,,
2479,915389,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/14,Other,,
2480,915390,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/14,Other,,
2481,915391,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/14,Other,,
2482,915392,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/14,Other,,
2483,915745,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/14,Other,,
2484,915746,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/14,Other,,
2485,915747,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/15,Other,,
2486,915748,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/15,Other,,
2487,915749,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/15,Other,,
2488,915750,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/15,Other,,
2489,915751,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/15,Other,,
2490,915752,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/15,Other,,
2491,915753,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/15,Other,,
2492,915754,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/15,Other,,
2493,915755,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/15,Other,,
2494,915756,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/15,Other,,
2495,915757,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/15,Other,,
2496,915758,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/15,Other,,
2497,915759,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/15,Other,,
2498,915760,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/15,Other,,
2499,915761,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/15,Other,,
2500,915762,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/15,Other,,
2501,915763,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/15,Other,,
2502,915764,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/15,Other,,
2503,915765,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/15,Other,,
2504,915766,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/15,Other,,
2505,915767,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/15,Other,,
2506,916205,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 664/16,Other,,
2507,916206,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 664/16,Other,,
2508,916207,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 664/16,Other,,
2509,916208,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 664/16,Other,,
2510,916209,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 664/16,Other,,
2511,916210,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 664/16,Other,,
2512,916211,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 664/16,Other,,
2513,916212,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 664/16,Other,,
2514,916213,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 664/16,Other,,
2515,916214,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 664/16,Other,,
2516,916215,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 664/16,Other,,
2517,916216,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 664/16,Other,,
2518,916217,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 664/16,Other,,
2519,916218,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 664/16,Other,,
2520,916219,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 664/16,Other,,
2521,916220,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 664/16,Other,,
2522,916221,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 664/16,Other,,
2523,916222,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 664/16,Other,,
2524,916223,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 664/16,Other,,
2525,916224,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 664/16,Other,,
2526,916225,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 664/16,Other,,
2527,927814,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011023,Other,,
2528,927815,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011023,Other,,
2529,927816,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011023,Other,,
2530,928321,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011023,Other,,
2531,928322,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011023,Other,,
2532,928323,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011023,Other,,
2533,928324,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011023,Other,,
2534,928325,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011023,Other,,
2535,928326,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011023,Other,,
2536,928327,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011023,Other,,
2537,928328,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011023,Other,,
2538,928329,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011023,Other,,
2539,928330,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011023,Other,,
2540,928331,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011023,Other,,
2541,928332,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011023,Other,,
2542,928333,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011023,Other,,
2543,928334,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011023,Other,,
2544,928962,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011023,Other,,
2545,928963,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011023",Other,,
2546,928964,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011023,Other,,
2547,928965,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011023",Other,,
2548,928966,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011023,Other,,
2549,928967,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011023,Other,,
2550,928968,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011023,Other,,
2551,928969,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011023,Other,,
2552,928970,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011023,Other,,
2553,928971,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011023,Other,,
2554,928972,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011023,Other,,
2555,928973,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011023,Other,,
2556,928974,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011023,Other,,
2557,928975,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011023,Other,,
2558,928976,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011023,Other,,
2559,928977,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011023,Other,,
2560,928978,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011023,Other,,
2561,928979,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011023,Other,,
2562,928980,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011023,Other,,
2563,928981,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011023,Other,,
2564,928982,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011023,Other,,
2565,938022,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011023,Other,,
2566,938023,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011023,Other,,
2567,938024,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011023,Other,,
2568,938025,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011023,Other,,
2569,938026,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011023,Other,,
2570,938027,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011023,Other,,
2571,938028,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011023",Other,,
2572,938029,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011023,Other,,
2573,946060,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011023,Other,,
2574,946061,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011023,Other,,
2575,946062,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011023,Other,,
2576,946694,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011023,Other,,
2577,946695,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011023,Other,,
2578,946696,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011023,Other,,
2579,946697,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011023,Other,,
2580,946698,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011023,Other,,
2581,946699,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011023,Other,,
2582,946700,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011023,Other,,
2583,946701,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011023,Other,,
2584,947221,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S011127,Other,,
2585,947222,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S011127,Other,,
2586,947223,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S011127,Other,,
2587,947224,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S011127,Other,,
2588,947225,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S011127,Other,,
2589,947226,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S011127,Other,,
2590,949360,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S011127,Other,,
2591,949361,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S011127,Other,,
2592,949362,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S011127,Other,,
2593,949363,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S011127,Other,,
2594,949364,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S011127,Other,,
2595,949365,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S011127",Other,,
2596,949366,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S011127,Other,,
2597,949367,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S011127,Other,,
2598,949368,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S011127,Other,,
2599,949369,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S011127,Other,,
2600,949370,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S011127,Other,,
2601,949371,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S011127,Other,,
2602,949372,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S011127,Other,,
2603,956164,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011023,Other,,
2604,956165,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011023,Other,,
2605,956166,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011023,Other,,
2606,956167,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011023,Other,,
2607,956168,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011023,Other,,
2608,956169,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011023,Other,,
2609,956170,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011023,Other,,
2610,956171,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011023,Other,,
2611,956172,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011023,Other,,
2612,956173,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011023,Other,,
2613,956174,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011023,Other,,
2614,956175,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011023,Other,,
2615,956176,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011023,Other,,
2616,956177,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011023,Other,,
2617,956178,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011023,Other,,
2618,956179,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011023,Other,,
2619,956180,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011023,Other,,
2620,956181,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011023,Other,,
2621,956182,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011023,Other,,
2622,959701,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011023,Other,,
2623,959702,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011023,Other,,
2624,959703,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011023,Other,,
2625,959704,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011023,Other,,
2626,959705,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011023,Other,,
2627,959706,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011023,Other,,
2628,959707,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011023,Other,,
2629,959708,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011023,Other,,
2630,959709,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011023,Other,,
2631,959710,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011023,Other,,
2632,959711,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011023,Other,,
2633,959712,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011023,Other,,
2634,959713,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011023,Other,,
2635,959714,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011023,Other,,
2636,959715,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011023,Other,,
2637,959716,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011023,Other,,
2638,959717,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011023,Other,,
2639,959718,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011023,Other,,
2640,959719,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011023,Other,,
2641,959720,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011023,Other,,
2642,959869,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011127,Other,,
2643,959870,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011127,Other,,
2644,959871,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011127,Other,,
2645,959872,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011127,Other,,
2646,959873,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S011127,Other,,
2647,959874,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011127,Other,,
2648,959875,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011127,Other,,
2649,959876,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011127,Other,,
2650,959877,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011127,Other,,
2651,959878,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011127,Other,,
2652,959879,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011127,Other,,
2653,960214,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011127,Other,,
2654,960215,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011127,Other,,
2655,960216,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011127,Other,,
2656,960650,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011127,Other,,
2657,960651,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011127,Other,,
2658,960652,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011127,Other,,
2659,965090,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S011023,Other,,
2660,965091,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011023,Other,,
2661,965092,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S011023,Other,,
2662,965093,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S011023,Other,,
2663,965094,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S011023,Other,,
2664,965095,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S011023,Other,,
2665,965096,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S011023,Other,,
2666,965097,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S011023,Other,,
2667,965098,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S011023,Other,,
2668,965099,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S011023,Other,,
2669,965100,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S011023,Other,,
2670,966496,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S011023,Other,,
2671,966497,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S011023,Other,,
2672,966498,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S011023,Other,,
2673,966499,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S011023,Other,,
2674,966500,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S011023,Other,,
2675,966501,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011023,Other,,
2676,966502,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S011023,Other,,
2677,966669,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S011127,Other,,
2678,966670,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S011127,Other,,
2679,977602,1,2,,104234229,5743,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
2680,977611,3,1,,208011902,5743,Active,,,0.019,Kd,Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB,Other,20355713.0,
2681,998625,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011023",Other,,
2682,998626,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S011023",Other,,
2683,998627,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S011023",Other,,
2684,998628,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S011023",Other,,
2685,998629,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S011023",Other,,
2686,1000492,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011023",Other,,
2687,1000493,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S011023",Other,,
2688,1000494,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S011023,Other,,
2689,1000495,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S011023",Other,,
2690,1000496,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S011023,Other,,
2691,1000497,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S011023",Other,,
2692,1000498,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S011023",Other,,
2693,1000499,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S011023",Other,,
2694,1000500,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S011023",Other,,
2695,1000501,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S011023",Other,,
2696,1000502,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S011023",Other,,
2697,1000503,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S011023",Other,,
2698,1001084,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S011023",Other,,
2699,1001085,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011023",Other,,
2700,1001086,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S011023",Other,,
2701,1001087,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S011023",Other,,
2702,1001088,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011023",Other,,
2703,1001089,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S011023",Other,,
2704,1001090,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S011023",Other,,
2705,1001091,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S011023",Other,,
2706,1001092,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S011023",Other,,
2707,1001093,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S011023",Other,,
2708,1001094,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S011023",Other,,
2709,1001095,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S011023",Other,,
2710,1001096,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S011023,Other,,
2711,1001097,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S011023,Other,,
2712,1001098,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S011023",Other,,
2713,1001099,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S011023",Other,,
2714,1001100,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011023",Other,,
2715,1001101,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S011023",Other,,
2716,1001102,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S011023,Other,,
2717,1001103,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011023",Other,,
2718,1001104,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S011023",Other,,
2719,1001105,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S011023",Other,,
2720,1001106,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S011023",Other,,
2721,1001107,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S011023,Other,,
2722,1001108,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S011023",Other,,
2723,1001109,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S011023",Other,,
2724,1001110,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S011023",Other,,
2725,1002976,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S011023",Other,,
2726,1002977,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S011023",Other,,
2727,1002978,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S011023",Other,,
2728,1002979,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S011023",Other,,
2729,1002980,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S011023,Other,,
2730,1002981,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S011023",Other,,
2731,1002982,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S011023",Other,,
2732,1002983,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S011023",Other,,
2733,1003566,1,3,,104234229,5743,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S011023,Other,,
2734,1003567,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S011023",Other,,
2735,1003568,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S011023",Other,,
2736,1003569,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S011023",Other,,
2737,1003570,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S011023",Other,,
2738,1003571,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S011023",Other,,
2739,1003572,1,3,,104234229,5743,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S011023",Other,,
2740,1046954,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/5,Other,,
2741,1046955,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/5,Other,,
2742,1047043,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/5,Other,,
2743,1047044,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/6,Other,,
2744,1047045,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/6,Other,,
2745,1047046,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/6,Other,,
2746,1047359,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/7,Other,,
2747,1047360,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/7,Other,,
2748,1047361,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/7,Other,,
2749,1047362,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/8,Other,,
2750,1047363,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/8,Other,,
2751,1047364,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/8,Other,,
2752,1047365,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/9,Other,,
2753,1047366,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/9,Other,,
2754,1047367,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/9,Other,,
2755,1047368,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/10,Other,,
2756,1047369,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/10,Other,,
2757,1047370,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/10,Other,,
2758,1047371,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/11,Other,,
2759,1047372,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/11,Other,,
2760,1047373,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/11,Other,,
2761,1047374,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/12,Other,,
2762,1047375,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/12,Other,,
2763,1047376,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/12,Other,,
2764,1047377,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/13,Other,,
2765,1047378,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/13,Other,,
2766,1047379,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/13,Other,,
2767,1047380,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/14,Other,,
2768,1047381,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/14,Other,,
2769,1047382,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/14,Other,,
2770,1047383,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/15,Other,,
2771,1047384,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/15,Other,,
2772,1047385,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/15,Other,,
2773,1047386,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 664/16,Other,,
2774,1047387,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 664/16,Other,,
2775,1047388,1,2,,104234229,5743,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 664/16,Other,,
2776,1053175,2,1,,125231101,5743,Inactive,,,,,A screen for compounds that inhibit growth of Escherichia coli,Other,,
2777,1053188,2,1,,85789486,5743,Inactive,,,,,Primary Screen Inhibitors of CD40 Signaling in BL2 Cells Measured in Cell-Based System Using Plate Reader - 7124-01_Inhibitor_SinglePoint_HTS_Activity,Screening,,
2778,1053197,1,1,,56320686,5743,Inactive,74734243.0,54414.0,,,Fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of sialic acid acetylesterase (SIAE),Screening,,
2779,1058573,1,4,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at glucocorticoid receptor in HFF assessed as inhibition of IL-1-induced IL-6 production at 2000 nM after 24 hrs relative to control,Other,24215891.0,
2780,1058574,2,3,,104234229,5743,Active,121069.0,2908.0,0.0005,IC50,Agonist activity at glucocorticoid receptor in HFF assessed as inhibition of IL-1-induced IL-6 production after 24 hrs,Confirmatory,24215891.0,
2781,1058575,2,3,,104234229,5743,Active,126885.0,4306.0,0.033,IC50,Binding affinity to mineralocorticoid receptor (unknown origin) by fluorescence polarization competitive binding assay,Confirmatory,24215891.0,
2782,1058576,2,3,,104234229,5743,Unspecified,90110048.0,5241.0,2.0,IC50,Displacement of TAMRA-labeled mifepristone from progesterone receptor (unknown origin) by fluorescence polarization competitive binding assay,Confirmatory,24215891.0,
2783,1058577,2,3,,104234229,5743,Active,121069.0,2908.0,0.0035,IC50,Displacement of TAMRA-labeled dexamethasone from glucocorticoid receptor (unknown origin) by fluorescence polarization competitive binding assay,Confirmatory,24215891.0,
2784,1071636,2,3,,104234229,5743,Active,90110048.0,5241.0,0.561,Ki,Displacement of [3H]-methyltrienolone from human progesterone receptor expressed in HEK293 cells,Confirmatory,24446728.0,
2785,1071637,2,3,,104234229,5743,Active,1018618719.0,367.0,1.41,Ki,Displacement of [3H]-methyltrienolone from human androgen receptor expressed in HEK293 cells,Confirmatory,24446728.0,
2786,1071638,2,3,,104234229,5743,Active,121069.0,2908.0,0.0006900000000000001,Ki,Displacement of [3H]-dexamethasone from human glucocorticoid receptor expressed in HEK293 cells,Confirmatory,24446728.0,
2787,1071639,2,3,,104234229,5743,Active,126885.0,4306.0,0.00036,Ki,Displacement of [3H]-aldosterone from human mineralocorticoid receptor expressed in HEK293 cells,Confirmatory,24446728.0,
2788,1079931,1,1,,104234229,5743,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
2789,1079932,1,1,,104234229,5743,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
2790,1079933,1,1,,104234229,5743,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
2791,1079934,1,1,,104234229,5743,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
2792,1079935,1,1,,104234229,5743,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
2793,1079936,1,1,,104234229,5743,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
2794,1079937,1,1,,104234229,5743,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
2795,1079938,1,1,,104234229,5743,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
2796,1079939,1,1,,104234229,5743,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
2797,1079940,1,1,,104234229,5743,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
2798,1079941,1,1,,104234229,5743,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
2799,1079942,1,1,,104234229,5743,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
2800,1079943,1,1,,104234229,5743,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
2801,1079944,1,1,,104234229,5743,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
2802,1079945,1,1,,104234229,5743,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
2803,1079946,1,1,,104234229,5743,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
2804,1079947,1,1,,104234229,5743,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
2805,1079948,1,1,,104234229,5743,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
2806,1079949,1,1,,104234229,5743,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
2807,1086163,1,2,,104234229,5743,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) CCK8 cells at 1 uM,Other,,
2808,1086164,1,2,,104234229,5743,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) THP1 cells assessed as inhibition of LPS-induced IL6 production at 1 uM incubated for 30 min prior to LPS-challenge measured after 24 hr by ELISA,Other,,
2809,1086165,1,2,,104234229,5743,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) THP1 cells assessed as inhibition of LPS-induced TNFalpha production at 1 uM incubated for 30 min prior to LPS-challenge measured after 24 hr by ELISA,Other,,
2810,1086347,1,2,,104234229,5743,Unspecified,,,,,Cytotoxicity against Homo sapiens (human) CCK8 cells at 1 uM after 24 hr,Other,,
2811,1086348,1,2,,104234229,5743,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) PMA-stimulated THP1 cells assessed as inhibition of LPS-induced IL6 production at 1 uM incubated for 30 min prior to LPS-challenge measured after 24 hr by ELISA,Other,,
2812,1086349,1,2,,104234229,5743,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) PMA-stimulated THP1 cells assessed as inhibition of LPS-induced TNFalpha production at 1 uM incubated for 30 min prior to LPS-challenge measured after 24 hr by ELISA,Other,,
2813,1091955,1,2,,104234229,5743,Unspecified,,,,,"Dissociation constant, pKa of the compound at pH 7.3",Other,20879794.0,
2814,1091956,1,1,,104234229,5743,Unspecified,,,,,"Apparent hydrophobicity, log D of the compound in Octanol-buffer",Other,20879794.0,
2815,1091957,1,1,,104234229,5743,Unspecified,,,,,Apparent permeability of the compound by PAMPA,Other,20879794.0,
2816,1091958,2,1,,104234229,5743,Unspecified,,,,,"Hydrophobicity, log P of the compound in octanol-water by shaking-flask method",Other,20879794.0,
2817,1094930,1,2,,104234229,5743,Unspecified,,,,,"Anti-inflammatory activity in fasted Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, ip administered 1 hr prior to carrageenan challenge measured at 5 hr relative to control",Other,,
2818,1094933,1,2,,104234229,5743,Unspecified,,,,,"Anti-inflammatory activity in fasted Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, ip administered 1 hr prior to carrageenan challenge measured at 3 hr relative to control",Other,,
2819,1094936,1,2,,104234229,5743,Unspecified,,,,,"Anti-inflammatory activity in fasted Rattus norvegicus Wistar (rat) assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, ip administered 1 hr prior to carrageenan challenge measured at 1 hr relative to control",Other,,
2820,1097186,1,2,,104234229,5743,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) THP1 cells assessed as inhibition of LPS-induced IL-6 production preincubated at 1 uM for 30 min before LPS treatment measured after 24 hr by ELISA,Other,,
2821,1097187,1,2,,104234229,5743,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) THP1 cells assessed as inhibition of LPS-induced TNF-alpha production preincubated at 1 uM for 30 min before LPS treatment measured after 24 hr by ELISA,Other,,
2822,1106554,1,2,,104234229,5743,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) THP1 cells assessed as inhibition of LPS-induced IL6 production at 1 uM incubated for 30 min prior to LPS-challenge measured after 24 hr by ELISA,Other,,
2823,1106555,1,2,,104234229,5743,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) THP1 cells assessed as inhibition of LPS-induced TNFalpha production at 1 uM incubated for 30 min prior to LPS-challenge measured after 24 hr by ELISA,Other,,
2824,1107129,1,2,,104234229,5743,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) THP1 cells assessed as inhibition of LPS-induced IL6 production at 1 uM incubated for 30 min prior to LPS-challenge measured after 24 hr by ELISA relative to control,Other,,
2825,1107130,1,2,,104234229,5743,Unspecified,,,,,Anti-inflammatory activity in Homo sapiens (human) THP1 cells assessed as inhibition of LPS-induced TNFalpha production at 1 uM incubated for 30 min prior to LPS-challenge measured after 24 hr by ELISA relative to control,Other,,
2826,1115838,1,2,,104234229,5743,Unspecified,,,,,"Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, ip administered 30 min prior to carrageenan-challenge measured at 6 hr by plethysmometric analysis relative to control",Other,,
2827,1115841,1,2,,104234229,5743,Unspecified,,,,,"Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, ip administered 30 min prior to carrageenan-challenge measured at 5 hr by plethysmometric analysis relative to control",Other,,
2828,1115844,1,2,,104234229,5743,Unspecified,,,,,"Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, ip administered 30 min prior to carrageenan-challenge measured at 4 hr by plethysmometric analysis relative to control",Other,,
2829,1115847,1,2,,104234229,5743,Unspecified,,,,,"Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, ip administered 30 min prior to carrageenan-challenge measured at 3 hr by plethysmometric analysis relative to control",Other,,
2830,1115850,1,2,,104234229,5743,Unspecified,,,,,"Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, ip administered 30 min prior to carrageenan-challenge measured at 2 hr by plethysmometric analysis relative to control",Other,,
2831,1115853,1,2,,104234229,5743,Unspecified,,,,,"Anti-inflammatory activity in Wistar Rattus norvegicus (rat) assessed as inhibition of carrageenan-induced paw edema at 1 mg/kg, ip administered 30 min prior to carrageenan-challenge measured at 1 hr by plethysmometric analysis relative to control",Other,,
2832,1116768,1,2,,104234229,5743,Unspecified,,,355.14,IC50,Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of PMA-induced macrophages respiratory burst measured up to 30 min by chemiluminescence method,Confirmatory,,
2833,1117298,1,2,,174007382,5743,Inactive,,,1.9953,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
2834,1117301,1,2,,26752877,5743,Inactive,,,50.1187,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
2835,1117302,1,2,,26752877,5743,Inactive,,,6.3096,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
2836,1117303,1,2,,26752877,5743,Inactive,,,31.63,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
2837,1117304,1,2,,174007382,5743,Inactive,,,22.3872,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
2838,1117305,1,2,,174007382,5743,Inactive,,,17.7828,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
2839,1117310,1,1,,174007382,5743,Inactive,,,1.9952599999999998,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
2840,1117311,1,1,,26752877,5743,Inactive,,,50.1187,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
2841,1117312,1,1,,174007382,5743,Inactive,,,17.7828,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
2842,1117314,1,1,,174007382,5743,Inactive,,,22.3872,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
2843,1117315,1,1,,26752877,5743,Inactive,,,6.30957,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
2844,1117318,1,1,,26752877,5743,Inactive,,,31.6228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
2845,1117326,1,1,,174007382,5743,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
2846,1117329,1,1,,174007382,5743,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
2847,1117336,1,1,,174007382,5743,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
2848,1117340,1,1,,174007382,5743,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
2849,1117341,1,1,,174007382,5743,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
2850,1117342,1,1,,174007382,5743,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
2851,1117343,1,1,,174007382,5743,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
2852,1117346,1,1,,174007382,5743,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
2853,1125607,1,3,,104234229,5743,Active,121069.0,2908.0,0.003,IC50,Displacement of TAMRA-labeled dexamethasone from glucocorticoid receptor (unknown origin) by fluorescence polarization assay,Confirmatory,24656565.0,
2854,1125608,2,2,,104234229,5743,Unspecified,90110048.0,5241.0,2.0,IC50,Displacement of TAMRA-labeled mifepristone from progesterone receptor (unknown origin) by fluorescence polarization assay,Confirmatory,24656565.0,
2855,1125609,1,3,,104234229,5743,Active,126885.0,4306.0,0.033,IC50,Displacement of TAMRA-labeled dexamethasone from mineralocorticoid receptor (unknown origin) by fluorescence polarization assay,Confirmatory,24656565.0,
2856,1125610,1,3,,104234229,5743,Active,121069.0,2908.0,0.0005,IC50,Agonist activity at glucocorticoid receptor in human foreskin fibroblasts assessed as inhibition of IL-1-induced IL-6 production by trans-repression assay,Confirmatory,24656565.0,
2857,1125614,1,3,,104234229,5743,Active,121069.0,2908.0,,IC50,Transactivation of glucocorticoid receptor in human HeLa cells harboring MMTV promoter by luciferase reporter gene assay,Confirmatory,24656565.0,
2858,1128037,1,1,,104234229,5743,Active,,,,,"Antiallergic activity in house dust mite-induced allergic airway disease BALB/c mouse model assessed as reduction in airway inflammation at 1 mg/kg, ip qd after 17 days",Other,24512187.0,
2859,1148617,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in immature rat assessed as inhibition of cantharidin-induced inflammation at 5 ug administered topically to outer surface of ear after 72 hrs relative to control,Other,71349.0,
2860,1148618,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in immature rat assessed as inhibition of cantharidin-induced inflammation at 10 ug administered topically to outer surface of ear after 72 hrs relative to control,Other,71349.0,
2861,1148619,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in immature rat assessed as inhibition of cantharidin-induced inflammation at 20 ug administered topically to outer surface of ear after 72 hrs relative to control,Other,71349.0,
2862,1148620,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in immature rat assessed as inhibition of cantharidin-induced inflammation at 40 ug administered topically to outer surface of ear after 72 hrs relative to control,Other,71349.0,
2863,1148621,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in immature rat assessed as inhibition of cantharidin-induced inflammation at 80 ug administered topically to outer surface of ear after 72 hrs relative to control,Other,71349.0,
2864,1148624,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in rat assessed as reduction in dry ganuloma tissue surrounding implanted cotton pellet at 10 ug per pellet after 72 hrs relative to control,Other,71349.0,
2865,1148625,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in rat assessed as reduction in dry ganuloma tissue surrounding implanted cotton pellet at 20 ug per pellet after 72 hrs relative to control,Other,71349.0,
2866,1148626,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in rat assessed as reduction in dry ganuloma tissue surrounding implanted cotton pellet at 40 ug per pellet after 72 hrs relative to control,Other,71349.0,
2867,1148627,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in rat assessed as reduction in dry ganuloma tissue surrounding implanted cotton pellet at 80 ug per pellet after 72 hrs relative to control,Other,71349.0,
2868,1152369,1,1,,104234229,5743,Active,,,,,Induction of apoptosis in mouse thymocytes assessed as internucleosomal DNA fragmentation at 1 uM after 24 hrs by agarose gel electrophoresis,Other,24794748.0,
2869,1159317,1,1,,104234229,5743,Unspecified,,,20.0,IC50,Anticancer against mouse B16F10 cells after 72 hrs by MTT assay,Confirmatory,24992071.0,
2870,1159318,1,1,,104234229,5743,Unspecified,,,15.0,IC50,Anticancer against human MCF7 cells after 72 hrs by MTT assay,Confirmatory,24992071.0,
2871,1159319,1,1,,104234229,5743,Unspecified,,,15.0,IC50,Anticancer against human A549 cells after 72 hrs by MTT assay,Confirmatory,24992071.0,
2872,1159320,1,1,,104234229,5743,Unspecified,,,20.0,IC50,Cytotoxicity against CHO cells after 72 hrs by MTT assay,Confirmatory,24992071.0,
2873,1159321,1,2,,104234229,5743,Unspecified,,,20.0,IC50,Cytotoxicity against HEK293T cells after 72 hrs by MTT assay,Confirmatory,24992071.0,
2874,1159322,1,1,,104234229,5743,Unspecified,,,15.0,IC50,Cytotoxicity against mouse fibroblasts after 72 hrs by MTT assay,Confirmatory,24992071.0,
2875,1159323,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells assessed as necrotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 1.7%),Other,24992071.0,
2876,1159324,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells assessed as late apoptotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 2.5%),Other,24992071.0,
2877,1159325,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells assessed as early apoptotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 0.7%),Other,24992071.0,
2878,1159326,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in mouse B16F10 cells assessed as viable cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 95.1%),Other,24992071.0,
2879,1159327,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 7.1%),Other,24992071.0,
2880,1159328,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 3.5%),Other,24992071.0,
2881,1159329,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 3%),Other,24992071.0,
2882,1159330,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in human MCF7 cells assessed as viable cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 86.4%),Other,24992071.0,
2883,1159331,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in CHO cells assessed as necrotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb =6.6%),Other,24992071.0,
2884,1159332,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in CHO cells assessed as late apoptotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 0%),Other,24992071.0,
2885,1159333,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in CHO cells assessed as early apoptotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 0.1%),Other,24992071.0,
2886,1159334,1,1,,104234229,5743,Unspecified,,,,,Induction of apoptosis in CHO cells assessed as viable cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 93.3%),Other,24992071.0,
2887,1159335,1,2,,104234229,5743,Unspecified,,,,,Induction of apoptosis in HEK293T cells assessed as necrotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 0.7%),Other,24992071.0,
2888,1159336,1,2,,104234229,5743,Unspecified,,,,,Induction of apoptosis in HEK293T cells assessed as late apoptotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 0.4%),Other,24992071.0,
2889,1159337,1,2,,104234229,5743,Unspecified,,,,,Induction of apoptosis in HEK293T cells assessed as early apoptotic cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 0.3%),Other,24992071.0,
2890,1159338,1,2,,104234229,5743,Unspecified,,,,,Induction of apoptosis in HEK293T cells assessed as viable cells at 10 uM after 48 hrs using FITC-annexin V-FITC/propidium iodide by flow cytometry (Rvb = 98.6%),Other,24992071.0,
2891,1159342,1,1,,104234229,5743,Active,,,,,"Antitumor activity against mouse B16F10 cells xenografted in C57BL/6 mouse assessed as inhibition tumor growth at 20 mg/kg, ip measured after 24 days of tumor inoculation",Other,24992071.0,
2892,1159343,1,1,,104234229,5743,Active,,,,,"Antitumor activity against mouse B16F10 cells xenografted in C57BL/6 mouse assessed as apoptotic regions at 20 mg/kg, ip measured after 24 days of tumor inoculation by TUNEL assay",Other,24992071.0,
2893,1159344,1,1,,104234229,5743,Active,,,,,"Antitumor activity against mouse B16F10 cells xenografted in C57BL/6 mouse assessed as apoptotic regions at 20 mg/kg, ip measured after 24 days of tumor inoculation by VE-cadherin",Other,24992071.0,
2894,1159348,1,1,,104234229,5743,Active,,,,,Induction of apoptosis in mouse B16F10 cells assessed as increase in ratio of BAX/Bcl2 expression at 10 uM after 48 hrs by Western blot analysis relative to untreated control,Other,24992071.0,
2895,1159387,1,2,,104234229,5743,Unspecified,,,,,"ASTRAZENECA: Octan-1-ol/water (pH7.4) distribution coefficent measured  by a shake flask method described in J. Biomol. Screen. 2011, 16, 348-355. Experimental range -1.5 to 4.5",Other,,
2896,1159388,1,2,,104234229,5743,Unspecified,,,,,"ASTRAZENECA: Solubility in pH7.4 buffer using solid starting material using the method described in J. Assoc. Lab. Autom. 2011, 16, 276-284. Experimental range 0.10 to 1500 uM",Other,,
2897,1159389,1,2,,104234229,5743,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole human plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
2898,1159390,1,2,,104234229,5743,Unspecified,,,,,"ASTRAZENECA: % bound to plasma by equilibrium dialysis. Compound is incubated with whole rat plasma  at 37C for >5hrs.  Method described in B. Testa et al (Eds.), Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical, and Computational Strategies, Wiley-VCH, Weinheim, 2006, pp.119-141. Experimental range 10% to 99.95% bound.",Other,,
2899,1159395,1,2,,104234229,5743,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
2900,1159509,1,1,,144207320,5743,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2901,1159515,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2902,1159516,1,1,,144207320,5743,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2903,1159517,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2904,1159518,1,1,,144207320,5743,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2905,1159519,1,1,,144207320,5743,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2906,1159520,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2907,1159521,1,1,,144207320,5743,Inconclusive,15928672.0,19885.0,43.894,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2908,1159523,1,1,,144207320,5743,Inconclusive,15928672.0,19885.0,43.894,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2909,1159524,1,1,,26752876,5743,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2910,1159524,1,1,,56314873,5743,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2911,1159524,1,1,,56320685,5743,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2912,1159525,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2913,1159526,1,1,,144207320,5743,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2914,1159527,1,1,,144207320,5743,Inconclusive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2915,1159528,1,1,,144207320,5743,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2916,1159529,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2917,1159531,1,1,,144207320,5743,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2918,1159550,3,1,,252401139,5743,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
2919,1159551,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2920,1159552,1,1,,144207320,5743,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2921,1159553,2,1,,144207320,5743,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2922,1159555,1,1,,144207320,5743,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2923,1159583,2,1,,125231101,5743,Inactive,,,,,High throughput screen for small molecule inhibitors of a hypoxia-regulated fluorescent biosensor in Mycobacterium tuberculosis,Other,,
2924,1159606,1,1,,56314873,5743,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
2925,1159606,1,1,,56320685,5743,Inactive,,,,,"uHTS identification of small molecule inhibitors of TWEAK-Fn14 interactions, using a cell-based reporter assay",Other,,
2926,1159607,2,1,,312310340,5743,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
2927,1159614,1,2,,174007382,5743,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
2928,1159620,1,1,,104234229,5743,Active,,,,,Summary of drug indications.,Other,,
2929,1168714,1,2,,104234229,5743,Active,121069.0,2908.0,0.0013,EC50,Agonist activity at human GCR expressed in HEK293 cells by luciferase reporter gene assay,Confirmatory,25305688.0,
2930,1169836,1,1,,104234229,5743,Active,,,0.008,IC50,Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-1beta expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry,Confirmatory,25338180.0,
2931,1169837,1,1,,104234229,5743,Active,,,0.009000000000000001,IC50,Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced IL-8 expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry,Confirmatory,25338180.0,
2932,1169838,1,1,,104234229,5743,Active,,,0.002,IC50,Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha expression pretreated 1 hr before LPS challenge followed by incubated for 16 hrs by flow cytometry,Confirmatory,25338180.0,
2933,1171139,1,1,,104234229,5743,Active,,,,,"Antiinflammatory activity in Swiss Webster mouse assessed as reduction in paw edema at 2 mg/kg, ip dosed 40 mins before CFA injection and measured 2 to 6 hrs post CFA stimulus",Other,25396337.0,
2934,1171140,1,1,,104234229,5743,Active,,,,,"Antiinflammatory activity in Swiss Webster mouse assessed as reduction in hyperalgesia at 2 mg/kg, ip dosed 40 mins before CFA injection and measured 2 to 6 hrs post CFA stimulus",Other,25396337.0,
2935,1171143,1,1,,104234229,5743,Active,,,,,"Reduction in TNFalpha level in Swiss Webster mouse 2 mg/kg, ip dosed 40 mins before CFA injection and measured 3 hrs post CFA stimulus by ELISA method",Other,25396337.0,
2936,1171144,1,1,,104234229,5743,Active,,,,,"Reduction in IL1-beta level in Swiss Webster mouse 2 mg/kg, ip dosed 40 mins before CFA injection and measured 3 hrs post CFA stimulus by ELISA method",Other,25396337.0,
2937,1175596,1,1,,104234229,5743,Unspecified,,,,,Inhibition of LPS-induced TNFalpha production in mouse inflammatory model at 1 mg/kg,Other,25479567.0,
2938,1175600,1,1,,104234229,5743,Unspecified,,,,,Inhibition of LPS-induced IL6 production in mouse inflammatory model at 1 mg/kg,Other,25479567.0,
2939,1176269,1,1,,104234229,5743,Active,,,0.8,IC50,Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay relative to vehicle-treated control,Confirmatory,25499882.0,
2940,1176700,1,2,,104234229,5743,Active,121069.0,2908.0,0.001,IC50,Agonist activity at GR in HFF cells assessed as suppression of IL-1-induced IL-6 production,Confirmatory,25516791.0,
2941,1178356,1,1,,104234229,5743,Unspecified,,,,,Inhibition of AP-1-mediated transcriptional activation in lipopolysaccharide-stimulated mouse RAW 264.7 cells assessed ratio of luciferase activity normalized to Renilla luciferase activity by luciferase reporter gene assay,Other,24831826.0,
2942,1179492,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production at 20 ug/ml incubated for 1 hr prior to LPS challenge measured after 6 hrs by sandwich ELISA relative to control,Other,24909081.0,
2943,1179493,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced TNF-alpha production at 20 ug/ml incubated for 1 hr prior to LPS challenge measured after 6 hrs by sandwich ELISA relative to control,Other,24909081.0,
2944,1179494,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL-1beta production at 20 ug/ml incubated for 1 hr prior to LPS challenge measured after 12 hrs by sandwich ELISA relative to control,Other,24909081.0,
2945,1179495,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced IL-1beta production at 20 ug/ml incubated for 1 hr prior to LPS challenge measured after 12 hrs by sandwich ELISA relative to control,Other,24909081.0,
2946,1180073,1,1,,104234229,5743,Active,,,0.61,IC50,"Inhibition of sPLA2-V (unknown origin) using substrate 1,2-bis(heptanoylthio)-glycerophosphocholine by Ellman's method based photometric assay",Confirmatory,24938495.0,
2947,1181684,1,2,,104234229,5743,Active,121069.0,2908.0,0.0012,Ki,Binding affinity to glucocorticoid receptor (unknown origin) by fluorescence polarization assay,Confirmatory,24980053.0,
2948,1181685,1,2,,104234229,5743,Active,90110048.0,5241.0,0.778,Ki,Binding affinity to progesterone receptor (unknown origin) by fluorescence polarization assay,Confirmatory,24980053.0,
2949,1181686,1,2,,104234229,5743,Active,121069.0,2908.0,0.0025,EC50,Agonist activity at glucocorticoid receptor in human A549 cells assessed as AP-1 transrepression by luciferase reporter gene assay,Confirmatory,24980053.0,
2950,1181688,1,2,,104234229,5743,Active,121069.0,2908.0,0.0011,EC50,Agonist activity at glucocorticoid receptor in human A549 cells assessed as E-selectin transrepression by luciferase reporter gene assay,Confirmatory,24980053.0,
2951,1181690,1,2,,104234229,5743,Active,121069.0,2908.0,0.0045,EC50,Agonist activity at glucocorticoid receptor in human HeLa cells assessed as NP-1 transactivation by luciferase reporter gene assay,Confirmatory,24980053.0,
2952,1181692,1,2,,104234229,5743,Active,121069.0,2908.0,0.0069,EC50,Agonist activity at glucocorticoid receptor in human whole blood assessed as inhibition of LPS-induced TNF production incubated for 20 hrs prior to LPS challenge measured after 5 hrs by ELISA,Confirmatory,24980053.0,
2953,1184782,1,1,,104234229,5743,Inactive,,,,,Induction of PARP1 cleavage in human CUTLL1 cells at 1 uM after 24 hrs by western blotting method,Other,25050160.0,
2954,1184796,1,1,,104234229,5743,Active,,,,,Growth inhibition of human CUTLL1 cells with high GR expression levels after 48 hrs by alamar blue assay,Other,25050160.0,
2955,1184798,1,1,,104234229,5743,Inactive,,,,,Growth inhibition of human CUTLL1 cells with low GR expression levels after 48 hrs by alamar blue assay,Other,25050160.0,
2956,1187040,1,1,,104234229,5743,Unspecified,,,,,"Antiasthmatic activity in ovalbumin-induced asthma model in Hartley guinea pig assessed as suppression of immediate asthmatic response at 10 mg/kg, po administered 16 hr before and 2 hrs after ovalbumin challenge",Other,25102418.0,
2957,1187043,1,1,,104234229,5743,Unspecified,,,,,"Antiasthmatic activity in ovalbumin-induced asthma model in Hartley guinea pig assessed as suppression of late asthmatic response at 10 mg/kg, po administered 16 hr before and 2 hrs after ovalbumin challenge",Other,25102418.0,
2958,1187046,1,1,,104234229,5743,Unspecified,,,,,"Antiasthmatic activity in ovalbumin-induced asthma model in Hartley guinea pig assessed as airway hyperactivity measured as provocative concentration of acetylcholine aerosols causing a 100% increase in the baseline airway resistance at 10 mg/kg, po administered 16 hr before and 2 hrs after ovalbumin challenge",Other,25102418.0,
2959,1187415,1,1,,104234229,5743,Unspecified,,,,,Inhibition of LPS-induced TNF-alpha release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay,Other,25113933.0,
2960,1187416,1,1,,104234229,5743,Unspecified,,,,,Inhibition of LPS-induced TNF-alpha release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay,Other,25113933.0,
2961,1187417,1,1,,104234229,5743,Unspecified,,,,,Inhibition of LPS-induced IL1-beta release in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay,Other,25113933.0,
2962,1187418,1,1,,104234229,5743,Unspecified,,,,,Inhibition of LPS-induced IL1-beta release in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay,Other,25113933.0,
2963,1192994,1,2,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity against ovalbumin-induced model of allergic inflammation in brown Norway rat assessed as inhibition of eosinophil infiltration in bronchoalveolar lavage fluid at 1 mg/kg, po bid 1 hr before and 6.5 hrs post ovalbumin challenge measured 24 hrs post challenge relative to vehicle-treated control",Other,25690784.0,
2964,1194666,1,1,,104234229,5743,Active,,,0.04,IC50,Inhibition of TNFalpha production in mouse RAW264.7 cells incubated for 6 hrs by sandwich immunoassay,Confirmatory,25824662.0,
2965,1194668,1,1,,104234229,5743,Active,,,0.4,IC50,Inhibition of TNFalpha production in mouse J774A.1 cells incubated for 6 hrs by sandwich immunoassay,Confirmatory,25824662.0,
2966,1194670,1,1,,104234229,5743,Active,,,4.7,IC50,Inhibition of IL-1beta production in mouse RAW264.7 cells incubated for 12 hrs by sandwich immunoassay,Confirmatory,25824662.0,
2967,1194672,1,1,,104234229,5743,Active,,,22.0,IC50,Inhibition of IL-1beta production in mouse J774A.1 cells incubated for 12 hrs by sandwich immunoassay,Confirmatory,25824662.0,
2968,1194675,1,1,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of LPS-induced IL-1beta production at 150 umol/kg, po pre-administered at interval of 12 hrs followed by LPS-stimulation 6 hrs after final dose and measured 2 hrs post LPS challenge by ELISA method",Other,25824662.0,
2969,1194676,1,1,,104234229,5743,Unspecified,,,,,"Antiinflammatory activity in Sprague-Dawley rat assessed as inhibition of LPS-induced TNFalpha production at 150 umol/kg, po pre-administered at interval of 12 hrs followed by LPS-stimulation 2 hrs after final dose and measured 2 hrs post LPS challenge by ELISA method",Other,25824662.0,
2970,1202340,1,1,,104234229,5743,Unspecified,,,,,"Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as white blood cells at 2.5 mg/kg/day, im administered twice each week for 8 weeks (Rvb = 6.28 +/- 2.78 x 10'9/L)",Other,25874339.0,
2971,1202345,1,1,,104234229,5743,Unspecified,,,,,"Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as lymph level at 2.5 mg/kg/day, im administered twice each week for 8 weeks (Rvb = 50.35 +/- 12.96%)",Other,25874339.0,
2972,1202348,1,1,,104234229,5743,Unspecified,,,,,"Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as neutrophilic granulocytes level at 2.5 mg/kg/day, im administered twice each week for 8 weeks (Rvb = 31.95 +/- 8.33%)",Other,25874339.0,
2973,1202359,1,1,,104234229,5743,Unspecified,,,,,"Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as aspartate transaminase level at 2.5 mg/kg/day, im administered twice each week for 8 weeks (Rvb = 177.55 +/- 116.98 U/L)",Other,25874339.0,
2974,1202363,1,1,,104234229,5743,Unspecified,,,,,"Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as alanine transaminase level at 2.5 mg/kg/day, im administered twice each week for 8 weeks (Rvb = 43.73 +/- 36.21 U/L)",Other,25874339.0,
2975,1202368,1,1,,104234229,5743,Unspecified,,,,,"Toxicity in glucocorticoid-induced Wistar rat osteoporosis model assessed as triglycerides level at 2.5 mg/kg/day, im administered twice each week for 8 weeks (Rvb = 1.13 +/- 0.69 mmol/L)",Other,25874339.0,
2976,1202384,1,1,,104234229,5743,Inactive,,,,,"Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as appearance of turbulent and sparse rarefection of trabecula at 2.5 mg/kg/day, im administered twice each week for 8 weeks by toluidine blue staining-based light microscopic analysis",Other,25874339.0,
2977,1202391,1,1,,104234229,5743,Unspecified,,,,,"Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as trabecular bone volume at 2.5 mg/kg/day, im administered twice each week for 8 weeks by fluorescence assay (Rvb = 33.09 +/- 5.15%)",Other,25874339.0,
2978,1202395,1,1,,104234229,5743,Unspecified,,,,,"Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as trabecula formation surface at 2.5 mg/kg/day, im administered twice each week for 8 weeks by fluorescence assay (Rvb = 7.82 +/- 2.46%)",Other,25874339.0,
2979,1202399,1,1,,104234229,5743,Unspecified,,,,,"Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as trabecula resorption surface at 2.5 mg/kg/day, im administered twice each week for 8 weeks by fluorescence assay (Rvb = 7.22 +/- 2.04%)",Other,25874339.0,
2980,1202403,1,1,,104234229,5743,Unspecified,,,,,"Antiosteoporotic activity in glucocorticoid-induced Wistar rat osteoporosis model assessed as mineral apposition rate at 2.5 mg/kg/day, im administered twice each week for 8 weeks by fluorescence assay (Rvb = 1.06 +/- 0.27 micrometer/day)",Other,25874339.0,
2981,1203066,1,2,,104234229,5743,Active,121069.0,2908.0,0.0035,IC50,Binding affinity to human GR,Confirmatory,25706100.0,
2982,1203067,1,2,,104234229,5743,Active,121069.0,2908.0,0.0018,IC50,Transrepression activity at glucocorticoid receptor in human SW1353 cells assessed as repression of IL-1-induced MMP-13 production after 24 hrs by ELISA,Confirmatory,25706100.0,
2983,1203073,1,2,,104234229,5743,Active,121069.0,2908.0,0.021,IC50,Transrepression activity at glucocorticoid receptor in human whole blood assessed as repression of IL-1-induced TNF-alpha production after 4 hrs by ELISA,Confirmatory,25706100.0,
2984,1204989,1,1,,104234229,5743,Active,,,,,Antiinflammatory activity against mouse RAW264.7 cells assessed as reduction of LPS-induced TNF mRNA expression cells at 1 mM treated 30 mins before LPS challenge measured after 3 hrs by qRT-PCR analysis,Other,25667960.0,
2985,1204992,1,1,,104234229,5743,Inactive,,,,,Inhibition of luminescence emission in mouse RAW264.7 cells transfected with luciferase plasmid containing universal promoter PKG at 1 mM after 6 hrs by luciferase reporter gene assay,Other,25667960.0,
2986,1209455,1,2,,104234229,5743,Unspecified,262527527.0,8647.0,137.4,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
2987,1209456,1,2,,104234229,5743,Unspecified,12585136.0,83569.0,231.9,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
2988,1209457,1,1,,104234229,5743,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
2989,1209476,1,2,,104234229,5743,Unspecified,10720242.0,84385.0,,,Activation of PXR in rat hepatocytes assessed as increase in CYP3A-mediated testosterone 6beta-hydroxylation at 10 uM after 24 hrs by HPLC analysis relative to control,Other,22019630.0,
2990,1209537,1,2,,104234229,5743,Unspecified,10720242.0,84385.0,,,Activation of PXR in rat hepatocytes assessed as upregulation of CYP3A23 mRNA expression at 10 uM after 24 hrs by RT-PCR analysis relative to control,Other,22019630.0,
2991,1210069,1,2,,104234229,5743,Unspecified,21264413.0,1573.0,50.0,IC50,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,Confirmatory,23033255.0,
2992,1215090,1,2,,104234229,5743,Active,10720242.0,84385.0,2.6,EC50,Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis,Confirmatory,20966043.0,
2993,1223488,1,1,,104234229,5743,Unspecified,,,,,"1-Octanol-water distribution coefficient, log D of the compound at pH 7.4",Other,22096083.0,
2994,1223490,1,1,,104234229,5743,Unspecified,,,,,Apparent permeability across human differentiated Caco2 cells,Other,22096083.0,
2995,1224824,1,1,,174007382,5743,Inactive,,,0.001,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
2996,1224825,1,1,,174007382,5743,Inactive,,,0.0662,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
2997,1224834,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2998,1224835,1,1,,144207320,5743,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2999,1224836,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3000,1224837,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
3001,1224838,1,1,,144207320,5743,Inconclusive,66775687.0,9970.0,1.1026,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3002,1224839,1,1,,144207320,5743,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
3003,1224840,3,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
3004,1224841,3,1,,144207320,5743,Inactive,325495545.0,2101.0,1.2371,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3005,1224842,3,1,,144207320,5743,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
3006,1224843,1,1,,144207320,5743,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3007,1224844,1,1,,144207320,5743,Inconclusive,,,12.4836,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
3008,1224845,1,1,,144207320,5743,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
3009,1224846,1,1,,144207320,5743,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
3010,1224847,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
3011,1224848,3,1,,144207320,5743,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3012,1224849,3,1,,144207320,5743,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
3013,1224857,2,1,,174007382,5743,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
3014,1224859,2,1,,174007382,5743,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
3015,1224863,1,1,,176484150,5743,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3016,1224863,1,1,,176484905,5743,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3017,1224863,1,1,,177319656,5743,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
3018,1224865,1,2,,56314873,5743,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3019,1224865,1,2,,56320685,5743,Inactive,578162.0,,,,Identify inhibitors of HNF4 alpha protein binding to DNA,Screening,,
3020,1224867,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
3021,1224868,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
3022,1224869,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
3023,1224870,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
3024,1224871,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
3025,1224872,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
3026,1224873,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
3027,1224874,1,1,,144207320,5743,Inconclusive,,,62.5661,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
3028,1224875,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
3029,1224876,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
3030,1224877,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
3031,1224878,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
3032,1224879,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
3033,1224880,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
3034,1224881,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
3035,1224882,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
3036,1224883,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
3037,1224884,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
3038,1224885,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
3039,1224886,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
3040,1224887,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
3041,1224888,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
3042,1224889,1,1,,144207320,5743,Active,,,22.1993,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
3043,1224890,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
3044,1224892,1,1,,144207320,5743,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3045,1224893,1,1,,144207320,5743,Inconclusive,66775687.0,9970.0,13.104000000000001,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
3046,1224894,1,1,,144207320,5743,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
3047,1224895,1,1,,144207320,5743,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3048,1224896,1,1,,144207320,5743,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
3049,1224905,2,1,,92308949,5743,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3050,1224905,2,1,,92308949,5743,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
3051,1228848,1,1,,104234229,5743,Unspecified,121069.0,2908.0,,,Agonist activity at human glucocorticoid receptor transfected in CHOK1 cells assessed as induction of transcriptional activity at 10 nM after 6 hrs by luciferase reporter gene assay relative to control,Other,25978072.0,
3052,1230792,1,1,,104234229,5743,Active,,,,,"Antiinflammatory activity in CIA-MAB-50-induced BALB/c mouse arthritis model assessed as decrease in LPS-induced paw size at 2 mg/kg, po qd administered on day 3 to 10 post LPS challenge measured on day 10 relative to vehicle-treated control",Other,26101573.0,
3053,1230955,1,1,,104234229,5743,Active,,,,,Antiinflammatory activity in C57BL/6 mouse assessed as suppression of LPS-induced IL-6 expression in lung at 10 mg/kg/day pretreated for 48 hrs followed by LPS challenge measured after 5 hrs by immunohistochemical analysis,Other,26111355.0,
3054,1230957,1,1,,104234229,5743,Active,,,,,In vivo activation of Nrf2 in LPS-stimulated C57BL/6 mouse lung at 10 mg/kg/day pretreated for 48 hrs followed by LPS challenge measured after 5 hrs by DAPI staining-based laser scanning confocal microscopic analysis,Other,26111355.0,
3055,1231004,1,1,,104234229,5743,Unspecified,,,,,Toxicity in C57BL/6 mouse assessed as effect on body weight at 10 mg/kg/day measured after 3 days,Other,26111355.0,
3056,1231010,1,1,,104234229,5743,Active,,,,,Antiinflammatory activity in C57BL/6 mouse assessed as reduction of LPS-induced TNF-alpha level in serum at 10 mg/kg/day pretreated for 48 hrs followed by LPS challenge measured after 5 hrs by ELISA,Other,26111355.0,
3057,1231011,1,1,,104234229,5743,Active,,,,,Antiinflammatory activity in C57BL/6 mouse assessed as reduction of LPS-induced IFN-gamma level in serum at 10 mg/kg/day pretreated for 48 hrs followed by LPS challenge measured after 5 hrs by ELISA,Other,26111355.0,
3058,1231012,1,1,,104234229,5743,Active,,,,,Antiinflammatory activity in C57BL/6 mouse assessed as reduction of LPS-induced IL-6 level in serum at 10 mg/kg/day pretreated for 48 hrs followed by LPS challenge measured after 5 hrs by ELISA,Other,26111355.0,
3059,1231013,1,1,,104234229,5743,Active,,,,,Antiinflammatory activity in C57BL/6 mouse assessed as reduction of LPS-induced IL-12 level in serum at 10 mg/kg/day pretreated for 48 hrs followed by LPS challenge measured after 5 hrs by ELISA,Other,26111355.0,
3060,1231014,1,1,,104234229,5743,Active,,,,,Antiinflammatory activity in C57BL/6 mouse assessed as reduction of LPS-induced IL-17 level in serum at 10 mg/kg/day pretreated for 48 hrs followed by LPS challenge measured after 5 hrs by ELISA,Other,26111355.0,
3061,1231016,1,1,,104234229,5743,Active,,,,,Antiinflammatory activity in C57BL/6 mouse assessed as prevention of LPS-induced morphological changes in lung at 10 mg/kg/day pretreated for 48 hrs followed by LPS challenge measured after 5 hrs,Other,26111355.0,
3062,1234855,1,1,,104234229,5743,Active,,,0.63,IC50,Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay,Confirmatory,26087384.0,
3063,1234856,1,1,,104234229,5743,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as survival rate at 200 uM after 48 hrs by MTT assay in absence of LPS relative to control,Other,26087384.0,
3064,1234857,1,1,,104234229,5743,Unspecified,,,,,Cytotoxicity against mouse RAW264.7 cells assessed as survival rate at 200 uM after 48 hrs by MTT assay in presence of LPS relative to control,Other,26087384.0,
3065,1235012,1,1,,104234229,5743,Active,,,0.025,IC50,Antiinflammatory activity in C57BL6/J mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay,Confirmatory,26110443.0,
3066,1235014,1,1,,104234229,5743,Unspecified,,,,,Antiinflammatory activity in ICR mouse assessed as inhibition of croton oil-induced ear edema at 1 mg/ml administered 1 hr prior to croton oil challenge measured after 4 hrs relative to control,Other,26110443.0,
3067,1237667,1,1,,104234229,5743,Active,,,,,"Anti-inflammatory activity in Wistar rat model complete Freund's adjuvant-induced arthritis assessed as reduction in paw edema at 5 umol/kg, ip dosed from day 14 to day 21 after immunization and measured on day 16",Other,26116178.0,
3068,1239381,1,1,,104234229,5743,Active,,,,,"Anti-inflammatory in LPS-challenged C57BL/6 mouse model of acute inflammation assessed as reduction in TNFalpha level at 10 mg/kg, ip for 3 days pre-treated for 3 days followed by LPS challenge 24 hrs after last dose and measured 5 hrs post LPS challenge by ELISA method",Other,26258437.0,
3069,1239382,1,1,,104234229,5743,Active,,,,,"Anti-inflammatory in LPS-challenged C57BL/6 mouse model of acute inflammation assessed as reduction in IFNgamma level at 10 mg/kg, ip for 3 days pre-treated for 3 days followed by LPS challenge 24 hrs after last dose and measured 5 hrs post LPS challenge by ELISA method",Other,26258437.0,
3070,1239383,1,1,,104234229,5743,Active,,,,,"Anti-inflammatory in LPS-challenged C57BL/6 mouse model of acute inflammation assessed as reduction in IL6 level at 10 mg/kg, ip for 3 days pre-treated for 3 days followed by LPS challenge 24 hrs after last dose and measured 5 hrs post LPS challenge by ELISA method",Other,26258437.0,
3071,1239384,1,1,,104234229,5743,Active,,,,,"Anti-inflammatory in LPS-challenged C57BL/6 mouse model of acute inflammation assessed as reduction in IL12 level at 10 mg/kg, ip for 3 days pre-treated for 3 days followed by LPS challenge 24 hrs after last dose and measured 5 hrs post LPS challenge by ELISA method",Other,26258437.0,
3072,1239385,1,1,,104234229,5743,Active,,,,,"Anti-inflammatory in LPS-challenged C57BL/6 mouse model of acute inflammation assessed as reduction in IL17 level at 10 mg/kg, ip for 3 days pre-treated for 3 days followed by LPS challenge 24 hrs after last dose and measured 5 hrs post LPS challenge by ELISA method",Other,26258437.0,
3073,1243533,1,1,,104234229,5743,Active,,,0.8,IC50,Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay,Confirmatory,26305406.0,
3074,1259241,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
3075,1259242,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
3076,1259243,1,1,,144207320,5743,Inactive,124375976.0,367.0,0.0062,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
3077,1259244,1,1,,144207320,5743,Inactive,348019627.0,2099.0,0.0039,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
3078,1259247,1,1,,144207320,5743,Inconclusive,124375976.0,367.0,60.6711,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
3079,1259248,1,1,,144207320,5743,Inconclusive,348019627.0,2099.0,0.010774700000000002,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
3080,1259252,1,1,,174007382,5743,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
3081,1259253,1,1,,174007382,5743,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
3082,1259255,1,1,,174007382,5743,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
3083,1259256,1,1,,174007382,5743,Inactive,169655958.0,,,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
3084,1259309,1,1,,125231101,5743,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220 with the processive glycosyltransferase UgtP deleted,Other,,
3085,1259311,1,1,,125231101,5743,Inactive,,,,,A screen for compounds that are lethal to S. aureus RN4220,Other,,
3086,1259313,1,1,,56314873,5743,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3087,1259313,1,1,,56320685,5743,Inactive,,,,,uHTS identification of small molecule modulators of NR3A,Screening,,
3088,1259318,1,1,,56320686,5743,Inactive,,,,,uHTS identification of small molecule modulators of Rev-erb Alpha.,Screening,,
3089,1259325,1,2,,336956296,5743,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
3090,1259364,1,1,,144207320,5743,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
3091,1259365,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
3092,1259366,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3093,1259367,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
3094,1259368,1,1,,144207320,5743,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3095,1259369,1,1,,144207320,5743,Active,109731339.0,2737.0,0.4925,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
3096,1259377,1,1,,144207320,5743,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3097,1259378,1,1,,144207320,5743,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
3098,1259379,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3099,1259380,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3100,1259381,1,1,,144207320,5743,Active,124375976.0,367.0,0.0124,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
3101,1259382,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
3102,1259383,1,1,,144207320,5743,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
3103,1259384,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
3104,1259385,1,1,,144207320,5743,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
3105,1259386,1,1,,144207320,5743,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
3106,1259387,1,1,,144207320,5743,Active,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
3107,1259388,1,1,,144207320,5743,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
3108,1259390,1,1,,144207320,5743,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3109,1259391,1,1,,144207320,5743,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
3110,1259392,1,1,,144207320,5743,Active,109731339.0,2737.0,0.49249899999999996,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
3111,1259393,1,1,,144207320,5743,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
3112,1259394,1,1,,144207320,5743,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3113,1259395,1,1,,144207320,5743,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
3114,1259396,1,1,,144207320,5743,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
3115,1259400,1,1,,174007382,5743,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
3116,1259401,1,1,,144207320,5743,Inconclusive,325495545.0,2101.0,0.19606700000000002,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3117,1259402,1,1,,144207320,5743,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
3118,1259403,1,1,,144207320,5743,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3119,1259404,1,1,,144207320,5743,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
3120,1259406,1,1,,363920452,5743,Unspecified,,,,,BK Channel Variant Modulator Selectivity Assay,Screening,,
3121,1259406,1,1,1.0,363920452,5743,Inactive,26638650.0,3778.0,0.0959883,LogChange(F380Y),BK Channel Variant Modulator Selectivity Assay,Screening,,
3122,1259406,1,1,2.0,363920452,5743,Inactive,4758626.0,3779.0,0.053401199999999996,LogChange(F380Y/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3123,1259406,1,1,3.0,363920452,5743,Inactive,5031823.0,10242.0,-0.0100428,LogChange(F380Y/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3124,1259406,1,1,4.0,363920452,5743,Inactive,26051275.0,27345.0,-0.00027543,LogChange(F380Y/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3125,1259406,1,1,5.0,363920452,5743,Inactive,160410009.0,389816.0,0.0358778,LogChange(F380Y/Slo1WT/gamma1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3126,1259406,1,1,6.0,363920452,5743,Inactive,26638650.0,3778.0,0.0247155,LogChange(R275C),BK Channel Variant Modulator Selectivity Assay,Screening,,
3127,1259406,1,1,7.0,363920452,5743,Inactive,4758626.0,3779.0,0.0604674,LogChange(R275C/beta1),BK Channel Variant Modulator Selectivity Assay,Screening,,
3128,1259406,1,1,8.0,363920452,5743,Inactive,5031823.0,10242.0,0.00011724399999999999,LogChange(R275C/beta2Delta),BK Channel Variant Modulator Selectivity Assay,Screening,,
3129,1259406,1,1,9.0,363920452,5743,Inactive,26051275.0,27345.0,0.06266849999999999,LogChange(R275C/beta4),BK Channel Variant Modulator Selectivity Assay,Screening,,
3130,1259406,1,1,10.0,363920452,5743,Inactive,5031823.0,10242.0,0.0456398,LogChange(R275C/Slo1WT/beta2),BK Channel Variant Modulator Selectivity Assay,Screening,,
3131,1259407,1,1,,363905017,5743,Active,,,,,CCRIS mutagenicity studies,Other,,
3132,1259409,1,1,,363905017,5743,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
3133,1259415,1,1,,56320686,5743,Inactive,,,,,qHTS Assay for inhibitors of the human cytomegalovirus (HCMV),Screening,,
3134,1259416,1,2,,85789486,5743,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
3135,1259421,1,1,,85789486,5743,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
3136,1259423,1,2,,354982089,5743,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
